gabapentin has been researched along with Nerve Pain in 471 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The inclusion criteria are adult patients with cancer suffering from neuropathic cancer pain refractory to opioids and gabapentinoids, patients with a Numerical Rating Scale (NRS) pain score of 4 or higher and patients with a total Hospital Anxiety and Depression Scale score of less than 20." | 9.24 | Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study. ( Ariyoshi, K; Ishiki, H; Iwase, S; Kawaguchi, T; Kizawa, Y; Koyama, A; Matsuda, Y; Matsuoka, H; Miyaji, T; Morita, T; Yamaguchi, T, 2017) |
| "Gabapentin has been shown to provide pain relief for post-herpetic neuralgia at dosage of 1200 to 2400 mg/day." | 9.11 | Starting dose of gabapentin for patients with post-herpetic neuralgia--a dose-response study. ( Jean, WH; Mok, MS; Sun, WZ; Wu, CC, 2005) |
| "The effect of the anticonvulsant gabapentin on neuropathic pain was studied in six male patients with Fabry disease, aged 15-45 years." | 9.10 | Use of gabapentin to reduce chronic neuropathic pain in Fabry disease. ( Beck, M; Birklein, F; Kim, KS; Krummenauer, F; Kutschke, G; Mengel, E; Ries, M, 2003) |
| "To assess the effectiveness and safety of the lidocaine patch 5%, a targeted peripheral analgesic, in the treatment of postherpetic neuralgia, painful diabetic neuropathy, and low back pain patients with incomplete responses to their current analgesic treatment regimen containing gabapentin." | 9.10 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "A multicentre double blind, randomised, placebo controlled 7-week study evaluated the efficacy and safety of gabapentin 1800 or 2400 mg/day in treating postherpetic neuralgia." | 9.09 | Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. ( Maton, S; Rice, ASC, 2001) |
| "The aim of this systematic review was to determine the efficacy of gabapentin (GBP) in the treatment of pain of idiopathic trigeminal neuralgia (TN)." | 9.01 | Efficacy of gabapentin in the treatment of trigeminal neuralgia: A systematic review of randomized controlled trials. ( Ariyawardana, A; Dinh, HQ; Lin, S; Nguyen, K; Ong, YL; Ta, PCP, 2019) |
| "Whilst pregabalin (PGB) and gabapentin (GBP) are both used to treat neuropathic pain, their relative role in sciatica is unclear." | 8.93 | Pregabalin and gabapentin for the treatment of sciatica. ( Marshman, LA; Plummer, D; Robertson, K, 2016) |
| "To assess the analgesic efficacy and adverse effects of gabapentin in chronic neuropathic pain and fibromyalgia." | 8.90 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Rice, AS; Toelle, T; Wiffen, PJ, 2014) |
| "Twenty-nine studies (3571 participants), studied gabapentin at daily doses of 1200 mg or more in 12 chronic pain conditions; 78% of participants were in studies of postherpetic neuralgia, painful diabetic neuropathy or mixed neuropathic pain." | 8.87 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; McQuay, HJ; Moore, RA; Wiffen, PJ, 2011) |
| "Multiple, large, high-quality trials have demonstrated the safety and efficacy of gabapentin and pregabalin in neuropathic pain." | 8.84 | Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions. ( Gilron, I, 2007) |
| " Gabapentin was effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes." | 8.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Gabapentin is a very promising medication in the treatment of post-herpetic neuralgia and pain." | 8.82 | The role of gabapentin in treating diseases with cutaneous manifestations and pain. ( Scheinfeld, N, 2003) |
| " Search terms used were postherpetic neuralgia; zoster; gabapentin; neuropathic pain; pain; pharmacoeconomic; cost; controlled clinical trial; randomized, controlled trial; postherpetic neuralgia and gabapentin; gabapentin and pain; treatment and postherpetic neuralgia; gabapentin and age; gabapentin and gender; gabapentin and ethnicity; and gabapentin and pharmacokinetics." | 8.82 | The use of gabapentin for the treatment of postherpetic neuralgia. ( Kennedy, DH; Singh, D, 2003) |
| "Gabapentin is a structural analogue of the neurotransmitter gamma-aminobutyric acid (GABA) approved for use in adults with postherpetic neuralgia." | 8.82 | Gabapentin: in postherpetic neuralgia. ( Curran, MP; Wagstaff, AJ, 2003) |
| "The literature search identified 2 published studies of the efficacy of gabapentin in a total of 563 patients with PHN that had persisted for at least 3 months after the healing of herpes zoster rash." | 8.82 | Use of gabapentin for postherpetic neuralgia: results of two randomized, placebo-controlled studies. ( Glanzman, RL; Stacey, BR, 2003) |
| "In this pooled analysis of adverse-event data from 3 clinical trials in patients with PHN, the incidence of peripheral edema was increased when gabapentin was titrated to >or=1800 mg/d." | 8.82 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "To evaluate the analgesic effectiveness and adverse effects of gabapentin for pain management in clinical practice." | 8.82 | Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005) |
| "A retrospective review of charts and pharmacy records of gabapentin and pregabalin dispensed to control pruritus and/or pain was conducted for burn survivors up to 20 years of age." | 7.88 | Use of gabapentin and pregabalin for pruritus and neuropathic pain associated with major burn injury: A retrospective chart review. ( Amin, A; Kaul, I; Meyer, WJ; Rosenberg, L; Rosenberg, M, 2018) |
| "In a 5-year follow-up study in a hospital in southern China, it was shown that intervertebral foramen (IVF) injection of ozone at the involved segmental levels could significantly alleviate paroxysmal spontaneous pain and mechanical allodynia in patients with chronic, intractable postherpetic neuralgia (PHN) and improve the quality of life." | 7.85 | Intervertebral Foramen Injection of Ozone Relieves Mechanical Allodynia and Enhances Analgesic Effect of Gabapentin in Animal Model of Neuropathic Pain. ( Chen, J; Guan, SM; Luo, WJ; Sun, W; Wang, JL; Wang, JS; Wang, XL; Wu, FF; Yang, F; Zheng, W, 2017) |
| " The effects of genistein were compared with those of gabapentin, which is widely used in clinical practice for peripheral nerve injury." | 7.85 | Neuroprotective Effect of Genistein in Peripheral Nerve Injury. ( Arslantas, A; Aydin, HE; Baycu, C; Bektur, E; Kocman, AE; Kose, A; Ozbek, Z; Ozkara, E; Sahin, E; Vural, M, 2017) |
| "Topical application of gabapentin gel ipsilaterally but not contralaterally alleviated CCI-induced static- (days 10-30) and dynamic-allodynia (days 15-30), suppressed cold-allodynia (days 10-30), heat- (days 15-30) and mechano-hyperalgesia (days 5-30) indicating a local action." | 7.85 | Topical gabapentin gel alleviates allodynia and hyperalgesia in the chronic sciatic nerve constriction injury neuropathic pain model. ( Ahmad, N; Akbar, S; Ali, G; Fawad, K; Sewell, RD; Shahid, M; Subhan, F, 2017) |
| "The analysis was based on a dynamic simulation model which estimated and compared the costs and outcomes of pregabalin and gabapentin in a hypothetical cohort of 1,000 patients suffering from painful Diabetic Peripheral Neuropathy (DPN) or Post-Herpetic Neuralgia (PHN)." | 7.79 | Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting. ( Athanasakis, K; Karampli, E; Kyriopoulos, J; Lyras, L; Petrakis, I; Vitsou, E, 2013) |
| "The involvement of voltage-dependent calcium channels and reactive oxygen species in the pathophysiology of neuropathic pain might justify the preventative administration of antioxidant enzymes, at low doses, in combination with gabapentin (GaP) to maximize its analgesic effect in an experimental model of neuropathic pain in rats." | 7.79 | Antioxidants and gabapentin prevent heat hypersensitivity in a neuropathic pain model. ( Arcos, M; Barrios, C; Montes, F; Palanca, JM, 2013) |
| "The frequency of PHN after untreated zoster varies widely." | 7.79 | Postherpetic neuralgia: role of gabapentin and other treatment modalities. ( Beydoun, A, 1999) |
| " We compared the efficacy of orally administered morphine, pregabalin, gabapentin, and duloxetine on mechanical allodynia with that on neuroma pain using the tibial neuroma transposition (TNT) model." | 7.78 | The efficacy of morphine, pregabalin, gabapentin, and duloxetine on mechanical allodynia is different from that on neuroma pain in the rat neuropathic pain model. ( Miyazaki, R; Yamamoto, T, 2012) |
| " The von Frey filaments, acetone drop, and radiant heat test were performed to assess the degree of mechanical allodynia, thermal allodynia and thermal hyperalgesia respectively, at different time intervals, i." | 7.78 | Evaluation of aqueous and ethanolic extracts of saffron, Crocus sativus L., and its constituents, safranal and crocin in allodynia and hyperalgesia induced by chronic constriction injury model of neuropathic pain in rats. ( Amin, B; Hosseinzadeh, H, 2012) |
| "In order to detect an anti-nociceptive interaction between morphine and gabapentin, the anti-allodynic and anti-hyperalgesic effects of these drugs, administered either separately or in combination, were determined using the von Frey and acetone tests in a rat model of neuropathic pain (Bennett model)." | 7.75 | Anti-nociceptive synergism of morphine and gabapentin in neuropathic pain induced by chronic constriction injury. ( Cortés-Arroyo, AR; De la O-Arciniega, M; Díaz-Reval, MI; Domínguez-Ramírez, AM; López-Muñoz, FJ, 2009) |
| "Gabapentin (Neurontin) is approved by the US Food and Drug Administration for treatment of epilepsy and post-herpetic neuralgia." | 7.75 | Gabapentin-induced delirium and dependence. ( Kahn, DA; Kruszewski, SP; Paczynski, RP, 2009) |
| "Clinical studies investigating the use of pregabalin and duloxetine for the management of diabetic peripheral neuropathy and post-herpetic neuralgia are reviewed." | 7.74 | Pregabalin and duloxetine for the treatment of neuropathic pain disorders. ( Terneus, W, 2007) |
| " Right hemichorea developed and was related to adjunctive therapy with gabapentin." | 7.74 | Hemichorea associated with gabapentin therapy with hypoperfusion in contralateral basal ganglion - a case of a paraplegic patient with neuropathic pain. ( Chang, CC; Chang, ST; Lai, MH; Tsai, KC; Wang, TY, 2008) |
| "Hindpaw mechanical allodynia was dose-dependently reversed by gabapentin (50 and 100 mg/kg, s." | 7.73 | Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain. ( Bjerrum, OJ; Blackburn-Munro, G; Broløs, T; Rode, F, 2006) |
| "Gabapentin (GBP) is a structural analog of gamma-aminobutyric acid (GABA) that is commonly used in palliative care for symptom management indications including neuropathic pain syndromes, hiccups, cough, and anxiety." | 7.01 | Gabapentin-Induced Overflow Urinary Incontinence: A Case Report and Review of the Literature. ( Juba, KM; Kenney, AE; Masri, S; Scigliano, D, 2023) |
| "Pruritus is common in dialysis patients." | 6.77 | Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. ( Atalay, H; Biyik, Z; Covic, A; Gaipov, A; Goldsmith, D; Guney, F; Kanbay, M; Solak, Y; Turk, S, 2012) |
| "Gabapentin was administered orally in gradually increasing doses up to a maximum of 2,400 mg/day." | 6.69 | Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: a pilot study. ( Attal, N; Bouhassira, D; Brasseur, L; Chauvin, M; Parker, F, 1998) |
| "A 4-week titration period to a maximum dosage of 3600 mg/d of gabapentin or matching placebo." | 6.69 | Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. ( Bernstein, P; Harden, N; Magnus-Miller, L; Rowbotham, M; Stacey, B, 1998) |
| "Neuropathic pain is more severe, with significant disability." | 6.53 | Gabapentinoids for chronic low back pain: a protocol for systematic review and meta-analysis of randomised controlled trials. ( AlAmri, R; Bhandari, M; Devereaux, PJ; Gilron, I; Kamath, S; Rajarathinam, M; Shanthanna, H; Thabane, L, 2016) |
| "Early treatment of herpes zoster neuralgia is of great significance to reduce the incidence of PHN." | 5.72 | Effective treatment of high-voltage pulsed radiofrequency combined with oxygen-ozone injection in acute zoster neuralgia. ( Du, HY; Jia, LL; Li, LM; Yu, WL; Zhang, ZL; Zheng, BS, 2022) |
| " We report on a case of a 31 year old female who presented to the emergency department with unilateral leg pain, weakness, and swelling after increasingly titrating her Gabapentin dosage over three weeks." | 5.46 | Radiologic Findings in Gabapentin-Induced Myositis. ( Chang, DR; Coupal, TM; Munk, PL; Ouellette, HA; Pennycooke, K, 2017) |
| "Haloperidol (HAL) is a compound that shows a high affinity with these receptors, acting as an antagonist." | 5.46 | Haloperidol Decreases Hyperalgesia and Allodynia Induced by Chronic Constriction Injury. ( Espinosa-Juárez, JV; Jaramillo-Morales, OA; López-Muñoz, FJ, 2017) |
| "Gabapentin (GBP) is an effective analgesic for neuropathic pain conditions but its clinical efficacy in cisplatin-induced neuropathic pain (CINP) is limited, in addition to generating unwanted side-effects." | 5.46 | Gabapentin and its salicylaldehyde derivative alleviate allodynia and hypoalgesia in a cisplatin-induced neuropathic pain model. ( Ahmad, N; Islam, NU; Rahman, FU; Sewell, RDE; Shahid, M; Subhan, F, 2017) |
| "Chronic pain is a multifactorial disease comprised of both inflammatory and neuropathic components that affect ∼20% of the world's population." | 5.46 | sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain. ( Bialer, M; Brennan, KC; Devor, M; Kaufmann, D; Smith, MD; West, PJ; White, HS; Yagen, B, 2017) |
| "Central poststroke pain is a neuropathic pain syndrome that can occur from pathology of the brain." | 5.43 | A Medication Combination for the Treatment of Central Poststroke Pain via the Adjuvant Use of Prednisone With Gabapentin: A Case Report. ( Batlle, L; Irwin, R; Mattie, R, 2016) |
| "Cathepsin S inhibitors attenuate mechanical allodynia in preclinical neuropathic pain models." | 5.43 | Selective Cathepsin S Inhibition with MIV-247 Attenuates Mechanical Allodynia and Enhances the Antiallodynic Effects of Gabapentin and Pregabalin in a Mouse Model of Neuropathic Pain. ( Classon, B; Edenius, C; Grabowska, U; Henderson, I; Hewitt, E; Lindström, E; Malcangio, M; Pitcher, T; Rizoska, B; Sahlberg, BL; Tunblad, K, 2016) |
| "Neuropathic vulvodynia is a state of vulval discomfort characterized by a burning sensation, diffuse pain, pruritus or rawness with an acute or chronic onset." | 5.42 | A streptozotocin-induced diabetic neuropathic pain model for static or dynamic mechanical allodynia and vulvodynia: validation using topical and systemic gabapentin. ( Abbas, M; Ali, G; Sewell, RD; Shahid, M; Subhan, F; Zeb, J, 2015) |
| "The gabapentin has beneficial effect in the FBSS associated neuropathic pain." | 5.37 | Beneficial response to gabapentin portraying with interval change of brain SPECT imaging in a case with failed back surgery syndrome. ( Chang, ST; Lai, MH; Lu, SC; Wu, YT, 2011) |
| "In both neuropathic pain models, rats exhibited mechanical hypersensitivity, whereas a significant increase in anxiety-like behaviour was observed only in CCI rats (time spent in open arms decreased significantly from 99+/-15." | 5.35 | Anxiety-like behaviour in rats with mononeuropathy is reduced by the analgesic drugs morphine and gabapentin. ( Arndt, K; Ceci, A; Doods, H; Roeska, K; Treede, RD, 2008) |
| "Neuropathic pain is commonly associated with affective disorders such as anxiety and depression." | 5.35 | Anxiety-like behaviour is attenuated by gabapentin, morphine and diazepam in a rodent model of HIV anti-retroviral-associated neuropathic pain. ( Blackbeard, J; Pheby, T; Rice, AS; Segerdahl, AR; Wallace, VC, 2008) |
| "Gabapentin (Neurontin) was then started with improvement at 1800 mg per day." | 5.31 | SUNCT syndrome responsive to gabapentin (Neurontin). ( Graff-Radford, SB, 2000) |
| "A number of studies have been published proposing various approaches to the treatment of neuropathic pain; however, to our knowledge, no attempts have been made to compare gabapentin and fentanyl in patients with lumbar radiculopathy." | 5.30 | Gabapentin versus Transdermal Fentanyl Matrix for the Alleviation of Chronic Neuropathic Pain of Radicular Origin: A Randomized Blind Multicentered Parallel-Group Noninferiority Trial. ( Hwang, CJ; Kim, JH; Lee, JH; Min, SH; Park, KW; Seo, HY; Song, KS, 2019) |
| "Gabapentin was concluded to be an effective therapeutic option for neuralgia of the IXth cranial nerve before surgery." | 5.30 | [Use of gabapentin in glossopharyngeal neuralgia]. ( Esparcia Navarro, M; García Callejo, FJ; Marco Algarra, J; Martínez Beneyto, MP; Morant Ventura, A; Talamantes Escribá, F, 1999) |
| "Gabapentin is an effective treatment for chronic neuropathic pain but may cause dizziness, drowsiness, and confusion in some older adults." | 5.27 | Gabapentin dose and the 30-day risk of altered mental status in older adults: A retrospective population-based study. ( Burneo, J; Dev, VK; Dixon, SN; Fleet, JL; Garg, AX; Kuwornu, PJ; Montero-Odasso, M, 2018) |
| " The inclusion criteria are adult patients with cancer suffering from neuropathic cancer pain refractory to opioids and gabapentinoids, patients with a Numerical Rating Scale (NRS) pain score of 4 or higher and patients with a total Hospital Anxiety and Depression Scale score of less than 20." | 5.24 | Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study. ( Ariyoshi, K; Ishiki, H; Iwase, S; Kawaguchi, T; Kizawa, Y; Koyama, A; Matsuda, Y; Matsuoka, H; Miyaji, T; Morita, T; Yamaguchi, T, 2017) |
| "Compared with gabapentin, duloxetine has no obvious advantage in the treatment of diabetic peripheral neuralgia, but it has less side effects and significantly higher safety." | 5.22 | Comparison of the Efficacy and Safety of Duloxetine and Gabapentin in Diabetic Peripheral Neuropathic Pain: A Meta-Analysis. ( Cui, J; Jiang, L; Xiong, Y, 2022) |
| " Gabapentin and pregabalin may cause dizziness or difficulty walking, but may have some benefit for neck and back nerve pain (e." | 5.22 | Pharmacotherapy for Spine-Related Pain in Older Adults. ( Fu, JL; Perloff, MD, 2022) |
| " She was injected with butylphthalide sodium chloride to improve nerve nutritional status and carbamazepine was prescribed to deal with prosopalgia and glossopharyngeal neuralgia." | 5.22 | Avellis syndrome with ipsilateral prosopalgia, glossopharyngeal neuralgia, and central post-stroke pain: A case report and literature review. ( Chen, Q; Gu, L; He, S; Jing, Z; Luo, K, 2022) |
| "A double-blind, randomized, placebo-controlled cross-over multi-center study was conducted to evaluate the efficacy and safety of gabapentin in the treatment of neuropathic pain caused by traumatic or postsurgical peripheral nerve injury, using doses up to 2400 mg/day." | 5.13 | Gabapentin in traumatic nerve injury pain: a randomized, double-blind, placebo-controlled, cross-over, multi-center study. ( Arnèr, S; Biber, B; Boivie, J; Gordh, TE; Jensen, TS; Kalliomäki, J; Kalso, E; Mannheimer, C; Stubhaug, A, 2008) |
| " Gabapentin (GBP) is effective in painful diabetic neuropathy and postherpetic neuralgia and its effectiveness on painful HIV-SN has been reported anecdotally." | 5.11 | A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. ( Arendt, G; Braun, JS; Hahn, K; Husstedt, IW; Maschke, M; Schielke, E; Straube, ME; von Giesen, HJ, 2004) |
| " We compared the efficacy of a combination of gabapentin and morphine with that of each as a single agent in patients with painful diabetic neuropathy or postherpetic neuralgia." | 5.11 | Morphine, gabapentin, or their combination for neuropathic pain. ( Bailey, JM; Gilron, I; Holden, RR; Houlden, RL; Tu, D; Weaver, DF, 2005) |
| "Gabapentin has been shown to provide pain relief for post-herpetic neuralgia at dosage of 1200 to 2400 mg/day." | 5.11 | Starting dose of gabapentin for patients with post-herpetic neuralgia--a dose-response study. ( Jean, WH; Mok, MS; Sun, WZ; Wu, CC, 2005) |
| "The effect of the anticonvulsant gabapentin on neuropathic pain was studied in six male patients with Fabry disease, aged 15-45 years." | 5.10 | Use of gabapentin to reduce chronic neuropathic pain in Fabry disease. ( Beck, M; Birklein, F; Kim, KS; Krummenauer, F; Kutschke, G; Mengel, E; Ries, M, 2003) |
| "To assess the effectiveness and safety of the lidocaine patch 5%, a targeted peripheral analgesic, in the treatment of postherpetic neuralgia, painful diabetic neuropathy, and low back pain patients with incomplete responses to their current analgesic treatment regimen containing gabapentin." | 5.10 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "A multicentre double blind, randomised, placebo controlled 7-week study evaluated the efficacy and safety of gabapentin 1800 or 2400 mg/day in treating postherpetic neuralgia." | 5.09 | Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. ( Maton, S; Rice, ASC, 2001) |
| "The aim of this systematic review was to determine the efficacy of gabapentin (GBP) in the treatment of pain of idiopathic trigeminal neuralgia (TN)." | 5.01 | Efficacy of gabapentin in the treatment of trigeminal neuralgia: A systematic review of randomized controlled trials. ( Ariyawardana, A; Dinh, HQ; Lin, S; Nguyen, K; Ong, YL; Ta, PCP, 2019) |
| "The gabapentinoid drugs gabapentin and pregabalin were originally developed as antiseizure drugs but now are prescribed mainly for treatment of pain." | 5.01 | A Clinical Overview of Off-label Use of Gabapentinoid Drugs. ( Brett, AS; Goodman, CW, 2019) |
| " Most studies used oral gabapentin or gabapentin encarbil at doses of 1200 mg or more daily in different neuropathic pain conditions, predominantly postherpetic neuralgia and painful diabetic neuropathy." | 4.95 | Gabapentin for chronic neuropathic pain in adults. ( Bell, RF; Derry, S; Moore, RA; Phillips, T; Rice, AS; Tölle, TR; Wiffen, PJ, 2017) |
| " Effective interventions were described for painful diabetic neuropathy (pregabalin, gabapentin, certain tricyclic antidepressants [TCAs], opioids, antidepressants, and anticonvulsants), postherpetic neuralgia (gabapentin, pregabalin, certain TCAs, antidepressants and anticonvulsants, opioids, sodium valproate, topical capsaicin, and lidocaine), lumbar radicular pain (epidural corticosteroids, repetitive transcranial magnetic stimulation [rTMS], and discectomy), cervical radicular pain (rTMS), carpal tunnel syndrome (carpal tunnel release), cubital tunnel syndrome (simple decompression and ulnar nerve transposition), trigeminal neuralgia (carbamazepine, lamotrigine, and pimozide for refractory cases, rTMS), HIV-related neuropathy (topical capsaicin), and central NeuP (certain TCAs, pregabalin, cannabinoids, and rTMS)." | 4.95 | Interventions for Neuropathic Pain: An Overview of Systematic Reviews. ( Biocic, M; Boric, K; Cavar, M; Dosenovic, S; Jelicic Kadic, A; Markovina, N; Miljanovic, M; Puljak, L; Vucic, K, 2017) |
| "We know from adult randomised controlled trials that some antiepileptics, such as gabapentin and pregabalin, can be effective in certain chronic pain conditions." | 4.95 | Antiepileptic drugs for chronic non-cancer pain in children and adolescents. ( Clinch, J; Cooper, TE; Heathcote, LC; Howard, R; Krane, E; Lord, SM; Schechter, N; Sethna, N; Wiffen, PJ; Wood, C, 2017) |
| "Whilst pregabalin (PGB) and gabapentin (GBP) are both used to treat neuropathic pain, their relative role in sciatica is unclear." | 4.93 | Pregabalin and gabapentin for the treatment of sciatica. ( Marshman, LA; Plummer, D; Robertson, K, 2016) |
| "With anticonvulsant, anxiolytic, and analgesic properties, pregabalin has been evaluated for neuropathic pain and fibromyalgia (FM)." | 4.91 | A systematic review of pharmacoeconomic studies for pregabalin. ( Huelin, R; Khankhel, Z; Mould, J; Parker, L; Wasiak, R, 2015) |
| "To assess the analgesic efficacy and adverse effects of gabapentin in chronic neuropathic pain and fibromyalgia." | 4.90 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Rice, AS; Toelle, T; Wiffen, PJ, 2014) |
| "Gabapentin is an anti-epileptic agent but now it is also recommended as first line agent in neuropathic pain, particularly in diabetic neuropathy and post herpetic neuralgia." | 4.89 | Implications and mechanism of action of gabapentin in neuropathic pain. ( Bali, A; Jaggi, AS; Kukkar, A; Singh, N, 2013) |
| "Clinical trial evidence supported the use of only gabapentin and pregabalin in some neuropathic pain conditions (painful diabetic neuropathy, postherpetic neuralgia, and central neuropathic pain) and fibromyalgia." | 4.89 | Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. ( Aldington, D; Cole, P; Derry, S; Haanpaa, M; Hamunen, K; Kalso, EA; Lunn, MP; Moore, RA; Rice, AS; Wiffen, PJ, 2013) |
| "Twenty-nine studies (3571 participants), studied gabapentin at daily doses of 1200 mg or more in 12 chronic pain conditions; 78% of participants were in studies of postherpetic neuralgia, painful diabetic neuropathy or mixed neuropathic pain." | 4.87 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; McQuay, HJ; Moore, RA; Wiffen, PJ, 2011) |
| " Finally, we consider the link between alpha2delta subunits and disease, both in terms of spontaneous and engineered mouse mutants that show cerebellar ataxia and spike-wave epilepsy, and in terms of neuropathic pain and the mechanism of action of the gabapentinoid drugs - small-molecule ligands of the alpha2delta-1 and alpha2delta-2 subunits." | 4.84 | Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels. ( Davies, A; Dolphin, AC; Douglas, L; Hendrich, J; Van Minh, AT; Wratten, J, 2007) |
| " Multiple multicentre randomised controlled trials have shown clear efficacy of gabapentin and pregabalin for postherpetic neuralgia and painful diabetic neuropathy." | 4.84 | Antiepileptic drugs in the treatment of neuropathic pain. ( Eisenberg, E; Krivoy, N; River, Y; Shifrin, A, 2007) |
| "Multiple, large, high-quality trials have demonstrated the safety and efficacy of gabapentin and pregabalin in neuropathic pain." | 4.84 | Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions. ( Gilron, I, 2007) |
| " Gabapentin was effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes." | 4.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Gabapentin is a very promising medication in the treatment of post-herpetic neuralgia and pain." | 4.82 | The role of gabapentin in treating diseases with cutaneous manifestations and pain. ( Scheinfeld, N, 2003) |
| " Search terms used were postherpetic neuralgia; zoster; gabapentin; neuropathic pain; pain; pharmacoeconomic; cost; controlled clinical trial; randomized, controlled trial; postherpetic neuralgia and gabapentin; gabapentin and pain; treatment and postherpetic neuralgia; gabapentin and age; gabapentin and gender; gabapentin and ethnicity; and gabapentin and pharmacokinetics." | 4.82 | The use of gabapentin for the treatment of postherpetic neuralgia. ( Kennedy, DH; Singh, D, 2003) |
| "Gabapentin is a structural analogue of the neurotransmitter gamma-aminobutyric acid (GABA) approved for use in adults with postherpetic neuralgia." | 4.82 | Gabapentin: in postherpetic neuralgia. ( Curran, MP; Wagstaff, AJ, 2003) |
| "The literature search identified 2 published studies of the efficacy of gabapentin in a total of 563 patients with PHN that had persisted for at least 3 months after the healing of herpes zoster rash." | 4.82 | Use of gabapentin for postherpetic neuralgia: results of two randomized, placebo-controlled studies. ( Glanzman, RL; Stacey, BR, 2003) |
| "In this pooled analysis of adverse-event data from 3 clinical trials in patients with PHN, the incidence of peripheral edema was increased when gabapentin was titrated to >or=1800 mg/d." | 4.82 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "To evaluate the analgesic effectiveness and adverse effects of gabapentin for pain management in clinical practice." | 4.82 | Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005) |
| " In the New Drug Application for gabapentin, data from two adequate and well-controlled clinical trials was submitted to the Food and Drug Administration (FDA) in support of the approval of the indication for the treatment of post-herpetic neuralgia." | 4.82 | How modeling and simulation have enhanced decision making in new drug development. ( Corrigan, BW; Donevan, S; El-Kattan, A; Ewy, W; Feltner, DE; Hermann, D; Koup, JR; Kowalski, KG; Lalonde, RL; Li, CS; Lockwood, P; Miller, R; Ouellet, D; Werth, JL, 2005) |
| " The meta-analysis of the 2 high-quality, placebo-controlled RCTs showed positive effect of gabapentin in diabetic neuropathy and post-herpetic neuralgia." | 4.81 | Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature. ( Furlan, AD; Mailis, A; Mellegers, MA, 2001) |
| "CCI increased mechanical allodynia, cold allodynia, and thermal hyperalgesia in rats which were reduced by treatment with EA (50 or 100 mg/kg), gabapentin, or their combination." | 4.31 | Synergistic effect of ellagic acid and gabapentin in a rat model of neuropathic pain. ( Esmaeili, M; Forouzanfar, F; Ghazavi, H; Mahdianpour, S; Pourbagher-Shahri, AM; Tanha, NK, 2023) |
| "This study aims to evaluate the anti-nociceptive effects of ECa 233 and its synergistic effect with gabapentin on chronic neuropathic orofacial pain after 3 weeks infraorbital nerve chronic constriction injury in mice." | 4.12 | Anti-nociceptive effects of ECa 233 a standardized extract of Centella asiatica (L.) Urban on chronic neuropathic orofacial pain in mice. ( Buapratoom, A; Khongsombat, O; Tantisira, MH; Wanasuntronwong, A, 2022) |
| " Potent analgesic activity was observed in models of neuropathic pain, and the compound blocked capsaicin induced allodynia, showing dermal accumulation with little transdermal absorption." | 3.96 | Discovery of Nonpungent Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist as Strong Topical Analgesic. ( Ann, J; Blumberg, PM; Choi, K; Esch, TE; Ha, HJ; Hwang, SW; Kim, H; Kim, HS; Kim, M; Kim, YH; Lee, J; Pearce, LV; Thorat, SA; Turcios, NA, 2020) |
| " Mechanical allodynia and thermal hyperalgesia were measured to confirm neuropathic pain induction following before and after gabapentin (GBP) treatment." | 3.88 | Investigation of spinal nerve ligation-mediated functional activation of the rat brain using manganese-enhanced MRI. ( Jeong, KY; Kang, JH, 2018) |
| "A retrospective review of charts and pharmacy records of gabapentin and pregabalin dispensed to control pruritus and/or pain was conducted for burn survivors up to 20 years of age." | 3.88 | Use of gabapentin and pregabalin for pruritus and neuropathic pain associated with major burn injury: A retrospective chart review. ( Amin, A; Kaul, I; Meyer, WJ; Rosenberg, L; Rosenberg, M, 2018) |
| "We studied 23 patients with severe pruritus scoring at least 5 on the visual analogue scale (VAS) and refractory to antihistamine and gabapentin administration." | 3.88 | Effect of cold pack therapy for management of burn scar pruritus: A pilot study. ( Cho, YS; Joo, SY; Kim, JB; Seo, CH, 2018) |
| "Prior work applied hierarchical clustering, coarsened exact matching (CEM), time series regressions with lagged variables as inputs, and microsimulation to data from three randomized clinical trials (RCTs) and a large German observational study (OS) to predict pregabalin pain reduction outcomes for patients with painful diabetic peripheral neuropathy." | 3.88 | Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy. ( Alexander, J; Bonfanti, G; Brodsky, M; Edwards, RA; Emir, B; Grugni, R; Manca, L; Parsons, B; Savoldelli, A; Watt, S; Whalen, E, 2018) |
| "In a 5-year follow-up study in a hospital in southern China, it was shown that intervertebral foramen (IVF) injection of ozone at the involved segmental levels could significantly alleviate paroxysmal spontaneous pain and mechanical allodynia in patients with chronic, intractable postherpetic neuralgia (PHN) and improve the quality of life." | 3.85 | Intervertebral Foramen Injection of Ozone Relieves Mechanical Allodynia and Enhances Analgesic Effect of Gabapentin in Animal Model of Neuropathic Pain. ( Chen, J; Guan, SM; Luo, WJ; Sun, W; Wang, JL; Wang, JS; Wang, XL; Wu, FF; Yang, F; Zheng, W, 2017) |
| "The combination of low-dose KML29:gabapentin additively attenuated mechanical allodynia and synergistically reduced cold allodynia." | 3.85 | The monoacylglycerol lipase inhibitor KML29 with gabapentin synergistically produces analgesia in mice. ( Banks, ML; Bradshaw, HB; Crowe, MS; Kinsey, SG; Leishman, E; Prather, PL; Wilson, CD, 2017) |
| " The effects of genistein were compared with those of gabapentin, which is widely used in clinical practice for peripheral nerve injury." | 3.85 | Neuroprotective Effect of Genistein in Peripheral Nerve Injury. ( Arslantas, A; Aydin, HE; Baycu, C; Bektur, E; Kocman, AE; Kose, A; Ozbek, Z; Ozkara, E; Sahin, E; Vural, M, 2017) |
| "Topical application of gabapentin gel ipsilaterally but not contralaterally alleviated CCI-induced static- (days 10-30) and dynamic-allodynia (days 15-30), suppressed cold-allodynia (days 10-30), heat- (days 15-30) and mechano-hyperalgesia (days 5-30) indicating a local action." | 3.85 | Topical gabapentin gel alleviates allodynia and hyperalgesia in the chronic sciatic nerve constriction injury neuropathic pain model. ( Ahmad, N; Akbar, S; Ali, G; Fawad, K; Sewell, RD; Shahid, M; Subhan, F, 2017) |
| " Daily gabapentin treatment attenuated mechanical allodynia and reduced face-grooming episodes in dIoN-CCI rats." | 3.85 | An Improved Rodent Model of Trigeminal Neuropathic Pain by Unilateral Chronic Constriction Injury of Distal Infraorbital Nerve. ( Chen, L; Ding, W; Doheny, JT; Lim, G; Mao, J; Shen, S; Yang, J; You, Z; Zhu, S, 2017) |
| "Gabapentin and pregabalin are antiepileptic drugs (AEDs) with epilepsy and neuropathic pain indications." | 3.81 | Experience from therapeutic drug monitoring and gender aspects of gabapentin and pregabalin in clinical practice. ( Baftiu, A; Beiske, G; Burns, ML; Johannessen Landmark, C; Johannessen, SI, 2015) |
| "To evaluate the antinociceptive and hypnotic effects of pregabalin, we established a neuropathic pain-like model in mice using partial sciatic nerve ligation (PSNL), and examined thermal hyperalgesia, mechanical allodynia, electroencephalogram, rota-rod testing, and c-Fos expression in the anterior cingulate cortex." | 3.81 | Antinociceptive and hypnotic activities of pregabalin in a neuropathic pain-like model in mice. ( Guo, W; Han, WJ; Hong, ZY; Huang, ZL; Li, YD; Liu, YY; Qu, WM; Wang, TX; Yin, D, 2015) |
| "Mechanical allodynia in SNL rats was attenuated by gabapentin (100 mg/kg) and AQU-118 (in a dose-dependent manner)." | 3.81 | Effect of a Novel, Orally Active Matrix Metalloproteinase-2 and -9 Inhibitor in Spinal and Trigeminal Rat Models of Neuropathic Pain. ( Davis, SF; Fairchild, DD; Hain, HS; Hanania, T; Henry, MA; Hu, A; Malekiani, SA; Nix, D; Patil, MJ; Sucholeiki, I; Sucholeiki, R, 2015) |
| " To address this issue, we obtained clinical trial data from the Food and Drug Administration (FDA) through the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership, and harmonized patient level data from 12 clinical trials (4 gabapentin and 8 pregabalin) in postherpetic neuralgia (PHN) and painful diabetic peripheral neuropathy (DPN)." | 3.80 | Effect of variability in the 7-day baseline pain diary on the assay sensitivity of neuropathic pain randomized clinical trials: an ACTTION study. ( Dworkin, RH; Farrar, JT; Gilron, I; Haynes, K; Katz, NP; Kerns, RD; Rappaport, BA; Rowbotham, MC; Tierney, AM; Troxel, AB; Turk, DC, 2014) |
| "The analysis was based on a dynamic simulation model which estimated and compared the costs and outcomes of pregabalin and gabapentin in a hypothetical cohort of 1,000 patients suffering from painful Diabetic Peripheral Neuropathy (DPN) or Post-Herpetic Neuralgia (PHN)." | 3.79 | Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting. ( Athanasakis, K; Karampli, E; Kyriopoulos, J; Lyras, L; Petrakis, I; Vitsou, E, 2013) |
| "The involvement of voltage-dependent calcium channels and reactive oxygen species in the pathophysiology of neuropathic pain might justify the preventative administration of antioxidant enzymes, at low doses, in combination with gabapentin (GaP) to maximize its analgesic effect in an experimental model of neuropathic pain in rats." | 3.79 | Antioxidants and gabapentin prevent heat hypersensitivity in a neuropathic pain model. ( Arcos, M; Barrios, C; Montes, F; Palanca, JM, 2013) |
| "The frequency of PHN after untreated zoster varies widely." | 3.79 | Postherpetic neuralgia: role of gabapentin and other treatment modalities. ( Beydoun, A, 1999) |
| "Lysophosphatidic acid (LPA), an initiator of neuropathic pain, causes allodynia." | 3.78 | Pharmacological characterization of lysophosphatidic acid-induced pain with clinically relevant neuropathic pain drugs. ( Kato, A; Ogawa, K; Shinohara, S; Takasu, K; Yoneda, Y, 2012) |
| " We compared the efficacy of orally administered morphine, pregabalin, gabapentin, and duloxetine on mechanical allodynia with that on neuroma pain using the tibial neuroma transposition (TNT) model." | 3.78 | The efficacy of morphine, pregabalin, gabapentin, and duloxetine on mechanical allodynia is different from that on neuroma pain in the rat neuropathic pain model. ( Miyazaki, R; Yamamoto, T, 2012) |
| " The von Frey filaments, acetone drop, and radiant heat test were performed to assess the degree of mechanical allodynia, thermal allodynia and thermal hyperalgesia respectively, at different time intervals, i." | 3.78 | Evaluation of aqueous and ethanolic extracts of saffron, Crocus sativus L., and its constituents, safranal and crocin in allodynia and hyperalgesia induced by chronic constriction injury model of neuropathic pain in rats. ( Amin, B; Hosseinzadeh, H, 2012) |
| "In order to detect an anti-nociceptive interaction between morphine and gabapentin, the anti-allodynic and anti-hyperalgesic effects of these drugs, administered either separately or in combination, were determined using the von Frey and acetone tests in a rat model of neuropathic pain (Bennett model)." | 3.75 | Anti-nociceptive synergism of morphine and gabapentin in neuropathic pain induced by chronic constriction injury. ( Cortés-Arroyo, AR; De la O-Arciniega, M; Díaz-Reval, MI; Domínguez-Ramírez, AM; López-Muñoz, FJ, 2009) |
| "Gabapentin (Neurontin) is approved by the US Food and Drug Administration for treatment of epilepsy and post-herpetic neuralgia." | 3.75 | Gabapentin-induced delirium and dependence. ( Kahn, DA; Kruszewski, SP; Paczynski, RP, 2009) |
| " Based on the need for new approaches in that field the effect of systemic administration of lacosamide (SPM 927, (R)-2-acetamido-N-benzyl-3-methoxypropionamide, previously referred to as harkoseride or ADD 234037), a member of a series of functionalized amino acids that were specifically synthesized as anticonvulsive drug candidates, was examined in rats in a tumor-induced bone cancer pain model and in a chemotherapy-induced neuropathic pain model." | 3.74 | Antinociceptive efficacy of lacosamide in rat models for tumor- and chemotherapy-induced cancer pain. ( Bain, SC; Beyreuther, BK; Brot, MD; Callizot, N; Feldman, R; Stöhr, T, 2007) |
| "Clinical studies investigating the use of pregabalin and duloxetine for the management of diabetic peripheral neuropathy and post-herpetic neuralgia are reviewed." | 3.74 | Pregabalin and duloxetine for the treatment of neuropathic pain disorders. ( Terneus, W, 2007) |
| " Right hemichorea developed and was related to adjunctive therapy with gabapentin." | 3.74 | Hemichorea associated with gabapentin therapy with hypoperfusion in contralateral basal ganglion - a case of a paraplegic patient with neuropathic pain. ( Chang, CC; Chang, ST; Lai, MH; Tsai, KC; Wang, TY, 2008) |
| "A 44-year-old female with gabapentin-responsive supraorbital neuralgia is presented." | 3.73 | Abnormal blink reflex studies in a patient with supraorbital neuralgia. ( Cohen, AS; Gantenbein, AR; Goadsby, PJ, 2006) |
| "Hindpaw mechanical allodynia was dose-dependently reversed by gabapentin (50 and 100 mg/kg, s." | 3.73 | Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain. ( Bjerrum, OJ; Blackburn-Munro, G; Broløs, T; Rode, F, 2006) |
| "Case report on a patient with SUNCT-syndrome (short lasting, unilateral neuralgiform headache attacks with conjunctival injection, sweating, and rhinorrhoea) who was successfully treated with gabapentin." | 3.72 | [Case report on a patient with SUNCT-syndrome]. ( Brinkschmidt, T; Jensen, U; Neumeier, S, 2003) |
| " Oxcarbazepine and carbamazepine (3-100 mg x kg(-1)) did not affect mechanical hyperalgesia or tactile allodynia induced by partial sciatic nerve ligation in the rat following oral administration." | 3.72 | Comparative activity of the anti-convulsants oxcarbazepine, carbamazepine, lamotrigine and gabapentin in a model of neuropathic pain in the rat and guinea-pig. ( Bevan, S; Fox, A; Gentry, C; Kesingland, A; Patel, S, 2003) |
| "Thirty patients with type 2 diabetes with peripheral neuropathy as assessed by a visual analog scale (VAS) and divided into two groups of 15 patients, treated for up to three months." | 3.30 | Effectiveness of oral clonidine and gabapentin on peripheral neuropathy in diabetic patients in southwestern Iran: a randomized clinical trial. ( Ahmadi, SA; Bagheri, S; Dolatkhah, H; Hassanzadeh, S; Majid Ahmadi, S; Moradishibany, I; Reisi, S, 2023) |
| "Children with acute lymphoblastic leukemia (ALL) often experience treatment-related neurocognitive deficits and significant pain." | 3.11 | Neuropathic pain and neurocognitive functioning in children treated for acute lymphoblastic leukemia. ( Alberts, NM; Anghelescu, DA; Conklin, HM; Jacola, LM; Krull, KR; Partanen, M; Pui, CH, 2022) |
| "Gabapentin (GBP) is a structural analog of gamma-aminobutyric acid (GABA) that is commonly used in palliative care for symptom management indications including neuropathic pain syndromes, hiccups, cough, and anxiety." | 3.01 | Gabapentin-Induced Overflow Urinary Incontinence: A Case Report and Review of the Literature. ( Juba, KM; Kenney, AE; Masri, S; Scigliano, D, 2023) |
| " The majority of adverse events pertained to the nervous system (7 effects) or psychiatric (3 effects) disorders." | 3.01 | The safety and efficacy of gabapentinoids in the management of neuropathic pain: a systematic review with meta-analysis of randomised controlled trials. ( Eldabe, S; Meaadi, J; Nazar, H; Obara, I, 2023) |
| "Managing cancer-related pain in patients who are also pregnant compounds the challenge for adequate pain management, as studies have largely excluded this population." | 3.01 | Pharmacologic Management of Cancer-Related Pain in Pregnant Patients. ( McGinn, R; Smith, MA; Zerfas, I, 2023) |
| " Only the risk classification of acute lymphoblastic leukemia was significantly associated with the daily morphine dosage (P = ." | 2.94 | Prospective randomized trial of interventions for vincristine-related neuropathic pain. ( Anghelescu, DL; Cheng, C; Jeha, S; Pauley, J; Pei, D; Pui, CH; Sandlund, JT; Tesney, JM; Trujillo, L; Wright, BB, 2020) |
| "Gabapentin has shown efficacy in the treatment of chronic neuropathic or mixed pain in adults." | 2.90 | Gabapentin as add-on to morphine for severe neuropathic or mixed pain in children from age 3 months to 18 years - evaluation of the safety, pharmacokinetics, and efficacy of a new gabapentin liquid formulation: study protocol for a randomized controlled t ( Ceci, A; de Leeuw, TG; de Wildt, SN; Kaguelidou, F; Lundin, R; Mangiarini, L; Pasqua, OD; Tibboel, D; van der Zanden, T, 2019) |
| "Gabapentin is currently used 'off-label' in children and adolescents with chronic neuropathic pain, and reliable evidence of its effects and optimal dosing are lacking." | 2.90 | Non-inferiority double-blind randomised controlled trial comparing gabapentin versus tramadol for the treatment of chronic neuropathic or mixed pain in children and adolescents: the GABA-1 trial-a study protocol. ( Alberti, C; Bonifazi, D; Ceci, A; de Leeuw, TG; de Wildt, SN; Della Pasqua, O; Felisi, M; Kaguelidou, F; Le Roux, E; Lundin, R; Mangiarini, L; Tibboel, D, 2019) |
| "3%) patients reported adverse events." | 2.87 | Efficacy and safety of oxycodone/naloxone as add-on therapy to gabapentin or pregabalin for the management of chemotherapy-induced peripheral neuropathy in Korea. ( Jin, JY; Kang, JH; Kim, BS; Ko, YH; Kwon, JH; Park, HJ; Park, SY; Woo, IS, 2018) |
| "Inflammation is the body's mechanism to trigger the immune system, thereby preventing bacteria and viruses from manifesting their toxic effect." | 2.82 | An Update On Proficiency of Voltage-gated Ion Channel Blockers in the Treatment of Inflammation-associated Diseases. ( Bhatia, NY; Doshi, G; Godad, AP; Kelkar, S; Nailwal, N; Sathaye, S, 2022) |
| "All nine drugs can relieve the pain of CPSP patients to different degrees; among them pregabalin and gabapentin have the most significant effect, and gabapentin and pregabalin also have the most adverse reactions." | 2.82 | Efficacy and safety of different antidepressants and anticonvulsants in central poststroke pain: A network meta-analysis and systematic review. ( Chen, KY; Li, RY, 2022) |
| "Treatment of neuropathic pain in children is challenging, and requires a multimodal approach of pharmacologic, physical, and psychological therapies; however there is little evidence to guide practice." | 2.82 | A randomized controlled trial of amitriptyline versus gabapentin for complex regional pain syndrome type I and neuropathic pain in children. ( Amaria, K; Brown, S; Campbell, F; Johnston, B; McGrath, P; Pehora, C; Watkins, J, 2016) |
| "Nabilone or placebo was titrated over 4 weeks (0." | 2.80 | Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial. ( Doupe, M; Esfahani, F; Ethans, K; Galloway, K; Gomori, A; Namaka, M; Torabi, M; Turcotte, D, 2015) |
| " Discontinuation because of adverse events was significantly greater in the duloxetine (19." | 2.79 | Comparative safety and tolerability of duloxetine vs. pregabalin vs. duloxetine plus gabapentin in patients with diabetic peripheral neuropathic pain. ( Irving, G; Malcolm, S; Raskin, J; Risser, RC; Tanenberg, RJ, 2014) |
| "Those patients who reported neuropathic pain were randomly treated with gabapentin or pregabalin." | 2.79 | Gabapentin versus pregabalin in relieving early post-surgical neuropathic pain in patients after lumbar disc herniation surgery: a prospective clinical trial. ( Comoglu, SS; Dolgun, H; Gurer, B; Kertmen, H; Sekerci, Z; Turkoglu, E; Yilmaz, ER, 2014) |
| "Oral morphine was used for rescue analgesic for continued pain." | 2.77 | A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. ( Bhatnagar, S; Goyal, GN; Mishra, S; Rana, SP; Upadhya, SP, 2012) |
| "Pruritus is common in dialysis patients." | 2.77 | Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. ( Atalay, H; Biyik, Z; Covic, A; Gaipov, A; Goldsmith, D; Guney, F; Kanbay, M; Solak, Y; Turk, S, 2012) |
| "Drugs for neuropathic pain have incomplete efficacy and dose-limiting side-effects when given as monotherapy." | 2.74 | Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. ( Bailey, JM; Gilron, I; Holden, RR; Houlden, RL; Jackson, AC; Tu, D, 2009) |
| "Neuropathic cancer pain represents a major challenge." | 2.73 | Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: a randomized open trial. ( Aydinli, I; Keskinbora, K; Pekel, AF, 2007) |
| "Fourty six patients with neuropathic pain which was burning, stabbing and shooting in quality were allocated to take gabapentin (group GBP) and amitriptyline (group AMI) monotherapy." | 2.72 | [Comparison of efficacy of gabapentin and amitriptyline in the management of peripheral neuropathic pain]. ( Aydinli, I; Keskinbora, K; Pekel, AF, 2006) |
| "Gabapentin is a new antiepileptic drug that may additionally have a role in the treatment of neuropathic pain." | 2.71 | Gabapentin effect on neuropathic pain compared among patients with spinal cord injury and different durations of symptoms. ( Ahn, SH; Bae, JH; Jang, SH; Lee, BS; Moon, HW; Park, HW; Sakong, J, 2003) |
| " This was followed by a 4-week stable dosing period when the patients continued to receive maximum tolerated doses, a 2-week washout period, then a crossover of 4 weeks of medication/placebo titration, and another 4 weeks of stable dosing period." | 2.71 | Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury. ( Levendoglu, F; Ogün, CO; Ogün, TC; Ozerbil, O; Ugurlu, H, 2004) |
| "Chronic neuropathic pain occurs in 10-15% of patients with neuroborreliosis and is difficult to treat." | 2.71 | Gabapentin for the symptomatic treatment of chronic neuropathic pain in patients with late-stage lyme borreliosis: a pilot study. ( Hofmann, H; Ring, J; Weissenbacher, S, 2005) |
| "Gabapentin has some beneficial effects on certain types of neuropathic pain." | 2.70 | Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double-blind, crossover trial. ( Chen, B; DeLisa, JA; Johnston, M; Kirshblum, S; Millis, S; Tai, Q, 2002) |
| "Gabapentin was administered orally in gradually increasing doses up to a maximum of 2,400 mg/day." | 2.69 | Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: a pilot study. ( Attal, N; Bouhassira, D; Brasseur, L; Chauvin, M; Parker, F, 1998) |
| "A 4-week titration period to a maximum dosage of 3600 mg/d of gabapentin or matching placebo." | 2.69 | Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. ( Bernstein, P; Harden, N; Magnus-Miller, L; Rowbotham, M; Stacey, B, 1998) |
| "Treatment with gabapentinoids (GBs) has been shown to reduce pain, but its effects on sleep health have not been systematically evaluated." | 2.66 | Evaluating the impact of gabapentinoids on sleep health in patients with chronic neuropathic pain: a systematic review and meta-analysis. ( Bhatia, A; Brull, R; Davidson, A; Kapustin, D; McParland, A; Singh, M; Trivedi, A, 2020) |
| "A subtype of chronic pain is neuropathic pain (NP), which is defined as "pain caused by a lesion or disease of the somatosensory system," according to the International Association for the Study of Pain (IASP)." | 2.66 | The use of antineuropathic medications for the treatment of chronic pain. ( Artounian, KA; Bandi, P; Berardino, K; Jung, JW; Kaye, AD; Kaye, AM; Kaye, RJ; Li, N; Manchikanti, L; Simopoulos, T; Torres, M; Urits, I; Viswanath, O, 2020) |
| "We examined systematic adverse events (AEs) in Part 1 (of 2) of a study describing the assessment and reporting of AEs in clinical trials." | 2.61 | Harms are assessed inconsistently and reported inadequately part 1: systematic adverse events. ( Canner, JK; Dickersin, K; Fusco, N; Hong, H; Li, T; Mayo-Wilson, E, 2019) |
| "We examined nonsystematic adverse events (AEs) in Part 2 (of 2) of a study describing the assessment and reporting AEs in clinical trials." | 2.61 | Harms are assessed inconsistently and reported inadequately Part 2: nonsystematic adverse events. ( Canner, JK; Dickersin, K; Fusco, N; Hong, H; Li, T; Mayo-Wilson, E, 2019) |
| "Processes involved in the onset of neuropathic pain differ from those involved in its long-term maintenance." | 2.58 | Etiology and Pharmacology of Neuropathic Pain. ( Alles, SRA; Smith, PA, 2018) |
| "The analgesic effect in neuropathic pain is well evidenced but the role in postoperative pain is less certain." | 2.58 | Analgesic mechanisms of gabapentinoids and effects in experimental pain models: a narrative review. ( Chincholkar, M, 2018) |
| "Eligible RCTs examined gabapentin for neuropathic pain and quetiapine for bipolar depression, reported in public (e." | 2.55 | Multiple outcomes and analyses in clinical trials create challenges for interpretation and research synthesis. ( Canner, JK; Dickersin, K; Fusco, N; Hong, H; Li, T; Mayo-Wilson, E, 2017) |
| "Indomethacin is the best treatment both for HC and PH." | 2.55 | Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal. ( Baraldi, C; Cainazzo, MM; Guerzoni, S; Pellesi, L; Pini, LA, 2017) |
| "Eligible RCTs examined gabapentin for neuropathic pain and quetiapine for bipolar depression, reported in public (e." | 2.55 | Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy. ( Bertizzolo, L; Canner, JK; Cowley, T; Dickersin, K; Doshi, P; Ehmsen, J; Fusco, N; Gresham, G; Guo, N; Haythornthwaite, JA; Heyward, J; Hong, H; Li, T; Mayo-Wilson, E; Payne, JL; Pham, D; Rosman, L; Stuart, EA; Suarez-Cuervo, C; Tolbert, E; Twose, C; Vedula, S, 2017) |
| "Patients with neuropathic pain may experience anxiety, depression, insomnia, disability, and reduced quality of life." | 2.55 | An update on the pharmacologic management and treatment of neuropathic pain. ( Rizzolo, D; Wright, ME, 2017) |
| "Multiple causes of neuropathic pain have been described and its incidence is likely to increase owing to the ageing global population, increased incidence of diabetes mellitus and improved survival from cancer after chemotherapy." | 2.55 | Neuropathic pain. ( Attal, N; Baron, R; Bennett, DL; Bouhassira, D; Colloca, L; Dickenson, AH; Dworkin, RH; Eccleston, C; Finnerup, NB; Freeman, R; Kalso, E; Ludman, T; Raja, SN; Truini, A; Yarnitsky, D, 2017) |
| "Neuropathic pain is one of the key features of (classical) Fabry disease (FD)." | 2.53 | Pain management strategies for neuropathic pain in Fabry disease--a systematic review. ( Biegstraaten, M; Hollak, CE; Linthorst, GE; Schuller, Y; Van Schaik, IN, 2016) |
| "Neuropathic pain is more severe, with significant disability." | 2.53 | Gabapentinoids for chronic low back pain: a protocol for systematic review and meta-analysis of randomised controlled trials. ( AlAmri, R; Bhandari, M; Devereaux, PJ; Gilron, I; Kamath, S; Rajarathinam, M; Shanthanna, H; Thabane, L, 2016) |
| "Neuropathic pain is considered as a special type of different pain conditions." | 2.52 | [DRUG THERAPY OF NEUROPATHIC PAIN BASED ON THE LATEST RECOMMENDATIONS]. ( Kiss, G, 2015) |
| "Opioid-induced hyperalgesia has recently been described as representing a challenge for physicians in the clinical setting." | 2.50 | Managing difficult pain conditions in the cancer patient. ( Mercadante, S, 2014) |
| "Neuropathic pain is a debilitating chronic pain condition, which remains difficult to treat." | 2.49 | Update on neuropathic pain treatment: ion channel blockers and gabapentinoids. ( Chen, L; Mao, J, 2013) |
| "Neuropathic pain is usually considered an "hard pain" both for the intrinsic difficulties in a correct diagnosis, and for the modest efficacy of the most part of conventional treatments." | 2.47 | [Neuropathic pain in oncology. Novel evidence for clinical practice]. ( Carloni, F; Castellani, C; Drudi, F; Possenti, C; Santelmo, C; Tassinari, D, 2011) |
| "Neuropathic pain is caused by lesion or dysfunction of the peripheral sensory nervous system." | 2.46 | The anti-allodynic alpha(2)delta ligand pregabalin inhibits the trafficking of the calcium channel alpha(2)delta-1 subunit to presynaptic terminals in vivo. ( Bauer, CS; Dickenson, AH; Dolphin, AC; Lujan, R; Rahman, W; Tran-van-Minh, A, 2010) |
| "A number of different treatments for neuropathic pain have been studied, but the literature is sizable, rapidly evolving, and lacks important information about practical aspects of patient management." | 2.45 | Treatment of neuropathic pain: an overview of recent guidelines. ( Dworkin, RH; O'Connor, AB, 2009) |
| " On the other hand, for GP a maximum dosage of 3,600 mg/day reduced VAS score (P = 0." | 2.44 | Efficacy of pregabalin and gabapentin for neuropathic pain in spinal-cord injury: an evidence-based evaluation of the literature. ( Amaniti, E; Kouvelas, D; Papazisis, G; Tzellos, TG, 2008) |
| "Some mechanisms of the development of neuropathic pain have been proposed; 1) sprouting of A beta fibers to the superficial layer of the dorsal horn, 2) ectopic discharge in the dorsal root ganglion and/or in neuroma at the nerve stump, 3) spinal sensitization." | 2.44 | [Mechanisms of the development of neuropathic pain and its treatment]. ( Yamamoto, T, 2008) |
| " Thus, monitoring and dosage adjustment are required, without discontinuation of the drug." | 2.43 | Therapeutic management of chronic neuropathic pain: an examination of pharmacologic treatment. ( Argyra, E; Moka, E; Siafaka, I; Vadalouca, A; Vrachnou, E, 2006) |
| "Managing patients with chronic neuropathic pain is a common clinical challenge due to variability in individual symptoms, mechanisms, and treatment responses." | 2.42 | Diagnosis and management of neuropathic pain: a balanced approach to treatment. ( Nicholson, BD, 2003) |
| "The most common risk factor for shingles and its potential sequela, PHN, is advanced age." | 2.42 | Post-herpetic neuralgia case study: optimizing pain control. ( Baron, R, 2004) |
| "Gabapentin is a newer generation antiepileptic drug that is commonly used in treatment of neuropathic pain." | 2.41 | Use of gabapentin in the treatment of neuropathic pain. ( Gidal, BE; Laird, MA, 2000) |
| "Gabapentin is a recently introduced anti-epileptic drug used as an adjuvant in partial and secondarily generalised tonic-clonic seizures." | 2.41 | [Gabapentin--yet another antiepileptic agent for the treatment of neuropathic pain?]. ( Kamp-Jensen, M; Werner, MU, 2001) |
| "Gabapentin is an anti-epileptic drug (AED) that was approved in 1993 for the adjunct treatment of complex partial seizures (CPS) with and without generalization." | 2.41 | Gabapentin: a unique anti-epileptic agent. ( Dougherty, JA; Rhoney, DH, 2001) |
| "Gabapentin, which has been approved for add-on therapy of focal seizures, is increasingly used for treatment of neuropathic pain." | 2.41 | [Gabapentin for therapy of neuropathic pain]. ( Block, F, 2001) |
| "Gabapentin proved to be a significantly better analgesic than placebo, was well tolerated in the elderly population, and had a significant positive impact on several subjective and objective outcome measures." | 2.40 | Gabapentin: a new tool in the treatment of neuropathic pain. ( Harden, RN, 1999) |
| "127 patients, aged 18-70 years, who had neuropathic pain related to spinal cord injury (SCI) and disease duration of at least 12 months." | 1.91 | Misuse of gabapentinoids (pregabalin and gabapentin) in patients with neuropathic pain related to spinal cord injury. ( Akıncı, MG; Altas, EU; Konak, HE; Onat, SS; Polat, CS, 2023) |
| "Gabapentin can treat neuropathic pain syndromes and has increasingly been prescribed to treat nociplastic pain." | 1.91 | Does gabapentin provide benefit for patients with knee OA? A benefit-harm and cost-effectiveness analysis. ( Bensen, GP; Collins, JE; Edwards, RR; Hunter, DJ; Katz, JN; Kostic, AM; Leifer, VP; Losina, E; Neogi, T; Paltiel, AD; Rogers, AC, 2023) |
| " Further research with more enrollment and longer study duration may help elucidate the appropriate dosing and potential associated side effects." | 1.91 | Case Series: Synergistic Effect of Gabapentin and Adjuvant Pregabalin in Neuropathic Pain. ( Chow, SP; Donelenko, S; Stevens, S; Tran, S, 2023) |
| "Chronic pain is an enormous public health concern, and its treatment is still an unmet medical need." | 1.91 | Ketoprofen, lysine and gabapentin co-crystal magnifies synergistic efficacy and tolerability of the constituent drugs: Pre-clinical evidences towards an innovative therapeutic approach for neuroinflammatory pain. ( Allegretti, M; Aramini, A; Bianchini, G; Boccella, S; Bordignon, S; Brandolini, L; Canestrari, D; Castelli, V; Chierotti, MR; Cimini, A; Cocchiaro, P; d'Angelo, M; d'Egidio, F; Dragani, MC; Lillini, S; Luongo, L; Maione, S; Mattioli, S; Novelli, R; Pacchiarotti, N; Palmerio, F; Tomassetti, M, 2023) |
| "Spinal cord injury (SCI)-induced neuropathic pain (SCI-NP) develops in up to 60 to 70% of people affected by traumatic SCI, leading to a major decline in quality of life and increased risk for depression, anxiety, and addiction." | 1.91 | Inhibition of T-Type Calcium Channels With TTA-P2 Reduces Chronic Neuropathic Pain Following Spinal Cord Injury in Rats. ( Gunaratna, K; Kaczocha, M; Lauzadis, J; Liu, H; Puopolo, M; Sipple, E, 2023) |
| " They were also excluded if they lacked sufficient information about how long or at what dosage they had been using the drug." | 1.91 | Abuse and addiction in gabapentinoid drug users for neuropathic pain. ( Aydin Özaslan, E; Kiliç, Z, 2023) |
| "Neuropathic pain was induced by spared nerve injury (SNI) of the sciatic nerve." | 1.72 | Heme oxygenase-1 in the spinal cord plays crucial roles in the analgesic effects of pregabalin and gabapentin in a spared nerve-injury mouse model. ( Godai, K; Moriyama, T, 2022) |
| "Gabapentin is a widely prescribed analgesic with increased popularity over recent years." | 1.72 | Gabapentin initiation in the inpatient setting: A characterization of prescribing. ( Covvey, JR; Jackson, S; Karuga, D; Knauss, G; Montepara, CA; Nemecek, BD; Rozic, M; Waterloo, M; Zimmerman, DE, 2022) |
| "In the 182 patients with chronic pain, those receiving combination therapy were more likely to respond than those taking AC alone (35." | 1.72 | Does gabapentin impact response to anticholinergics for overactive bladder? ( Alfahmy, A; Dao, A; Mitchell, D; Roberts, K; Sheyn, D, 2022) |
| "The etiology of neuropathic pain is complex, and the patients are distressed." | 1.72 | Antagonistic Effect and Mechanism of Gabapentin on Neuropathic Pain in Rats through P38 MAPK Signaling Pathway. ( Chu, X; Huang, L; Jin, Q; Li, W, 2022) |
| "Neuropathic pain affects 7-10% of the adult population." | 1.72 | Development of a PET radioligand for α2δ-1 subunit of calcium channels for imaging neuropathic pain. ( Andrews, N; Belov, V; Brugarolas, P; Sun, Y; Takahashi, K; Woolf, CJ; Zhou, YP, 2022) |
| "Early treatment of herpes zoster neuralgia is of great significance to reduce the incidence of PHN." | 1.72 | Effective treatment of high-voltage pulsed radiofrequency combined with oxygen-ozone injection in acute zoster neuralgia. ( Du, HY; Jia, LL; Li, LM; Yu, WL; Zhang, ZL; Zheng, BS, 2022) |
| "Chronic neuropathic pain (CNP) after burn injury to the hand/upper extremity is relatively common, but not well described in the literature." | 1.62 | Chronic Neuropathic Pain Following Hand Burns: Etiology, Treatment, and Long-Term Outcomes. ( Dellon, AL; Hultman, CS; Klifto, KM; Lifchez, SD; Yesantharao, PS, 2021) |
| "In behavioral studies, mechanical allodynia was induced by intraplantar injection of cisplatin (40 μg/paw) in Sprague Dawley rats, and behavioral assessments were made 24 h after injection." | 1.62 | Involvement of selective GABA-A receptor subtypes in amelioration of cisplatin-induced neuropathic pain by 2'-chloro-6-methyl flavone (2'-Cl-6MF). ( Abdelhalim, A; Ahmad, W; Al-Harrasi, A; Altaf, N; Ghaffar, R; Halim, SA; Karim, N; Khan, A; Khan, I, 2021) |
| "Neuropathic pain is a chronic debilitating condition caused by injury or disease of the nerves of the somatosensory system." | 1.62 | Synergistic interaction between trazodone and gabapentin in rodent models of neuropathic pain. ( Amato, A; Di Giorgio, FP; di Matteo, A; Durando, L; Garrone, B; Milanese, C; Pistillo, L; Tongiani, S, 2021) |
| "Gabapentinoid misuse was defined as ≥ 3 claims exceeding daily doses of 3600 mg for gabapentin and 600 mg for pregabalin." | 1.62 | Prevalence of and Factors Associated with Gabapentinoid Use and Misuse Among Texas Medicaid Recipients. ( Barner, JC; Evoy, KE; Ibiloye, EA; Lawson, KA; Peckham, AM; Rascati, KL, 2021) |
| "Gabapentin (GBP) is an FDA-approved drug for the treatment of partial and secondary generalized seizures, apart from being used for diabetic neuropathic pain." | 1.62 | In-Silico Validation and Fabrication of Matrix Diffusion-Based Polymeric Transdermal Patches for Repurposing Gabapentin Hydrochloride in Neuropathic Pain. ( Agarwal, S; Agarwal, V; Kaur, H; Kaur, R; Pancham, P; Singh, M, 2021) |
| "Gabapentin (GBP) is an established drug that has been used in the management of symptoms of neuropathy but it is associated with unwanted side effects such as sedation and motor incoordination." | 1.62 | A novel gabapentin analogue assuages neuropathic pain response in chronic sciatic nerve constriction model in rats. ( Ahmad, N; Akbar, S; Amin, MU; Islam, NU; Khurram, M; Sewell, RDE; Shahid, M; Subhan, F; Ullah, I; Ullah, N; Ullah, R, 2021) |
| "Furthermore, the induced vulvodynia was validated by investigating the potentiation of a flinch response threshold, upon topical application and systemic administration of gabapentin, a commonly used medication for treating neuropathic pain." | 1.62 | Chemotherapeutic Agent-Induced Vulvodynia, an Experimental Model. ( Jo, S; Murthy, SN; Rangappa, S; Repka, MA; Shankar, VK, 2021) |
| "Many patients with chronic pain conditions suffer from depression." | 1.62 | Dynamic Change of Endocannabinoid Signaling in the Medial Prefrontal Cortex Controls the Development of Depression After Neuropathic Pain. ( Chao, D; Feng, Y; Hillard, CJ; Hogan, QH; Mecca, CM; Pan, B; Pawela, CP; Rodriguez-Garcia, DM; Segel, I; Yu, G; Zhang, Z, 2021) |
| "Pre-treatment with modafinil prevented sensorimotor neuropathy by raising latencies, MNCV and excitation, reducing TRPA1, TNF-α and IL-1β levels." | 1.56 | The protective effect of modafinil on vincristine-induced peripheral neuropathy in rats: A possible role for TRPA1 receptors. ( Abdollahi, A; Amirkhanloo, F; Dehpour, AR; Karimi, G; Roohbakhsh, A; Yousefi-Manesh, H, 2020) |
| "A frail 85-year-old woman with chronic neuropathic pain after hip surgery, not responding to treatment with acetaminophen and morphine patches." | 1.56 | [Whether or not to use gabapentinoids in adults with chronic neuropathic pain]. ( El Houssein, L; Hollmann, MW; Kallewaard, J; Steegers, MAH; van Poelgeest, EP; Wartenberg, HCH, 2020) |
| "Canine neuropathic pain (NeuP) has been poorly investigated." | 1.56 | Pain burden, sensory profile and inflammatory cytokines of dogs with naturally-occurring neuropathic pain treated with gabapentin alone or with meloxicam. ( Auger, JP; Beauchamp, G; Evangelista, MC; Ruel, HLM; Segura, M; Steagall, PV; Watanabe, R, 2020) |
| "Gabapentin has antihyperalgesic action, decreasing central sensitization in neuropathic pain models; this effect depends on the mobilization of endogenous pain control pathways." | 1.56 | Role of the endocannabinoid system on the antihyperalgesic action of gabapentin in animal model of neuropathic pain induced by partial sciatic nerve ligation. ( Buffon, AC; Heymanns, AC; Horewicz, VV; Javornik, MA; Martins, DF; Piovezan, AP; Salm, DC, 2020) |
| "A 23-year-old woman diagnosed with type 1 diabetes mellitus in 2011 came to our outpatient office because of an inability to walk correctly." | 1.56 | Treatment-induced diabetes neuropathy: description of singular clinical signs to reach a prompt diagnosis. ( Cano-Megías, M; Cortés-Berdonces, M; Guisado Vasco, P; Llanero-Luque, M, 2020) |
| "Gabapentin gel (10% w/w) was applied three-times daily on the hind paws while in a concurrent systemic study, gabapentin was administered daily (75 mg/kg, intraperitoneally) for 4 weeks." | 1.51 | Efficacy of a topical gabapentin gel in a cisplatin paradigm of chemotherapy-induced peripheral neuropathy. ( Ahmad, N; Sewell, RDE; Shahid, M; Subhan, F, 2019) |
| " Different methods for reporting adverse events across trials or across sources for a single trial may produce inconsistent information about the adverse events associated with interventions." | 1.51 | Opportunities for selective reporting of harms in randomized clinical trials: Selection criteria for non-systematic adverse events. ( Canner, JK; Dickersin, K; Fusco, N; Hong, H; Li, T; Mayo-Wilson, E, 2019) |
| "Chronic neuropathic pain following traumatic brachial plexus injury could be successfully managed by chemical neurolysis and oral gabapentin." | 1.51 | Management of neuropathic pain following traumatic brachial plexus injury with neurolysis and oral gabapentin: A case report. ( Aaron, OI; Adetoye, AO; Orimolade, EA; P Adetifa, KA, 2019) |
| "Tramadol was 1." | 1.51 | Interleukin-1beta in synergism gabapentin with tramadol in murine model of diabetic neuropathy. ( Miranda, HF; Noriega, V; Poblete, P; Prieto, JC; Sierralta, F; Zepeda, RJ, 2019) |
| "Sleep quality, chronotype, daytime sleepiness, neuropathic pain severity and interference were assessed based on questionnaires." | 1.51 | Actigraphy-based evaluation of sleep quality and physical activity in individuals with spinal cord injury. ( Albu, S; Forner-Cordero, A; Umemura, G, 2019) |
| "Gabapentin has analgesic efficacy for neuropathic pain and is increasingly used in burn care." | 1.51 | The Effects of Early Neuropathic Pain Control With Gabapentin on Long-Term Chronic Pain and Itch in Burn Patients. ( Carrougher, GJ; Gibran, NS; Kneib, CJ; Mandell, SP; Muffley, LA; Sibbett, SH, 2019) |
| "Sinomenine can enhance the efficacy of gabapentin or ligustrazine hydrochloride in rodent models of peripheral or central neuropathic pain, without introducing tolerance or other notable side effects." | 1.51 | Sinomenine facilitates the efficacy of gabapentin or ligustrazine hydrochloride in animal models of neuropathic pain. ( Gao, T; Jiang, JD; Li, T; Shi, T; Wiesenfeld-Hallin, Z; Xu, XJ, 2019) |
| "Static and dynamic mechanical allodynia was evaluated using von Frey hair filaments and cotton buds, respectively." | 1.51 | Attenuation of vincristine-induced neuropathy by synthetic cyclohexenone-functionalized derivative in mice model. ( Ali, G; Khan, J; Khan, R; Ullah, R; Ullah, S, 2019) |
| "Neuropathic pain is among the most common and difficult-to-treat types of chronic pain and is associated with sodium channel malfunction." | 1.48 | Effects of ralfinamide in models of nerve injury and chemotherapy-induced neuropathic pain. ( Liang, X; Su, R; Yu, G, 2018) |
| "Left sciatic nerve ligation was used as neuropathic pain model." | 1.48 | Efficacy and safety of combined low doses of either diclofenac or celecoxib with gabapentin versus their single high dose in treatment of neuropathic pain in rats. ( Abdelwahab, S; Abdelzaher, WY; Ibrahim, MA; Rofaeil, RR, 2018) |
| "Von Frey filaments were used to assess tactile allodynia." | 1.48 | Evaluation of the neonatal streptozotocin model of diabetes in rats: Evidence for a model of neuropathic pain. ( Barragán-Iglesias, P; Delgado-Lezama, R; Granados-Soto, V; Hong, E; Loeza-Alcocer, E; Oidor-Chan, VH; Pineda-Farias, JB; Price, TJ; Salinas-Abarca, AB; Sánchez-Mendoza, A; Velazquez-Lagunas, I, 2018) |
| "Neuropathic pain was the most common indication (33." | 1.48 | Patterns of pain medication use in older individuals with cardiovascular disease. ( Dimassi, H; Kabbara, WK; Sheikh-Taha, M, 2018) |
| "To analyze the cost of peripheral neuropathic pain (PNP) treatment with pregabalin or gabapentin at therapeutic doses in routine clinical practice." | 1.48 | Cost of treating peripheral neuropathic pain with pregabalin or gabapentin at therapeutic doses in routine practice. ( Navarro-Artieda, R; Perez-Paramo, M; Rejas-Gutiérrez, J; Sicras-Mainar, A, 2018) |
| " Nine adverse drug reactions, mostly mild, nonserious, and nonpreventable, were reported." | 1.48 | An Evaluation of Efficacy and Safety of Commonly Prescribed Drugs and Effect of These Drugs on Quality of Sleep in Patients Suffering From Zoster-Associated Pain. ( Desai, CK; Desai, MK; Kapadia, JD; Nayak, MK; Shah, BJ, 2018) |
| "Our findings reveal that neuropathic pain-related cognitive impairments in male mice are correlated to bilateral morphological changes in PV interneurons and layer 5/6 IL pyramidal neuron AIS." | 1.48 | Neuropathic Pain Creates an Enduring Prefrontal Cortex Dysfunction Corrected by the Type II Diabetic Drug Metformin But Not by Gabapentin. ( Ahmad, A; Kroener, S; Mejia, G; Mwirigi, J; Pradhan, G; Price, T; Shiers, S, 2018) |
| "Neuropathic pain is associated with several conditions such as surgery, cancer, and diabetes and can be induced experimentally." | 1.48 | Synergism between gabapentin-tramadol in experimental diabetic neuropathic pain. ( Aranda, N; Miranda, HF; Noriega, V; Poblete, P; Prieto, JC; Sierralta, F, 2018) |
| "Compound 10 exhibited diabetic neuropathic pain-alleviating effects in a streptozotocin-induced peripheral diabetic neuropathy (PDN) model." | 1.46 | Synthesis and diabetic neuropathic pain-alleviating effects of 2N-(pyrazol-3-yl)methylbenzo[d]isothiazole-1,1-dioxide derivatives. ( Choi, YJ; Hong, JR; Keum, G; Nam, G, 2017) |
| "Neuropathic pain is a debilitating pathological condition that is poorly understood." | 1.46 | Neuropathic pain-induced enhancement of spontaneous and pain-evoked neuronal activity in the periaqueductal gray that is attenuated by gabapentin. ( Faingold, CL; Premkumar, LS; Samineni, VK, 2017) |
| "A distinct acute, severe form of neuropathic pain, called insulin neuritis or treatment-induced painful neuropathy of diabetes (TIND), may also occur shortly after initiation of intensive glycemic control, with an incidence rate of up to 10." | 1.46 | Murine model and mechanisms of treatment-induced painful diabetic neuropathy. ( Anaya, CJ; Enriquez, C; Jolivalt, CG; Marquez, A; Nicodemus, JM, 2017) |
| " Patients' demographic and clinical characteristics, resource utilization data and adverse drug reactions (ADRs) as described in the leaflet were extracted." | 1.46 | Characteristics, resource utilization and safety profile of patients prescribed with neuropathic pain treatments: a real-world evidence study on general practices in Europe - the role of the lidocaine 5% medicated plaster. ( Katz, P; Liedgens, H; Pegoraro, V, 2017) |
| " We report on a case of a 31 year old female who presented to the emergency department with unilateral leg pain, weakness, and swelling after increasingly titrating her Gabapentin dosage over three weeks." | 1.46 | Radiologic Findings in Gabapentin-Induced Myositis. ( Chang, DR; Coupal, TM; Munk, PL; Ouellette, HA; Pennycooke, K, 2017) |
| "Compared with nociceptive pain, neuropathic pain is a challenging diagnosis to make and successfully treat in children with cancer." | 1.46 | Very-Low-Dose Methadone To Treat Refractory Neuropathic Pain in Children with Cancer. ( Bruera, E; Madden, K, 2017) |
| "Haloperidol (HAL) is a compound that shows a high affinity with these receptors, acting as an antagonist." | 1.46 | Haloperidol Decreases Hyperalgesia and Allodynia Induced by Chronic Constriction Injury. ( Espinosa-Juárez, JV; Jaramillo-Morales, OA; López-Muñoz, FJ, 2017) |
| "Gabapentin (GBP) is a first-line therapy for neuropathic pain, but its mechanisms and sites of action remain uncertain." | 1.46 | Multiple sites and actions of gabapentin-induced relief of ongoing experimental neuropathic pain. ( Bannister, K; Dickenson, AH; King, T; Navratilova, E; Oyarzo, J; Porreca, F; Qu, C; Xie, JY, 2017) |
| "Gabapentin (GBP) is an effective analgesic for neuropathic pain conditions but its clinical efficacy in cisplatin-induced neuropathic pain (CINP) is limited, in addition to generating unwanted side-effects." | 1.46 | Gabapentin and its salicylaldehyde derivative alleviate allodynia and hypoalgesia in a cisplatin-induced neuropathic pain model. ( Ahmad, N; Islam, NU; Rahman, FU; Sewell, RDE; Shahid, M; Subhan, F, 2017) |
| "Here we report a case of possible small fiber neuropathy associated with hantavirus infection, in a patient who survived HCPS." | 1.46 | A neuropathic pain syndrome associated with hantavirus infection. ( Anderson, D; Beecher, G; Bridgland, L; Power, C; Zochodne, DW, 2017) |
| "The rat model of neuropathic pain was successfully established." | 1.46 | [Effects of HCN2 in the development of peripheral neuropathic pain in rats]. ( Fu, B; Huang, T; Liu, SJ; Wang, B; Wang, J; Weng, XC, 2017) |
| "Treatment with gabapentin, but not amitriptyline, was associated with a complete attenuation of hind paw mechanical hypersensitivity observed with indinavir treatment." | 1.46 | A rodent model of HIV protease inhibitor indinavir induced peripheral neuropathy. ( Bennett, DLH; Calvo, M; Huang, W; Pheby, T; Rice, ASC, 2017) |
| "CFA-induced hyperalgesia and sensitivity to morphine (0." | 1.46 | Vendor-derived differences in injury-induced pain phenotype and pharmacology of Sprague-Dawley rats: Does it matter? ( Bjerrum, OJ; Heegaard, AM; Hestehave, S; Jeggo, RD; Kristensen, PJ; Munro, G, 2017) |
| "Chronic pain is a multifactorial disease comprised of both inflammatory and neuropathic components that affect ∼20% of the world's population." | 1.46 | sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain. ( Bialer, M; Brennan, KC; Devor, M; Kaufmann, D; Smith, MD; West, PJ; White, HS; Yagen, B, 2017) |
| "Using 3 rat models of neuropathic pain of toxic (oxaliplatin/OXA), metabolic (streptozocin/STZ), and traumatic (sciatic nerve ligation/CCI [chronic constriction nerve injury]) etiologies, we investigated the antihypersensitivity effect of acute and repeated agomelatine administration." | 1.46 | Agomelatine: a new opportunity to reduce neuropathic pain-preclinical evidence. ( Authier, N; Bertrand, M; Chapuy, E; Chenaf, C; Courteix, C; Eschalier, A; Gabriel, C; Libert, F; Marchand, F; Mocaër, E, 2017) |
| "Donepezil was started at 3-5 mg/day upon experiencing gabapentinoid-induced somnolence." | 1.46 | Donepezil, an Acetylcholinesterase Inhibitor, Can Attenuate Gabapentinoid-Induced Somnolence in Patients with Neuropathic Pain: A Retrospective Chart Review. ( Abe, H; Hozumi, J; Ikegami, K; Inoue, R; Kawahara, K; Kogure, T; Sumitani, M; Yamada, Y, 2017) |
| "Among them, 9a and 9b exhibited neuropathic pain alleviation effects in mechanical and cold allodynia induced in the SNL rat model." | 1.43 | Synthesis and T-type calcium channel-blocking effects of aryl(1,5-disubstituted-pyrazol-3-yl)methyl sulfonamides for neuropathic pain treatment. ( Chung, H; Keum, G; Kim, JH; Nam, G, 2016) |
| "The Dunning rat model of prostate cancer was used." | 1.43 | Gabapentin, an Analgesic Used Against Cancer-Associated Neuropathic Pain: Effects on Prostate Cancer Progression in an In Vivo Rat Model. ( Altun, S; Bugan, I; Djamgoz, MB; Karagoz, Z, 2016) |
| "Central poststroke pain is a neuropathic pain syndrome that can occur from pathology of the brain." | 1.43 | A Medication Combination for the Treatment of Central Poststroke Pain via the Adjuvant Use of Prednisone With Gabapentin: A Case Report. ( Batlle, L; Irwin, R; Mattie, R, 2016) |
| "The pharmacotherapy for neuropathic pain includes gabapentin and tramadol, but these are only partially effective when given alone." | 1.43 | Antinociceptive Interaction of Tramadol with Gabapentin in Experimental Mononeuropathic Pain. ( Aranda, N; Castillo, R; Miranda, HF; Noriega, V; Prieto, JC; Sierralta, F; Zanetta, P, 2016) |
| "Gabapentin is a good alternative therapeutic option to anesthetic blockade." | 1.43 | Auriculotemporal Neuralgia: Eight New Cases Report. ( Cuadrado, ML; de la Cruz, C; Garcia-Ptacek, S; Guerrero, AL; Porta-Etessam, J; Ruiz, M, 2016) |
| "The treatment with gabapentin at an average dose of 1,135 mg for 14 weeks reduced pain in 80% of the patients (p < 0." | 1.43 | [Postmastectomy pain syndrome in our region: characteristics, treatment, and experience with gabapentin]. ( de Miguel-Jimeno, JM; Forner-Cordero, I; Matute-Tobias, B; Zabalza-Azparren, M, 2016) |
| "Preclinical Research Neuropathic pain is particularly difficult to treat because of its diverse etiologies and underlying pathophysiological mechanisms." | 1.43 | Antinociceptive Interactions Between Meloxicam and Gabapentin in Neuropathic Pain Depend on the Ratio used in Combination in Rats. ( Corona-Ramos, JN; Espinosa-Juárez, JV; Jaramillo-Morales, OA; López-Muñoz, FJ; Medina-López, JR, 2016) |
| "The development of hind paw mechanical allodynia was measured after BCAO using the von Frey test." | 1.43 | Effects of Adjuvant Analgesics on Cerebral Ischemia-Induced Mechanical Allodynia. ( Harada, S; Matsuura, W; Tokuyama, S, 2016) |
| "After MPNL, mechanical allodynia was established, and mice quickly recovered from the surgery without any significant motor impairment." | 1.43 | Medial plantar nerve ligation as a novel model of neuropathic pain in mice: pharmacological and molecular characterization. ( Alves-Filho, JC; Bassi, GS; Bozzo, TA; Cunha, FQ; Cunha, TM; Ferreira, SH; Kusuda, R; Sant'Anna, MB; Souza, GR, 2016) |
| "Gabapentin (Gap) relieves neuropathic pain, but it has several adverse effects as well." | 1.43 | Vitamin C enhances the analgesic effect of gabapentin on rats with neuropathic pain. ( Huang, Y; Li, R; Ma, C; Shen, L; Yu, X, 2016) |
| " Dose-response curves (DRC) and isobolographic analysis were used to confirm their synergistic antihyperalgesic and anti-allodynic responses in a rat neuropathic pain model involving chronic constriction injury of the sciatic nerve and in von Frey and acetone tests." | 1.43 | The Antinociceptive Effects of Tramadol and/or Gabapentin on Rat Neuropathic Pain Induced by a Chronic Constriction Injury. ( Corona-Ramos, JN; De la O-Arciniega, M; Déciga-Campos, M; Domínguez-Ramírez, AM; Espinosa-Juárez, JV; Jaramillo-Morales, OA; López-Muñoz, FJ; Medina-López, JR, 2016) |
| "Cathepsin S inhibitors attenuate mechanical allodynia in preclinical neuropathic pain models." | 1.43 | Selective Cathepsin S Inhibition with MIV-247 Attenuates Mechanical Allodynia and Enhances the Antiallodynic Effects of Gabapentin and Pregabalin in a Mouse Model of Neuropathic Pain. ( Classon, B; Edenius, C; Grabowska, U; Henderson, I; Hewitt, E; Lindström, E; Malcangio, M; Pitcher, T; Rizoska, B; Sahlberg, BL; Tunblad, K, 2016) |
| "Neuropathic pain is a severe and unbearable condition which arises due to activation of peripheral nociceptors after tissue damage, neuropathic pain is caused from anomalous physiology of central or peripheral nervous system and it may not be related to the ongoing tissue damage or inflammation." | 1.43 | Potential Contribution of Antioxidant Mechanism in the Defensive Effect of Lycopene Against Partial Sciatic Nerve Ligation Induced Behavioral, Biochemical and Histopathological Modification in Wistar Rats. ( Goel, R; Tyagi, N, 2016) |
| "Robust allodynia was observed in all three ligation groups." | 1.42 | Ligation of mouse L4 and L5 spinal nerves produces robust allodynia without major motor function deficit. ( Baker, KB; Lanthorn, TH; Mason, S; Rajan, I; Savelieva, KV; Vogel, P; Ye, GL, 2015) |
| "The ongoing use of gabapentin for neuropathic pain was primarily driven by the perception that it was a safe, non-addictive drug with few drug interactions, by possible similarities between the physiology of chronic pain and other neurological conditions, by the well-established clinical precedent of using antiepileptic drugs in pain management, and by the lack of alternative options available in the market." | 1.42 | Evidence, regulation and 'rational' prescribing: the case of gabapentin for neuropathic pain. ( Ghinea, N; Kerridge, I; Lipworth, W, 2015) |
| "Gabapentin was effective in transiently reversing mechanical allodynia in those mice with lowered thresholds." | 1.42 | Differences in cisplatin-induced mechanical allodynia in male and female mice. ( Corr, M; Woller, SA; Yaksh, TL, 2015) |
| "A hallmark of peripheral neuropathic pain (PNP) is chronic spontaneous pain and/or hypersensitivity to normally painful stimuli (hyperalgesia) or normally nonpainful stimuli (allodynia)." | 1.42 | Increased expression of HCN2 channel protein in L4 dorsal root ganglion neurons following axotomy of L5- and inflammation of L4-spinal nerves in rats. ( Al Otaibi, M; Djouhri, L; Sathish, J; Smith, T, 2015) |
| "Neuropathic vulvodynia is a state of vulval discomfort characterized by a burning sensation, diffuse pain, pruritus or rawness with an acute or chronic onset." | 1.42 | A streptozotocin-induced diabetic neuropathic pain model for static or dynamic mechanical allodynia and vulvodynia: validation using topical and systemic gabapentin. ( Abbas, M; Ali, G; Sewell, RD; Shahid, M; Subhan, F; Zeb, J, 2015) |
| "Neuropathic pain is a prevalent and distressing problem faced by people with life-limiting illness that is often difficult to palliate." | 1.42 | Routine prescribing of gabapentin or pregabalin in supportive and palliative care: what are the comparative performances of the medications in a palliative care population? ( Clark, K; Currow, DC; Doogue, M; Lovell, M; Quinn, SJ; Sanderson, C, 2015) |
| "Gabapentin (GBP) is an anti-convulsive drug often used as analgesic to control neuropathic pain." | 1.42 | Gabapentin attenuates neuropathic pain and improves nerve myelination after chronic sciatic constriction in rats. ( Araújo, CV; Brito, GAC; Câmara, CC; de Sousa, KKO; Martinez, AMB; Mendonça, FE; Mietto, BS; Oriá, RB; Raposo, RDS; Vale, ML, 2015) |
| " Since, 5-HT6 antagonists improved the effectiveness of gabapentinoids, reduction in the dosage and frequency of gabapentinoids treatment may reduce the side effects." | 1.42 | 5-HT6 receptor antagonist attenuates the memory deficits associated with neuropathic pain and improves the efficacy of gabapentinoids. ( Babu, VA; Bhyrapuneni, G; Goura, V; Jayarajan, P; Nirogi, R; Shinde, A; Yathavakilla, S, 2015) |
| "Ambroxol acts as a strong local anaesthetic and preferentially inhibits the nociceptively relevant sodium channel subtype Nav 1." | 1.42 | Topical ambroxol for the treatment of neuropathic pain. An initial clinical observation. ( Kern, KU; Weiser, T, 2015) |
| "In addition, PLSN-induced mechanical and thermal hyperalgesia was prevented by systemic (i." | 1.40 | The role of keratinocyte-derived chemokine (KC) on hyperalgesia caused by peripheral nerve injury in mice. ( Calixto, JB; Costa, R; Manjavachi, MN; Quintão, NL, 2014) |
| " Time-course data for the dose-response effects were analyzed using two-way analysis of variance and the posthoc Tukey-Kramer multiple-comparison test." | 1.40 | Antinociceptive effects of mirtazapine, pregabalin, and gabapentin after chronic constriction injury of the infraorbital nerve in rats. ( Hashimoto, R; Hosokawa, K; Mashimo, T; Nakae, A; Nakai, K, 2014) |
| "Gabapentin has shown to be effective in animals and humans with acute postoperative and chronic pain." | 1.40 | Gabapentin increases extracellular glutamatergic level in the locus coeruleus via astroglial glutamate transporter-dependent mechanisms. ( Eisenach, JC; Hayashida, K; Severino, AL; Suto, T, 2014) |
| "Koumine treatment of diabetic rats decreased neuropathic pain behavior as early as after the first administration." | 1.40 | Anti-allodynic and neuroprotective effects of koumine, a Benth alkaloid, in a rat model of diabetic neuropathy. ( Huang, HH; Ling, Q; Liu, M; Wu, MX; Xu, Y; Yang, J; Yu, CX, 2014) |
| "Gabapentin, commonly used to treat neuropathic pain, produced increased NAc DA in rats with SNL but not in animals with incisional, injury." | 1.40 | Activation of mesocorticolimbic reward circuits for assessment of relief of ongoing pain: a potential biomarker of efficacy. ( Becerra, L; Borsook, D; Navratilova, E; Ossipov, MH; Patwardhan, A; Porreca, F; Qu, C; Xie, JY, 2014) |
| "Neuropathic pain is currently an insufficiently treated clinical condition." | 1.40 | Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy. ( Hammock, BD; Inceoglu, B; Wagner, K; Yang, J, 2014) |
| "Although mouse models of experimental autoimmune encephalomyelitis (EAE) have provided insight on the pathobiology of MS-induced neuropathic pain, concurrent severe motor impairments confound quantitative assessment of pain behaviors over the disease course." | 1.40 | Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods. ( Khan, N; Smith, MT; Woodruff, TM, 2014) |
| "Occipital neuralgia is a pain in the distribution of the occipital nerves, accompanied by hypersensitivity to touch in the corresponding territory." | 1.39 | [Occipital neuralgia: clinical and therapeutic characteristics of a series of 14 patients]. ( Barón, J; Guerrero-Peral, ÁL; Herrero-Velázquez, S; Mulero, P; Muñoz, I; Pedraza, MI; Rodríguez, C; Ruiz, M, 2013) |
| "Lacosamide is a third-generation antiepileptic drug that has been proven to be effective, safe and with few side effects." | 1.39 | [Lacosamide as an alternative in the treatment of post-surgery neuropathic pain in an allergic patient]. ( Márquez-Rivas, J; Mayorga-Buiza, MJ; Monge-Márquez, ME; Rivero-Garvía, M, 2013) |
| "Gabapentin (GBP) is an anti-convulsive drug often used as analgesic to control neuropathic pain." | 1.39 | Oral gabapentin treatment accentuates nerve and peripheral inflammatory responses following experimental nerve constriction in Wistar rats. ( Araújo, CV; Barbosa, AL; Brito, GA; Câmara, CC; Costa, CM; da Silva, AP; Gomes, AS; Oriá, RB; Ramos, HF; Ribeiro, RA; Vale, ML, 2013) |
| "Mechanical allodynia in paclitaxel-treated Sprague Dawley (SD) rats was measured using a dynamic plantar aesthesiometer before and after treatment with E139 (10 and 20 mg/kg) or its vehicle for four consecutive days from day 7 after first administration of paclitaxel (16 mg/kg on two alternate days)." | 1.39 | The anticonvulsant enaminone E139 attenuates paclitaxel-induced neuropathic pain in rodents. ( Edafiogho, IO; Masocha, W; Thangamani, D, 2013) |
| "Its use to treat lingual neuralgia has not to our knowledge been described previously, and we report a case." | 1.38 | Pulsed radiofrequency modulation for lingual neuralgia. ( Hussain, R; Jamshed, A; Khan, MZ; Rehman, SU, 2012) |
| "The L5 spinal nerve ligation induced tactile allodynia, an increase of CD11b expression, and an increase in the protein expression level of the voltage-dependent Ca(2+) channel α(2)/δ-1 subunit in the spinal dorsal horn on the injured side." | 1.38 | Spinal mechanism underlying the antiallodynic effect of gabapentin studied in the mouse spinal nerve ligation model. ( Adachi-Akahane, S; Ito, M; Kuroda, M; Morimoto, S; Oda, S; Sugiyama, A, 2012) |
| "It has been suggested that peripheral neuropathic pain (PNP) may affect up to 3% of the general population." | 1.38 | Pain alleviation and patient-reported health outcomes following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain in routine medical practice. ( Masramón, X; Navarro, A; Pérez, C; Rejas, J; Saldaña, MT, 2012) |
| "Mice exhibited spontaneous neuropathic pain behaviors, which were most obvious after ischemia for 5 h." | 1.38 | Patterns of nerve injury and neuropathic pain in ischemic neuropathy after ligation-reperfusion of femoral artery in mice. ( Chiang, HY; Hsieh, JH; Hsieh, ST; Lee, JE; Wang, KC, 2012) |
| "Neuropathic pain is a chronic pain condition that occurs and persists in a heterogeneous group of etiologically different diseases characterized by a primary lesion or dysfunction of the peripheral or central nervous system." | 1.37 | Discovery of molecules for the treatment of neuropathic pain: synthesis, antiallodynic and antihyperalgesic activities of 5-(4-nitrophenyl)furoic-2-acid hydrazones. ( Arjun, M; Menon, N; Semwal, A; Sriram, D; Yogeeswari, P, 2011) |
| "Many drugs approved for neuropathic pain engage spinal noradrenergic and cholinergic systems for analgesia." | 1.37 | A tropomyosine receptor kinase inhibitor blocks spinal neuroplasticity essential for the anti-hypersensitivity effects of gabapentin and clonidine in rats with peripheral nerve injury. ( Eisenach, JC; Hayashida, K, 2011) |
| "Mechanical allodynia was assessed by measuring the forepaw withdrawal threshold to von Frey filaments, and cold allodynia was evaluated by measuring the time spent in lifting or licking the forepaw after applying acetone to it." | 1.37 | A novel rat forelimb model of neuropathic pain produced by partial injury of the median and ulnar nerves. ( Back, SK; Eun, JS; Kim, MA; Na, HS; Yi, H, 2011) |
| "In a model of neuropathic pain, sciatic nerve ligation caused a marked decrease in the latency of paw withdrawal in response to a thermal stimulus only on the ipsilateral side." | 1.37 | Effects of gabapentin on brain hyperactivity related to pain and sleep disturbance under a neuropathic pain-like state using fMRI and brain wave analysis. ( Furuya, M; Hatakeyama, N; Horiuchi, H; Imai, S; Kinoshita, H; Kuzumaki, N; Matoba, M; Narita, M; Niikura, K; Senba, E; Suzuki, T; Takemura, Y; Tsukiyama, Y; Yamashita, A; Yamazaki, M; Yanase, M, 2011) |
| "Accordingly, we hypothesized that tactile allodynia post SCI is mediated by an upregulation of Ca(v)α2δ-1 in dorsal spinal cord." | 1.37 | Calcium channel alpha-2-delta-1 protein upregulation in dorsal spinal cord mediates spinal cord injury-induced neuropathic pain states. ( Boroujerdi, A; Kim, D; Luo, DZ; Sharp, K; Steward, O; Zeng, J, 2011) |
| "Improved cure rates for childhood acute lymphoblastic leukemia (ALL) over the past 2 decades have allowed greater attention to patients' quality of life." | 1.37 | Neuropathic pain during treatment for childhood acute lymphoblastic leukemia. ( Anghelescu, DL; Cheng, C; Faughnan, LG; Hankins, G; Hinds, PS; Jeha, S; Pauley, JL; Pei, D; Pui, CH; Relling, MV; Sandlund, JT, 2011) |
| "Three patients with cancer experienced severe side-effects after starting anti-neuropathic pain therapy." | 1.37 | [Pitfalls in the treatment of neuropathic pain in patients with cancer]. ( Engels, Y; Hekster, YA; Schalkwijk, A; Verhagen, CA; Vissers, KC, 2011) |
| "The gabapentin has beneficial effect in the FBSS associated neuropathic pain." | 1.37 | Beneficial response to gabapentin portraying with interval change of brain SPECT imaging in a case with failed back surgery syndrome. ( Chang, ST; Lai, MH; Lu, SC; Wu, YT, 2011) |
| "Gabapentin was identified in 7013 specimens (12." | 1.37 | Urine drug testing of chronic pain patients. IV. prevalence of gabapentin and pregabalin. ( Black, DL; Caplan, YH; Cone, EJ; Depriest, A; Heltsley, R; Robert, T, 2011) |
| "In rats with four ligatures, prominent mechanical allodynia and thermal hyperalgesia developed; these behavioral signs were not prominent in rats with two ligatures." | 1.37 | Pharmacological and behavioral characterization of the saphenous chronic constriction injury model of neuropathic pain in rats. ( Buldum, D; Gunduz, O; Guven, R; Oltulu, C; Ulugol, A, 2011) |
| "Patients suffering from neuropathic pain are difficult to treat and many methods are used to resolve this issue." | 1.37 | Biphasic effects of chronic intrathecal gabapentin administration on the expression of protein kinase C gamma in the spinal cord of neuropathic pain rats. ( Chung, SC; Liu, YC; Tsai, YC; Tseng, FL; Yeh, CY, 2011) |
| "Gabapentin has been widely and successfully used in the clinic for many neuropathic pain syndromes since last decade, however its analgesic mechanisms are still elusive." | 1.37 | Analgesic effect of gabapentin in a rat model for chronic constrictive injury. ( Huang, YG; Liu, W; Ma, LL; Yang, N; Zuo, PP, 2011) |
| "Current drugs for the treatment of seizure disorders, although effective in many patients, still suffer from a number of failures and are not effective in some forms of resistant epilepsies." | 1.36 | Novel KCNQ2/Q3 agonists as potential therapeutics for epilepsy and neuropathic pain. ( Amato, GS; Burns, JF; Eargle, CW; Fritch, PC; Harrison, W; Jones, L; McNaughton-Smith, G; Roeloffs, R; Wickenden, AD, 2010) |
| "Current clinical treatments for neuropathic pain include amitriptyline, a tricyclic antidepressant with mixed pharmacology that is also clinically reported to impair cognitive performance; and gabapentin, a compound that selectively interacts with alpha2delta-1 calcium channel subunits." | 1.36 | Treatments for neuropathic pain differentially affect delayed matching accuracy by macaques: effects of amitriptyline and gabapentin. ( Arneric, SP; Buccafusco, JJ; Snutch, TP; Terry, AV; Vazdarjanova, A, 2010) |
| "Gabapentin and clonidine were concomitantly administered in a fixed-dose ratio proportional to the predetermined ED(50) of these drugs, thereby obtaining a dose-response curve for the drug combination and its ED(50)." | 1.36 | Intrathecal gabapentin and clonidine synergistically inhibit allodynia in spinal nerve-ligated rats. ( Asada, A; Funao, T; Mori, T; Nishikawa, K; Yamama, Y, 2010) |
| " Single, parenteral dosing of donepezil (1, 1." | 1.36 | Low dose of donepezil improves gabapentin analgesia in the rat spared nerve injury model of neuropathic pain: single and multiple dosing studies. ( Andersen, LM; Bjerrum, OJ; Folkesson, A; Honoré, PH; Kristensen, P, 2010) |
| " The PWT in PSL mice was dose-dependently increased by intraperitoneal injection of gabapentin, but the anti-allodynic effects varied according to its dosing time." | 1.36 | Molecular basis for the dosing time-dependency of anti-allodynic effects of gabapentin in a mouse model of neuropathic pain. ( Hamamura, K; Inoue, K; Koyanagi, S; Kusunose, N; Matsunaga, N; Ohdo, S; Tsuda, M; Uchida, T; Yoshida, M, 2010) |
| "In both neuropathic pain models, rats exhibited mechanical hypersensitivity, whereas a significant increase in anxiety-like behaviour was observed only in CCI rats (time spent in open arms decreased significantly from 99+/-15." | 1.35 | Anxiety-like behaviour in rats with mononeuropathy is reduced by the analgesic drugs morphine and gabapentin. ( Arndt, K; Ceci, A; Doods, H; Roeska, K; Treede, RD, 2008) |
| "Neuropathic pain is commonly associated with affective disorders such as anxiety and depression." | 1.35 | Anxiety-like behaviour is attenuated by gabapentin, morphine and diazepam in a rodent model of HIV anti-retroviral-associated neuropathic pain. ( Blackbeard, J; Pheby, T; Rice, AS; Segerdahl, AR; Wallace, VC, 2008) |
| "Gabapentin was effective and well tolerated in the treatment of neuropathic pain in children." | 1.35 | [Gabapentin for neurophatic pain in children: a case report]. ( Dayioğlu, M; Reisli, R; Tuncer, S, 2008) |
| "Neuropathic pain was induced in male Sprague-Dawley rats by a surgical ligation of left L5 nerve." | 1.35 | Protective effects of gabapentin on allodynia and alpha 2 delta 1-subunit of voltage-dependent calcium channel in spinal nerve-ligated rats. ( Ahn, HJ; Bae, CD; Cho, HS; Choi, SJ; Gwak, MS; Hahm, TS; Kim, HS; Kim, JA; Lee, SM; Lim, SW; Sim, WS, 2009) |
| "gabapentin was studied by isobolographic analysis." | 1.35 | Antinociceptive effects of NCX-701 (nitro-paracetamol) in neuropathic rats: enhancement of antinociception by co-administration with gabapentin. ( Curros-Criado, MM; Herrero, JF, 2009) |
| "Both indomethacin and morphine were able to block or reverse thermal hyperalgesia and normalize gait in the CARR model." | 1.35 | Abnormal gait, due to inflammation but not nerve injury, reflects enhanced nociception in preclinical pain models. ( Cummons, TA; Harrison, JE; Leventhal, L; Lu, P; Piesla, MJ; Strassle, BW; Whiteside, GT, 2009) |
| "Gabapentin has been used effectively for neuropathic pain with mild side effects." | 1.35 | Gabapentin and sexual dysfunction: report of two cases. ( Dalal, A; Zhou, L, 2008) |
| " We used a repeated dosing paradigm because there are precedents showing that repeated drug exposure may be necessary to demonstrate analgesia in neuropathic pain models." | 1.34 | Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit. ( Bennett, GJ; Boroujerdi, A; Luo, ZD; Xiao, W, 2007) |
| "Animal models of neuropathic pain have enabled the identification of key pathophysiological changes occurring within nociceptive pathways as a result of injury, and serve an invaluable role for preclinical screening of novel analgesic candidates." | 1.34 | The importance of genetic background on pain behaviours and pharmacological sensitivity in the rat spared serve injury model of peripheral neuropathic pain. ( Bjerrum, OJ; Blackburn-Munro, G; Broløs, T; Jensen, DG; Rode, F; Thomsen, M, 2007) |
| "Gabapentin, which has been suggested as an adjuvant analgesic for neuropathic pain introduced orally, rapidly and significantly alleviated his pain and we could subsequently dispense with ketamine and mexiletine." | 1.34 | [Gabapentin mitigates neuropathic pain in cancer patients--a case report]. ( Okada, M; Shinjo, T, 2007) |
| "Gabapentin appeared to be a safe, effective, and economical treatment for neuropathic pain in this horse." | 1.34 | Gabapentin for the treatment of neuropathic pain in a pregnant horse. ( Davis, JL; Elce, Y; Posner, LP, 2007) |
| "Signs of allodynia also extended to the sciatic nerve territory." | 1.33 | Behavioral, pharmacological and molecular characterization of the saphenous nerve partial ligation: a new model of neuropathic pain. ( Beaulieu, P; Desbiens, K; Leblond, F; Pichette, V; Walczak, JS, 2005) |
| "Gabapentin is an anticonvulsant that successfully treats many neuropathic pain syndromes, although the mechanism of its antihyperalgesic action remains elusive." | 1.33 | Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate. ( Coderre, TJ; Kumar, N; Lefebvre, CD; Yu, JS, 2005) |
| "Carbamazepine (300 mg/d) was required for pain control." | 1.33 | Occipital neuralgia secondary to respiratory tract infection. ( Anagnostopoulou, S; Mourouzis, C; Rallis, G; Saranteas, T; Tesseromatis, C, 2005) |
| "Amitriptyline was the cheapest strategy, followed by carbamazepine, and both were equally beneficial." | 1.33 | Economic evaluation of oral treatments for neuropathic pain. ( Cepeda, MS; Farrar, JT, 2006) |
| "Four were cancer patients and one suffered from neuropathic pain in the neck (C3)." | 1.33 | Experience with gabapentin for neuropathic pain in adolescents: report of five cases. ( Butkovic, D; Mihovilovic-Novak, B; Toljan, S, 2006) |
| "Gabapentin was the most widely used AED (92% of all AED patients); amitriptyline was the most widely used TCA (79% of all TCA patients)." | 1.33 | Use of antiepileptics and tricyclic antidepressants in cancer patients with neuropathic pain. ( Berger, A; Dukes, E; Mercadante, S; Oster, G, 2006) |
| "The basis of the treatment of painful diabetic neuropathy is the use of drugs that block the transmission of pain (antineuritics) and a good metabolic control of underlying disease." | 1.33 | [Intensified insulin therapy plus antineuritic medication is more effective than antineuritics alone in painful diabetic neuropathy]. ( Bastías A, MJ; Olmos C, P; Toro C, L, 2006) |
| "Allodynia and hyperalgesia appeared on day 5 post-inoculation." | 1.31 | Pharmacological and immunohistochemical characterization of a mouse model of acute herpetic pain. ( Andoh, T; Kuraishi, Y; Nemoto, H; Nitta, M; Nojima, H; Shiraki, K; Takahata, H; Takasaki, I, 2000) |
| "Gabapentin (Neurontin) was then started with improvement at 1800 mg per day." | 1.31 | SUNCT syndrome responsive to gabapentin (Neurontin). ( Graff-Radford, SB, 2000) |
| "Many patients with neuropathic pain have coexistent sensory deficits." | 1.31 | Case reports - reversal of sensory deficit associated with pain relief after treatment with gabapentin. ( Chong, MS; Hanna, M; Smith, TE, 2002) |
| "Based on the observations of other authors, we used this drug in dosage varying between 900 and 1,200 mg/day, in three patients with neuropathic pain, of both central and peripheral origin, and in whom the usual treatments had been unsatisfactory or could not be tolerated because of side-effects." | 1.30 | [Treatment of neuropathic pain with gabapentin ++]. ( Sánchez-Valiente, S, 1998) |
| "The management of patients with neuropathic pain is challenging." | 1.30 | The anti-allodynic effects of amitriptyline, gabapentin, and lidocaine in a rat model of neuropathic pain. ( Abdi, S; Chung, JM; Lee, DH, 1998) |
| "Gabapentin was concluded to be an effective therapeutic option for neuralgia of the IXth cranial nerve before surgery." | 1.30 | [Use of gabapentin in glossopharyngeal neuralgia]. ( Esparcia Navarro, M; García Callejo, FJ; Marco Algarra, J; Martínez Beneyto, MP; Morant Ventura, A; Talamantes Escribá, F, 1999) |
| "Gabapentin is an anticonvulsant medication used recently as an effective adjuvant agent for treating neuropathic pain." | 1.30 | Using gabapentin to treat neuropathic pain. ( Hays, H; Woodroffe, MA, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 17 (3.61) | 18.2507 |
| 2000's | 122 (25.90) | 29.6817 |
| 2010's | 251 (53.29) | 24.3611 |
| 2020's | 81 (17.20) | 2.80 |
| Authors | Studies |
|---|---|
| Farina, C | 1 |
| Gagliardi, S | 1 |
| Ghelardini, C | 1 |
| Martinelli, M | 1 |
| Norcini, M | 1 |
| Parini, C | 1 |
| Petrillo, P | 1 |
| Ronzoni, S | 1 |
| Worm, K | 1 |
| Zhou, QJ | 1 |
| Saeui, CT | 1 |
| Green, RC | 1 |
| Cassel, JA | 1 |
| Stabley, GJ | 1 |
| DeHaven, RN | 1 |
| Conway-James, N | 1 |
| LaBuda, CJ | 1 |
| Koblish, M | 1 |
| Little, PJ | 1 |
| Dolle, RE | 1 |
| Fritch, PC | 1 |
| McNaughton-Smith, G | 1 |
| Amato, GS | 1 |
| Burns, JF | 1 |
| Eargle, CW | 1 |
| Roeloffs, R | 1 |
| Harrison, W | 1 |
| Jones, L | 1 |
| Wickenden, AD | 1 |
| Kam, YL | 1 |
| Rhee, HK | 1 |
| Rhim, H | 1 |
| Back, SK | 2 |
| Na, HS | 2 |
| Choo, HY | 1 |
| Yogeeswari, P | 2 |
| Menon, N | 1 |
| Semwal, A | 2 |
| Arjun, M | 1 |
| Sriram, D | 2 |
| Woo, HM | 1 |
| Lee, YS | 1 |
| Roh, EJ | 1 |
| Seo, SH | 3 |
| Song, CM | 1 |
| Chung, HJ | 1 |
| Pae, AN | 5 |
| Shin, KJ | 1 |
| Walls, TH | 1 |
| Grindrod, SC | 1 |
| Beraud, D | 1 |
| Zhang, L | 1 |
| Baheti, AR | 1 |
| Dakshanamurthy, S | 1 |
| Patel, MK | 1 |
| Brown, ML | 1 |
| MacArthur, LH | 1 |
| Shao, PP | 1 |
| Ye, F | 1 |
| Chakravarty, PK | 1 |
| Varughese, DJ | 1 |
| Herrington, JB | 1 |
| Dai, G | 1 |
| Bugianesi, RM | 1 |
| Haedo, RJ | 1 |
| Swensen, AM | 1 |
| Warren, VA | 2 |
| Smith, MM | 2 |
| Garcia, ML | 2 |
| McManus, OB | 1 |
| Lyons, KA | 2 |
| Li, X | 2 |
| Green, M | 2 |
| Jochnowitz, N | 2 |
| McGowan, E | 2 |
| Mistry, S | 1 |
| Sun, SY | 1 |
| Abbadie, C | 3 |
| Kaczorowski, GJ | 2 |
| Duffy, JL | 2 |
| Son, MH | 1 |
| Kim, JY | 2 |
| Lim, EJ | 2 |
| Baek, DJ | 2 |
| Choi, K | 2 |
| Lee, JK | 1 |
| Min, SJ | 3 |
| Cho, YS | 5 |
| Hoyt, SB | 1 |
| London, C | 1 |
| Felix, JP | 1 |
| Karanam, BV | 1 |
| Priest, BT | 1 |
| Thomas-Fowlkes, BS | 1 |
| Sharma, M | 1 |
| Samala, G | 1 |
| Gangadhar, M | 1 |
| Karthick, S | 1 |
| Mallipeddi, S | 1 |
| Wu, YJ | 1 |
| Conway, CM | 1 |
| Sun, LQ | 1 |
| Machet, F | 1 |
| Chen, J | 4 |
| Chen, P | 1 |
| He, H | 1 |
| Bourin, C | 1 |
| Calandra, V | 1 |
| Polino, JL | 1 |
| Davis, CD | 1 |
| Heman, K | 1 |
| Gribkoff, VK | 1 |
| Boissard, CG | 1 |
| Knox, RJ | 1 |
| Thompson, MW | 1 |
| Fitzpatrick, W | 1 |
| Weaver, D | 1 |
| Harden, DG | 1 |
| Natale, J | 1 |
| Dworetzky, SI | 1 |
| Starrett, JE | 1 |
| Cho, GH | 1 |
| Kim, T | 2 |
| Son, WS | 2 |
| Keum, G | 4 |
| Jeong, KS | 2 |
| Koh, HY | 1 |
| Lee, J | 5 |
| Nam, M | 1 |
| Kwak, J | 1 |
| Ko, MK | 1 |
| Huang, B | 2 |
| Zhang, F | 1 |
| Yu, G | 3 |
| Song, Y | 1 |
| Wang, X | 1 |
| Wang, M | 1 |
| Gong, Z | 1 |
| Su, R | 2 |
| Jia, Y | 1 |
| Kim, JH | 3 |
| Chung, H | 1 |
| Nam, G | 4 |
| Hong, JR | 2 |
| Choi, YJ | 1 |
| Choo, H | 1 |
| Rais, R | 1 |
| Vávra, J | 1 |
| Tichý, T | 1 |
| Dash, RP | 1 |
| Gadiano, AJ | 1 |
| Tenora, L | 1 |
| Monincová, L | 1 |
| Bařinka, C | 1 |
| Alt, J | 1 |
| Zimmermann, SC | 1 |
| Slusher, CE | 1 |
| Wu, Y | 1 |
| Wozniak, K | 1 |
| Majer, P | 1 |
| Tsukamoto, T | 1 |
| Slusher, BS | 1 |
| Lim, SM | 1 |
| Ann, J | 1 |
| Kim, HS | 2 |
| Thorat, SA | 1 |
| Kim, H | 1 |
| Ha, HJ | 1 |
| Kim, YH | 1 |
| Kim, M | 1 |
| Hwang, SW | 1 |
| Pearce, LV | 1 |
| Esch, TE | 1 |
| Turcios, NA | 1 |
| Blumberg, PM | 1 |
| Ramdas, V | 1 |
| Talwar, R | 1 |
| Kanoje, V | 1 |
| Loriya, RM | 1 |
| Banerjee, M | 1 |
| Patil, P | 1 |
| Joshi, AA | 1 |
| Datrange, L | 1 |
| Das, AK | 1 |
| Walke, DS | 1 |
| Kalhapure, V | 1 |
| Khan, T | 1 |
| Gote, G | 1 |
| Dhayagude, U | 1 |
| Deshpande, S | 1 |
| Shaikh, J | 1 |
| Chaure, G | 1 |
| Pal, RR | 1 |
| Parkale, S | 1 |
| Suravase, S | 1 |
| Bhoskar, S | 1 |
| Gupta, RV | 1 |
| Kalia, A | 1 |
| Yeshodharan, R | 1 |
| Azhar, M | 1 |
| Daler, J | 1 |
| Mali, V | 1 |
| Sharma, G | 1 |
| Kishore, A | 1 |
| Vyawahare, R | 1 |
| Agarwal, G | 1 |
| Pareek, H | 1 |
| Budhe, S | 1 |
| Nayak, A | 1 |
| Warude, D | 1 |
| Gupta, PK | 1 |
| Joshi, P | 1 |
| Joshi, S | 1 |
| Darekar, S | 1 |
| Pandey, D | 1 |
| Wagh, A | 1 |
| Nigade, PB | 1 |
| Mehta, M | 1 |
| Patil, V | 1 |
| Modi, D | 1 |
| Pawar, S | 1 |
| Verma, M | 1 |
| Singh, M | 3 |
| Das, S | 1 |
| Gundu, J | 1 |
| Nemmani, K | 1 |
| Bock, MG | 1 |
| Sharma, S | 1 |
| Bakhle, D | 1 |
| Kamboj, RK | 1 |
| Palle, VP | 1 |
| Peng, Y | 1 |
| Zhang, Q | 1 |
| Welsh, WJ | 1 |
| Belgi, A | 1 |
| Burnley, JV | 1 |
| MacRaild, CA | 1 |
| Chhabra, S | 1 |
| Elnahriry, KA | 1 |
| Robinson, SD | 1 |
| Gooding, SG | 1 |
| Tae, HS | 1 |
| Bartels, P | 1 |
| Sadeghi, M | 1 |
| Zhao, FY | 2 |
| Wei, H | 2 |
| Spanswick, D | 1 |
| Adams, DJ | 1 |
| Norton, RS | 1 |
| Robinson, AJ | 1 |
| Hartz, RA | 1 |
| Ahuja, VT | 1 |
| Nara, SJ | 2 |
| Kumar, CMV | 1 |
| Brown, JM | 1 |
| Bristow, LJ | 1 |
| Rajamani, R | 1 |
| Muckelbauer, JK | 1 |
| Camac, D | 1 |
| Kiefer, SE | 1 |
| Hunihan, L | 1 |
| Gulianello, M | 1 |
| Lewis, M | 1 |
| Easton, A | 1 |
| Lippy, JS | 1 |
| Surti, N | 1 |
| Pattipati, SN | 1 |
| Dokania, M | 1 |
| Elavazhagan, S | 1 |
| Dandapani, K | 2 |
| Hamman, BD | 1 |
| Allen, J | 1 |
| Kostich, W | 2 |
| Bronson, JJ | 1 |
| Macor, JE | 2 |
| Dzierba, CD | 1 |
| Jaiswal, S | 1 |
| Uniyal, A | 1 |
| Tiwari, V | 1 |
| Raja Ayyannan, S | 1 |
| Marchesi, N | 1 |
| Govoni, S | 1 |
| Allegri, M | 1 |
| Buapratoom, A | 1 |
| Wanasuntronwong, A | 1 |
| Khongsombat, O | 1 |
| Tantisira, MH | 1 |
| Godai, K | 1 |
| Moriyama, T | 1 |
| Partanen, M | 1 |
| Alberts, NM | 1 |
| Conklin, HM | 1 |
| Krull, KR | 1 |
| Pui, CH | 3 |
| Anghelescu, DA | 1 |
| Jacola, LM | 1 |
| Migeon, M | 1 |
| Yamada, T | 1 |
| Mitsuboshi, S | 1 |
| Makino, J | 1 |
| Suzuki, K | 1 |
| Nishihara, M | 1 |
| Neo, M | 1 |
| Mastrangelo, S | 1 |
| Rivetti, S | 1 |
| Triarico, S | 1 |
| Romano, A | 1 |
| Attinà, G | 1 |
| Maurizi, P | 1 |
| Ruggiero, A | 1 |
| Ozcan, S | 1 |
| Kelestemur, MM | 1 |
| Hekim, MG | 1 |
| Bulmus, O | 1 |
| Bulut, F | 1 |
| Bilgin, B | 1 |
| Canpolat, S | 1 |
| Ozcan, M | 1 |
| Althunian, TA | 1 |
| Alomran, MI | 1 |
| Alsagri, GM | 1 |
| Alrasheed, MM | 1 |
| Alshammari, TM | 1 |
| Polat, CS | 1 |
| Konak, HE | 1 |
| Akıncı, MG | 1 |
| Onat, SS | 1 |
| Altas, EU | 1 |
| Jiang, L | 1 |
| Xiong, Y | 1 |
| Cui, J | 1 |
| Alcántara-Montero, A | 1 |
| Pacheco-de Vasconcelos, SR | 1 |
| Waterloo, M | 1 |
| Rozic, M | 1 |
| Knauss, G | 1 |
| Jackson, S | 1 |
| Karuga, D | 1 |
| Zimmerman, DE | 1 |
| Montepara, CA | 1 |
| Covvey, JR | 1 |
| Nemecek, BD | 1 |
| Roberts, K | 1 |
| Dao, A | 1 |
| Alfahmy, A | 1 |
| Mitchell, D | 1 |
| Sheyn, D | 1 |
| Fu, JL | 1 |
| Perloff, MD | 1 |
| Jin, Q | 1 |
| Li, W | 1 |
| Chu, X | 1 |
| Huang, L | 1 |
| Kelkar, S | 1 |
| Nailwal, N | 1 |
| Bhatia, NY | 1 |
| Doshi, G | 1 |
| Sathaye, S | 1 |
| Godad, AP | 1 |
| Lee, N | 1 |
| Nho, B | 1 |
| Ko, KR | 1 |
| Kim, S | 1 |
| Zhou, YP | 2 |
| Sun, Y | 2 |
| Takahashi, K | 1 |
| Belov, V | 2 |
| Andrews, N | 1 |
| Woolf, CJ | 1 |
| Brugarolas, P | 2 |
| Qureshi, R | 2 |
| Chen, X | 2 |
| Goerg, C | 1 |
| Mayo-Wilson, E | 9 |
| Dickinson, S | 2 |
| Golzarri-Arroyo, L | 2 |
| Hong, H | 8 |
| Phillips, R | 1 |
| Cornelius, V | 1 |
| McAdams DeMarco, M | 1 |
| Guallar, E | 1 |
| Li, T | 10 |
| Khan, FA | 1 |
| Ali, G | 5 |
| Rahman, K | 1 |
| Khan, Y | 1 |
| Ayaz, M | 1 |
| Mosa, OF | 1 |
| Nawaz, A | 1 |
| Hassan, SSU | 1 |
| Bungau, S | 1 |
| Padín, JF | 1 |
| Maroto, M | 1 |
| Entrena, JM | 1 |
| Egea, J | 1 |
| Montell, E | 1 |
| Vergés, J | 1 |
| López, MG | 1 |
| Cobos, EJ | 1 |
| García, AG | 1 |
| He, S | 1 |
| Chen, Q | 1 |
| Jing, Z | 1 |
| Gu, L | 1 |
| Luo, K | 1 |
| Chen, KY | 1 |
| Li, RY | 1 |
| Zhang, J | 2 |
| Chen, SR | 3 |
| Zhou, MH | 2 |
| Jin, D | 1 |
| Chen, H | 2 |
| Wang, L | 1 |
| DePinho, RA | 1 |
| Pan, HL | 3 |
| Zhang, E | 1 |
| Fei, Y | 1 |
| Xu, L | 1 |
| Yao, M | 1 |
| Li, J | 1 |
| Huang, Y | 2 |
| Lin, J | 1 |
| Li, LM | 1 |
| Zhang, ZL | 1 |
| Zheng, BS | 1 |
| Jia, LL | 1 |
| Yu, WL | 1 |
| Du, HY | 1 |
| Bensen, GP | 3 |
| Rogers, AC | 3 |
| Leifer, VP | 3 |
| Edwards, RR | 3 |
| Neogi, T | 3 |
| Kostic, AM | 3 |
| Paltiel, AD | 3 |
| Collins, JE | 3 |
| Hunter, DJ | 3 |
| Katz, JN | 3 |
| Losina, E | 3 |
| Guerreiro, SR | 2 |
| Guimarães, MR | 2 |
| Silva, JM | 2 |
| Dioli, C | 2 |
| Vamvaka-Iakovou, A | 2 |
| Sousa, R | 2 |
| Gomes, P | 2 |
| Megalokonomou, A | 2 |
| Campos-Marques, C | 2 |
| Cunha, AM | 2 |
| Almeida, A | 2 |
| Sousa, N | 2 |
| Leite-Almeida, H | 2 |
| Sotiropoulos, I | 2 |
| Chow, SP | 2 |
| Stevens, S | 2 |
| Tran, S | 2 |
| Donelenko, S | 2 |
| Masri, S | 1 |
| Kenney, AE | 1 |
| Scigliano, D | 1 |
| Juba, KM | 1 |
| Oggianu, L | 1 |
| Garrone, B | 2 |
| Fiorentini, F | 1 |
| Del Bene, F | 1 |
| Rosignoli, MT | 1 |
| Di Giorgio, FP | 2 |
| Kaminski, RM | 1 |
| Forouzanfar, F | 1 |
| Tanha, NK | 1 |
| Pourbagher-Shahri, AM | 1 |
| Mahdianpour, S | 1 |
| Esmaeili, M | 1 |
| Ghazavi, H | 1 |
| Meaadi, J | 1 |
| Obara, I | 1 |
| Eldabe, S | 2 |
| Nazar, H | 1 |
| Aramini, A | 1 |
| Bianchini, G | 1 |
| Lillini, S | 1 |
| Tomassetti, M | 1 |
| Pacchiarotti, N | 1 |
| Canestrari, D | 1 |
| Cocchiaro, P | 1 |
| Novelli, R | 1 |
| Dragani, MC | 1 |
| Palmerio, F | 1 |
| Mattioli, S | 1 |
| Bordignon, S | 1 |
| d'Angelo, M | 1 |
| Castelli, V | 1 |
| d'Egidio, F | 1 |
| Maione, S | 1 |
| Luongo, L | 1 |
| Boccella, S | 1 |
| Cimini, A | 1 |
| Brandolini, L | 1 |
| Chierotti, MR | 1 |
| Allegretti, M | 1 |
| Liu, H | 1 |
| Lauzadis, J | 1 |
| Gunaratna, K | 1 |
| Sipple, E | 1 |
| Kaczocha, M | 1 |
| Puopolo, M | 1 |
| Zerfas, I | 1 |
| McGinn, R | 1 |
| Smith, MA | 1 |
| Kiliç, Z | 1 |
| Aydin Özaslan, E | 1 |
| Hassanzadeh, S | 1 |
| Bagheri, S | 1 |
| Majid Ahmadi, S | 1 |
| Ahmadi, SA | 1 |
| Moradishibany, I | 1 |
| Dolatkhah, H | 1 |
| Reisi, S | 1 |
| Normandin, MD | 1 |
| Macdonald-Soccorso, MT | 1 |
| Moon, SH | 1 |
| El Fakhri, G | 1 |
| Guehl, NJ | 1 |
| Ta, PCP | 1 |
| Dinh, HQ | 1 |
| Nguyen, K | 1 |
| Lin, S | 1 |
| Ong, YL | 1 |
| Ariyawardana, A | 1 |
| Shahid, M | 7 |
| Subhan, F | 7 |
| Ahmad, N | 6 |
| Sewell, RDE | 4 |
| Fusco, N | 7 |
| Canner, JK | 5 |
| Dickersin, K | 8 |
| Adetoye, AO | 1 |
| Aaron, OI | 1 |
| Orimolade, EA | 1 |
| P Adetifa, KA | 1 |
| Coraci, D | 1 |
| Giovannini, S | 1 |
| Loreti, C | 1 |
| Fusco, A | 1 |
| Padua, L | 1 |
| Kapustin, D | 1 |
| Bhatia, A | 1 |
| McParland, A | 1 |
| Trivedi, A | 1 |
| Davidson, A | 1 |
| Brull, R | 1 |
| Ozmen, MC | 1 |
| Moore, J | 1 |
| Gaines, C | 1 |
| Bao, J | 1 |
| He, C | 1 |
| Chen, B | 2 |
| Zhao, J | 1 |
| Merante, D | 1 |
| Leisengang, S | 1 |
| Ott, D | 1 |
| Murgott, J | 1 |
| Nürnberger, F | 1 |
| Gerstberger, R | 1 |
| Rummel, C | 1 |
| Schmidt, M | 1 |
| Roth, J | 1 |
| Puljak, L | 2 |
| Mathieson, S | 1 |
| Lin, CC | 1 |
| Underwood, M | 1 |
| Zheng, C | 1 |
| Childers, J | 1 |
| Rabinovich, E | 1 |
| Nazareth-Pidgeon, K | 1 |
| Cragg, JJ | 1 |
| Jutzeler, CR | 1 |
| Grassner, L | 1 |
| Ramer, M | 1 |
| Bradke, F | 1 |
| Kramer, JLK | 1 |
| Capuco, A | 1 |
| Urits, I | 2 |
| Orhurhu, V | 1 |
| Chun, R | 1 |
| Shukla, B | 1 |
| Burke, M | 1 |
| Kaye, RJ | 2 |
| Garcia, AJ | 1 |
| Kaye, AD | 2 |
| Viswanath, O | 2 |
| Amirkhanloo, F | 1 |
| Karimi, G | 1 |
| Yousefi-Manesh, H | 1 |
| Abdollahi, A | 1 |
| Roohbakhsh, A | 1 |
| Dehpour, AR | 1 |
| Anghelescu, DL | 2 |
| Tesney, JM | 1 |
| Jeha, S | 2 |
| Wright, BB | 1 |
| Trujillo, L | 1 |
| Sandlund, JT | 2 |
| Pauley, J | 1 |
| Cheng, C | 2 |
| Pei, D | 2 |
| Cortellazzo Wiel, L | 1 |
| De Nardi, L | 1 |
| Magnolato, A | 1 |
| Sirchia, F | 1 |
| Bruno, I | 1 |
| Barbi, E | 1 |
| Callaghan, BC | 1 |
| Price, RS | 1 |
| Feldman, EL | 1 |
| Klifto, KM | 1 |
| Yesantharao, PS | 1 |
| Dellon, AL | 1 |
| Hultman, CS | 1 |
| Lifchez, SD | 1 |
| Dragic, L | 1 |
| Webb, T | 1 |
| Chandler, M | 1 |
| Harrington, SB | 1 |
| McDade, E | 1 |
| Dayer, L | 1 |
| Painter, JT | 1 |
| van Poelgeest, EP | 1 |
| El Houssein, L | 1 |
| Kallewaard, J | 1 |
| Hollmann, MW | 1 |
| Steegers, MAH | 1 |
| Wartenberg, HCH | 1 |
| Gonçalves Dos Santos, G | 1 |
| Jimenéz-Andrade, JM | 1 |
| Woller, SA | 2 |
| Muñoz-Islas, E | 1 |
| Ramírez-Rosas, MB | 1 |
| Ohashi, N | 1 |
| Ferreira Catroli, G | 1 |
| Fujita, Y | 1 |
| Yaksh, TL | 2 |
| Corr, M | 2 |
| Li, N | 1 |
| Berardino, K | 1 |
| Artounian, KA | 1 |
| Bandi, P | 1 |
| Jung, JW | 1 |
| Manchikanti, L | 1 |
| Kaye, AM | 1 |
| Simopoulos, T | 1 |
| Torres, M | 1 |
| Costa, ACC | 1 |
| de Lima Benzi, JR | 1 |
| Yamamoto, PA | 1 |
| de Freitas, MCF | 1 |
| de Paula, FJA | 1 |
| Zanelli, CF | 1 |
| Lauretti, GR | 1 |
| de Moraes, NV | 1 |
| Shaheen, A | 1 |
| Alam, SM | 1 |
| Azam, F | 1 |
| Khan, M | 1 |
| Ahmad Saleem, S | 1 |
| Liaquat, A | 1 |
| Mumtaz, S | 1 |
| Karim, N | 2 |
| Khan, I | 1 |
| Abdelhalim, A | 1 |
| Halim, SA | 1 |
| Khan, A | 1 |
| Altaf, N | 1 |
| Ahmad, W | 1 |
| Ghaffar, R | 1 |
| Al-Harrasi, A | 1 |
| Ruel, HLM | 1 |
| Watanabe, R | 1 |
| Evangelista, MC | 1 |
| Beauchamp, G | 1 |
| Auger, JP | 1 |
| Segura, M | 1 |
| Steagall, PV | 1 |
| Buffon, AC | 1 |
| Javornik, MA | 1 |
| Heymanns, AC | 1 |
| Salm, DC | 1 |
| Horewicz, VV | 1 |
| Martins, DF | 1 |
| Piovezan, AP | 1 |
| Guisado Vasco, P | 1 |
| Llanero-Luque, M | 1 |
| Cano-Megías, M | 1 |
| Cortés-Berdonces, M | 1 |
| di Matteo, A | 1 |
| Amato, A | 1 |
| Pistillo, L | 1 |
| Durando, L | 1 |
| Milanese, C | 1 |
| Tongiani, S | 1 |
| Ibiloye, EA | 1 |
| Barner, JC | 1 |
| Lawson, KA | 1 |
| Rascati, KL | 1 |
| Evoy, KE | 1 |
| Peckham, AM | 1 |
| Agarwal, S | 1 |
| Pancham, P | 1 |
| Agarwal, V | 1 |
| Kaur, H | 1 |
| Kaur, R | 1 |
| Islam, NU | 2 |
| Ullah, N | 1 |
| Ullah, R | 2 |
| Akbar, S | 3 |
| Amin, MU | 1 |
| Khurram, M | 1 |
| Ullah, I | 1 |
| Rangappa, S | 1 |
| Shankar, VK | 1 |
| Jo, S | 1 |
| Repka, MA | 1 |
| Murthy, SN | 1 |
| Görg, C | 1 |
| Egan, KE | 1 |
| Caldwell, GM | 1 |
| Eckmann, MS | 1 |
| Mecca, CM | 1 |
| Chao, D | 1 |
| Feng, Y | 1 |
| Segel, I | 1 |
| Zhang, Z | 1 |
| Rodriguez-Garcia, DM | 1 |
| Pawela, CP | 1 |
| Hillard, CJ | 1 |
| Hogan, QH | 1 |
| Pan, B | 1 |
| Louis, JV | 1 |
| Lu, Y | 1 |
| Pieschl, R | 1 |
| Tian, Y | 2 |
| Hong, Y | 1 |
| Naidu, S | 1 |
| Vikramadithyan, RK | 1 |
| Dzierba, C | 1 |
| Sarvasiddhi, SK | 1 |
| Bronson, J | 1 |
| Albright, C | 1 |
| Li, YW | 1 |
| Samineni, VK | 1 |
| Premkumar, LS | 1 |
| Faingold, CL | 1 |
| Emiroglu, N | 1 |
| Cengiz, FP | 1 |
| Su, O | 1 |
| Onsun, N | 1 |
| Wee, TC | 1 |
| Nicodemus, JM | 1 |
| Enriquez, C | 1 |
| Marquez, A | 1 |
| Anaya, CJ | 1 |
| Jolivalt, CG | 1 |
| Lee, KH | 1 |
| Rhee, KH | 1 |
| Katz, P | 1 |
| Pegoraro, V | 1 |
| Liedgens, H | 1 |
| Coupal, TM | 1 |
| Chang, DR | 1 |
| Pennycooke, K | 1 |
| Ouellette, HA | 1 |
| Munk, PL | 1 |
| Wiffen, PJ | 9 |
| Derry, S | 6 |
| Bell, RF | 1 |
| Rice, AS | 5 |
| Tölle, TR | 1 |
| Phillips, T | 1 |
| Moore, RA | 8 |
| Madden, K | 1 |
| Bruera, E | 1 |
| Sahn, JJ | 1 |
| Mejia, GL | 1 |
| Ray, PR | 1 |
| Martin, SF | 1 |
| Price, TJ | 2 |
| Espinosa-Juárez, JV | 3 |
| Jaramillo-Morales, OA | 3 |
| López-Muñoz, FJ | 4 |
| Luo, WJ | 1 |
| Yang, F | 4 |
| Sun, W | 2 |
| Zheng, W | 1 |
| Wang, XL | 1 |
| Wu, FF | 1 |
| Wang, JL | 1 |
| Wang, JS | 1 |
| Guan, SM | 1 |
| Baraldi, C | 1 |
| Pellesi, L | 1 |
| Guerzoni, S | 1 |
| Cainazzo, MM | 1 |
| Pini, LA | 1 |
| Dosenovic, S | 1 |
| Jelicic Kadic, A | 1 |
| Miljanovic, M | 1 |
| Biocic, M | 1 |
| Boric, K | 1 |
| Cavar, M | 1 |
| Markovina, N | 1 |
| Vucic, K | 1 |
| Jeong, KY | 1 |
| Kang, JH | 2 |
| Goodman, CW | 2 |
| Brett, AS | 2 |
| Cooper, TE | 2 |
| Heathcote, LC | 2 |
| Clinch, J | 2 |
| Gold, JI | 1 |
| Howard, R | 2 |
| Lord, SM | 2 |
| Schechter, N | 2 |
| Wood, C | 2 |
| Krane, E | 1 |
| Sethna, N | 1 |
| Kaul, I | 1 |
| Amin, A | 1 |
| Rosenberg, M | 1 |
| Rosenberg, L | 1 |
| Meyer, WJ | 1 |
| Bannister, K | 1 |
| Qu, C | 2 |
| Navratilova, E | 2 |
| Oyarzo, J | 1 |
| Xie, JY | 2 |
| King, T | 1 |
| Dickenson, AH | 3 |
| Porreca, F | 2 |
| Bertizzolo, L | 1 |
| Cowley, T | 2 |
| Doshi, P | 2 |
| Ehmsen, J | 2 |
| Gresham, G | 2 |
| Guo, N | 1 |
| Haythornthwaite, JA | 2 |
| Heyward, J | 2 |
| Pham, D | 1 |
| Payne, JL | 2 |
| Rosman, L | 2 |
| Stuart, EA | 2 |
| Suarez-Cuervo, C | 2 |
| Tolbert, E | 2 |
| Twose, C | 2 |
| Vedula, S | 2 |
| Brown, S | 1 |
| Johnston, B | 1 |
| Amaria, K | 1 |
| Watkins, J | 1 |
| Campbell, F | 1 |
| Pehora, C | 1 |
| McGrath, P | 1 |
| Matsuoka, H | 1 |
| Ishiki, H | 1 |
| Iwase, S | 1 |
| Koyama, A | 1 |
| Kawaguchi, T | 1 |
| Kizawa, Y | 1 |
| Morita, T | 1 |
| Matsuda, Y | 1 |
| Miyaji, T | 1 |
| Ariyoshi, K | 1 |
| Yamaguchi, T | 1 |
| Rahman, FU | 1 |
| Chaumette, T | 1 |
| Chapuy, E | 3 |
| Berrocoso, E | 1 |
| Llorca-Torralba, M | 1 |
| Bravo, L | 1 |
| Mico, JA | 1 |
| Chalus, M | 1 |
| Eschalier, A | 3 |
| Ardid, D | 2 |
| Marchand, F | 2 |
| Sors, A | 1 |
| Anderson, D | 1 |
| Beecher, G | 1 |
| Power, C | 1 |
| Bridgland, L | 1 |
| Zochodne, DW | 1 |
| Crowe, MS | 1 |
| Wilson, CD | 1 |
| Leishman, E | 1 |
| Prather, PL | 1 |
| Bradshaw, HB | 1 |
| Banks, ML | 1 |
| Kinsey, SG | 1 |
| Senderovich, H | 1 |
| Jeyapragasan, G | 1 |
| Shepherd, AJ | 1 |
| Mohapatra, DP | 1 |
| Masuda, R | 1 |
| Ajimi, J | 1 |
| Murata, T | 1 |
| Kim, BS | 1 |
| Jin, JY | 1 |
| Kwon, JH | 1 |
| Woo, IS | 1 |
| Ko, YH | 1 |
| Park, SY | 1 |
| Park, HJ | 1 |
| Oliveira, MEF | 1 |
| Sayed, C | 1 |
| McKinley, EC | 1 |
| Richardson, EJ | 1 |
| McGwin, G | 1 |
| Liang, X | 1 |
| Joo, SY | 1 |
| Kim, JB | 1 |
| Seo, CH | 1 |
| Ibrahim, MA | 1 |
| Abdelzaher, WY | 1 |
| Rofaeil, RR | 1 |
| Abdelwahab, S | 1 |
| Barragán-Iglesias, P | 2 |
| Oidor-Chan, VH | 1 |
| Loeza-Alcocer, E | 1 |
| Pineda-Farias, JB | 2 |
| Velazquez-Lagunas, I | 1 |
| Salinas-Abarca, AB | 2 |
| Hong, E | 1 |
| Sánchez-Mendoza, A | 1 |
| Delgado-Lezama, R | 1 |
| Granados-Soto, V | 2 |
| Li, L | 1 |
| Xie, JD | 1 |
| Sirrieh, RE | 1 |
| MacLean, DM | 1 |
| Zhang, Y | 1 |
| Jayaraman, V | 1 |
| Kabbara, WK | 1 |
| Dimassi, H | 1 |
| Sheikh-Taha, M | 1 |
| Alles, SRA | 2 |
| Smith, PA | 2 |
| Fleet, JL | 1 |
| Dixon, SN | 1 |
| Kuwornu, PJ | 1 |
| Dev, VK | 1 |
| Montero-Odasso, M | 1 |
| Burneo, J | 1 |
| Garg, AX | 1 |
| Sicras-Mainar, A | 3 |
| Rejas-Gutiérrez, J | 3 |
| Perez-Paramo, M | 3 |
| Navarro-Artieda, R | 3 |
| Chincholkar, M | 1 |
| Nayak, MK | 1 |
| Kapadia, JD | 1 |
| Desai, CK | 1 |
| Desai, MK | 1 |
| Shah, BJ | 1 |
| Zeng, Y | 1 |
| Hu, D | 1 |
| Yang, W | 1 |
| Hayashinaka, E | 1 |
| Wada, Y | 1 |
| Watanabe, Y | 1 |
| Zeng, Q | 1 |
| Cui, Y | 1 |
| Huang, T | 1 |
| Fu, B | 1 |
| Wang, J | 1 |
| Wang, B | 1 |
| Liu, SJ | 1 |
| Weng, XC | 1 |
| Shi, T | 2 |
| Hao, JX | 1 |
| Wiesenfeld-Hallin, Z | 2 |
| Xu, XJ | 2 |
| Patel, KV | 1 |
| Allen, R | 1 |
| Burke, L | 1 |
| Farrar, JT | 3 |
| Gewandter, JS | 1 |
| Gilron, I | 8 |
| Katz, NP | 2 |
| Markman, JD | 2 |
| Marshall, SF | 1 |
| Resnick, M | 1 |
| Rice, ASC | 3 |
| Rowbotham, MC | 2 |
| Smith, SM | 1 |
| Vanhove, GF | 1 |
| Wasan, AD | 1 |
| Zhang, S | 1 |
| Dworkin, RH | 7 |
| Turk, DC | 3 |
| Shiers, S | 1 |
| Pradhan, G | 1 |
| Mwirigi, J | 1 |
| Mejia, G | 1 |
| Ahmad, A | 1 |
| Kroener, S | 1 |
| Price, T | 1 |
| Miranda, HF | 4 |
| Sierralta, F | 4 |
| Aranda, N | 2 |
| Poblete, P | 2 |
| Noriega, V | 4 |
| Prieto, JC | 4 |
| Atwal, N | 1 |
| Casey, SL | 1 |
| Mitchell, VA | 1 |
| Vaughan, CW | 1 |
| Zepeda, RJ | 1 |
| Alexander, J | 1 |
| Edwards, RA | 1 |
| Brodsky, M | 1 |
| Manca, L | 1 |
| Grugni, R | 1 |
| Savoldelli, A | 1 |
| Bonfanti, G | 1 |
| Emir, B | 1 |
| Whalen, E | 1 |
| Watt, S | 1 |
| Parsons, B | 3 |
| de Leeuw, TG | 2 |
| Mangiarini, L | 2 |
| Lundin, R | 2 |
| Kaguelidou, F | 2 |
| van der Zanden, T | 1 |
| Pasqua, OD | 1 |
| Tibboel, D | 2 |
| Ceci, A | 3 |
| de Wildt, SN | 2 |
| Albu, S | 1 |
| Umemura, G | 1 |
| Forner-Cordero, A | 1 |
| Le Roux, E | 1 |
| Della Pasqua, O | 3 |
| Felisi, M | 1 |
| Bonifazi, D | 1 |
| Alberti, C | 1 |
| Davison, SN | 1 |
| McQuoid, P | 1 |
| Hwang, CJ | 1 |
| Lee, JH | 2 |
| Min, SH | 1 |
| Park, KW | 1 |
| Seo, HY | 1 |
| Song, KS | 1 |
| Kneib, CJ | 1 |
| Sibbett, SH | 1 |
| Carrougher, GJ | 1 |
| Muffley, LA | 1 |
| Gibran, NS | 1 |
| Mandell, SP | 1 |
| Viniol, A | 1 |
| Ploner, T | 1 |
| Hickstein, L | 1 |
| Haasenritter, J | 1 |
| Klein, KM | 1 |
| Walker, J | 1 |
| Donner-Banzhoff, N | 1 |
| Becker, A | 1 |
| Gao, T | 1 |
| Jiang, JD | 1 |
| Khan, J | 1 |
| Khan, R | 1 |
| Ullah, S | 1 |
| Bender, HU | 1 |
| Borggraefe, I | 1 |
| Coppenrath, E | 1 |
| Maier, EM | 1 |
| Kukkar, A | 1 |
| Bali, A | 1 |
| Singh, N | 1 |
| Jaggi, AS | 1 |
| Hopkins, SC | 1 |
| Bowen, CA | 1 |
| Fang, X | 1 |
| Heffernan, ML | 1 |
| Spear, KL | 1 |
| Spanswick, DC | 1 |
| Varney, MA | 1 |
| Large, TH | 1 |
| Haribabu, PK | 1 |
| Eliav, E | 2 |
| Heir, GM | 1 |
| Athanasakis, K | 1 |
| Petrakis, I | 1 |
| Karampli, E | 1 |
| Vitsou, E | 1 |
| Lyras, L | 1 |
| Kyriopoulos, J | 1 |
| Lin, TC | 1 |
| Lai, SL | 1 |
| Hsu, SP | 1 |
| Ro, LS | 1 |
| Hooker, BA | 1 |
| Tobon, G | 1 |
| Baker, SJ | 1 |
| Zhu, C | 1 |
| Hesterman, J | 1 |
| Schmidt, K | 1 |
| Rajagovindan, R | 1 |
| Chandran, P | 1 |
| Joshi, SK | 1 |
| Bannon, AW | 1 |
| Hoppin, J | 1 |
| Beaver, J | 1 |
| Fox, GB | 1 |
| Day, M | 1 |
| Upadhyay, J | 1 |
| Chen, L | 2 |
| Mao, J | 2 |
| Yezierski, RP | 1 |
| Murphy, K | 1 |
| Vierck, CJ | 1 |
| Pedraza, MI | 1 |
| Ruiz, M | 4 |
| Rodríguez, C | 1 |
| Muñoz, I | 1 |
| Barón, J | 1 |
| Mulero, P | 1 |
| Herrero-Velázquez, S | 1 |
| Guerrero-Peral, ÁL | 1 |
| Marchiori, ÉC | 1 |
| Barber, JS | 1 |
| Williams, WB | 1 |
| Bui, PQ | 1 |
| O'Ryan, FS | 1 |
| Monge-Márquez, ME | 1 |
| Márquez-Rivas, J | 1 |
| Mayorga-Buiza, MJ | 1 |
| Rivero-Garvía, M | 1 |
| Câmara, CC | 2 |
| Ramos, HF | 1 |
| da Silva, AP | 1 |
| Araújo, CV | 2 |
| Gomes, AS | 1 |
| Vale, ML | 2 |
| Barbosa, AL | 1 |
| Ribeiro, RA | 1 |
| Brito, GA | 1 |
| Costa, CM | 1 |
| Oriá, RB | 2 |
| Manjavachi, MN | 1 |
| Costa, R | 1 |
| Quintão, NL | 2 |
| Calixto, JB | 2 |
| Aldington, D | 2 |
| Cole, P | 1 |
| Lunn, MP | 1 |
| Hamunen, K | 1 |
| Haanpaa, M | 2 |
| Kalso, EA | 1 |
| Basnet, A | 1 |
| Butler, S | 1 |
| Honoré, PH | 2 |
| Butler, M | 1 |
| Gordh, TE | 3 |
| Kristensen, K | 1 |
| Bjerrum, OJ | 5 |
| Guy, S | 1 |
| Mehta, S | 2 |
| Leff, L | 1 |
| Teasell, R | 1 |
| Loh, E | 2 |
| Jiang, YQ | 1 |
| Andrade, A | 1 |
| Lipscombe, D | 1 |
| Thangamani, D | 1 |
| Edafiogho, IO | 1 |
| Masocha, W | 1 |
| Mercadante, S | 2 |
| Nakai, K | 1 |
| Nakae, A | 1 |
| Hashimoto, R | 1 |
| Mashimo, T | 1 |
| Hosokawa, K | 1 |
| Suto, T | 1 |
| Severino, AL | 1 |
| Eisenach, JC | 3 |
| Hayashida, K | 4 |
| Dwyer, JP | 1 |
| Jayasekera, C | 1 |
| Nicoll, A | 1 |
| Bao, YH | 1 |
| Zhou, QH | 1 |
| Chen, R | 1 |
| Xu, H | 1 |
| Zeng, LL | 1 |
| Zhang, X | 1 |
| Jiang, W | 1 |
| Du, DP | 1 |
| Hershman, DL | 1 |
| Lacchetti, C | 1 |
| Lavoie Smith, EM | 1 |
| Bleeker, J | 1 |
| Cavaletti, G | 1 |
| Chauhan, C | 1 |
| Gavin, P | 1 |
| Lavino, A | 1 |
| Lustberg, MB | 1 |
| Paice, J | 1 |
| Schneider, B | 1 |
| Smith, ML | 1 |
| Smith, T | 2 |
| Terstriep, S | 1 |
| Wagner-Johnston, N | 1 |
| Bak, K | 1 |
| Loprinzi, CL | 1 |
| Toelle, T | 1 |
| Ye, GL | 1 |
| Savelieva, KV | 1 |
| Vogel, P | 1 |
| Baker, KB | 1 |
| Mason, S | 1 |
| Lanthorn, TH | 1 |
| Rajan, I | 1 |
| Ling, Q | 1 |
| Liu, M | 1 |
| Wu, MX | 1 |
| Xu, Y | 1 |
| Yang, J | 4 |
| Huang, HH | 1 |
| Yu, CX | 1 |
| Parker, L | 1 |
| Huelin, R | 1 |
| Khankhel, Z | 1 |
| Wasiak, R | 1 |
| Mould, J | 1 |
| Iwanowski, P | 1 |
| Kozubski, W | 1 |
| Losy, J | 1 |
| Troxel, AB | 1 |
| Haynes, K | 1 |
| Kerns, RD | 1 |
| Rappaport, BA | 1 |
| Tierney, AM | 1 |
| Irving, G | 1 |
| Tanenberg, RJ | 2 |
| Raskin, J | 1 |
| Risser, RC | 2 |
| Malcolm, S | 1 |
| Patwardhan, A | 1 |
| Ossipov, MH | 1 |
| Becerra, L | 1 |
| Borsook, D | 1 |
| Wagner, K | 1 |
| Inceoglu, B | 1 |
| Hammock, BD | 2 |
| Dolgun, H | 1 |
| Turkoglu, E | 1 |
| Kertmen, H | 1 |
| Gurer, B | 1 |
| Yilmaz, ER | 1 |
| Comoglu, SS | 1 |
| Sekerci, Z | 1 |
| Ghinea, N | 1 |
| Lipworth, W | 1 |
| Kerridge, I | 1 |
| McIntyre, A | 1 |
| Dijkers, M | 1 |
| Teasell, RW | 1 |
| Lee, KS | 1 |
| Liu, JY | 1 |
| Wagner, KM | 1 |
| Pakhomova, S | 1 |
| Dong, H | 1 |
| Morisseau, C | 1 |
| Fu, SH | 1 |
| Wang, P | 1 |
| Ulu, A | 1 |
| Mate, CA | 1 |
| Nguyen, LV | 1 |
| Hwang, SH | 1 |
| Edin, ML | 1 |
| Mara, AA | 1 |
| Wulff, H | 1 |
| Newcomer, ME | 1 |
| Zeldin, DC | 1 |
| Capasso, KE | 1 |
| Manners, MT | 1 |
| Quershi, RA | 1 |
| Gao, R | 1 |
| Hu, H | 1 |
| Barrett, JE | 1 |
| Sacan, A | 1 |
| Ajit, SK | 1 |
| Khan, N | 1 |
| Woodruff, TM | 1 |
| Smith, MT | 1 |
| Lin, HC | 1 |
| Huang, YH | 1 |
| Chao, TH | 1 |
| Lin, WY | 1 |
| Sun, WZ | 2 |
| Yen, CT | 1 |
| Turcotte, D | 1 |
| Doupe, M | 1 |
| Torabi, M | 1 |
| Gomori, A | 1 |
| Ethans, K | 1 |
| Esfahani, F | 1 |
| Galloway, K | 1 |
| Namaka, M | 1 |
| Sanderson, C | 2 |
| Quinn, SJ | 2 |
| Agar, M | 1 |
| Chye, R | 1 |
| Clark, K | 2 |
| Doogue, M | 2 |
| Fazekas, B | 1 |
| Lovell, MR | 1 |
| Rowett, D | 1 |
| Spruyt, O | 1 |
| Currow, DC | 2 |
| Hiom, S | 1 |
| Patel, GK | 1 |
| Newcombe, RG | 1 |
| Khot, S | 1 |
| Martin, C | 1 |
| Zepeda, R | 1 |
| Zanetta, P | 2 |
| Prieto-Rayo, J | 1 |
| Johannessen Landmark, C | 1 |
| Beiske, G | 1 |
| Baftiu, A | 1 |
| Burns, ML | 1 |
| Johannessen, SI | 1 |
| Sommer, C | 1 |
| Al Otaibi, M | 1 |
| Sathish, J | 1 |
| Djouhri, L | 1 |
| Wang, TX | 1 |
| Yin, D | 1 |
| Guo, W | 1 |
| Liu, YY | 1 |
| Li, YD | 1 |
| Qu, WM | 1 |
| Han, WJ | 1 |
| Hong, ZY | 1 |
| Huang, ZL | 1 |
| Griggs, RB | 1 |
| Bardo, MT | 1 |
| Taylor, BK | 1 |
| Evrensel, A | 1 |
| Ünsalver, BÖ | 1 |
| Yang, M | 1 |
| Qian, C | 1 |
| Liu, Y | 1 |
| Abbas, M | 1 |
| Zeb, J | 1 |
| Sewell, RD | 2 |
| Lovell, M | 1 |
| Henry, MA | 1 |
| Fairchild, DD | 1 |
| Patil, MJ | 1 |
| Hanania, T | 1 |
| Hain, HS | 1 |
| Davis, SF | 1 |
| Malekiani, SA | 1 |
| Hu, A | 1 |
| Sucholeiki, R | 1 |
| Nix, D | 1 |
| Sucholeiki, I | 1 |
| Plessas, IN | 2 |
| Volk, HA | 2 |
| Rusbridge, C | 2 |
| Vanhaesebrouck, AE | 1 |
| Jeffery, ND | 1 |
| Bugan, I | 1 |
| Karagoz, Z | 1 |
| Altun, S | 1 |
| Djamgoz, MB | 1 |
| de Sousa, KKO | 1 |
| Brito, GAC | 1 |
| Raposo, RDS | 1 |
| Mendonça, FE | 1 |
| Mietto, BS | 1 |
| Martinez, AMB | 1 |
| Jayarajan, P | 1 |
| Nirogi, R | 1 |
| Shinde, A | 1 |
| Goura, V | 1 |
| Babu, VA | 1 |
| Yathavakilla, S | 1 |
| Bhyrapuneni, G | 1 |
| Batlle, L | 1 |
| Mattie, R | 1 |
| Irwin, R | 1 |
| Kiss, G | 1 |
| Castel, D | 1 |
| Sabbag, I | 1 |
| Brenner, O | 1 |
| Meilin, S | 1 |
| Gill, I | 1 |
| Parrent, AG | 1 |
| Steven, DA | 1 |
| Hutfless, S | 1 |
| Lock, D | 1 |
| Haythornthwaite, J | 1 |
| Singh, S | 1 |
| Kern, KU | 1 |
| Weiser, T | 1 |
| Robertson, K | 1 |
| Marshman, LA | 1 |
| Plummer, D | 1 |
| Garcia, D | 1 |
| Yang, Y | 1 |
| Li, CL | 1 |
| Wang, Y | 1 |
| Li, Z | 1 |
| Lu, YF | 1 |
| Yu, YQ | 1 |
| Fu, H | 1 |
| He, T | 1 |
| Wang, RR | 1 |
| Castillo, R | 1 |
| Schuller, Y | 1 |
| Linthorst, GE | 1 |
| Hollak, CE | 1 |
| Van Schaik, IN | 1 |
| Biegstraaten, M | 1 |
| Porta-Etessam, J | 2 |
| Garcia-Ptacek, S | 1 |
| de la Cruz, C | 1 |
| Cuadrado, ML | 1 |
| Guerrero, AL | 1 |
| de Miguel-Jimeno, JM | 1 |
| Forner-Cordero, I | 1 |
| Zabalza-Azparren, M | 1 |
| Matute-Tobias, B | 1 |
| Corona-Ramos, JN | 2 |
| Medina-López, JR | 2 |
| Kim, DG | 1 |
| Kim, SH | 3 |
| Kwon, OW | 1 |
| You, YS | 1 |
| Matsuura, W | 1 |
| Harada, S | 1 |
| Tokuyama, S | 1 |
| Sant'Anna, MB | 1 |
| Kusuda, R | 1 |
| Bozzo, TA | 1 |
| Bassi, GS | 1 |
| Alves-Filho, JC | 1 |
| Cunha, FQ | 1 |
| Ferreira, SH | 1 |
| Souza, GR | 1 |
| Cunha, TM | 1 |
| Li, R | 1 |
| Shen, L | 1 |
| Yu, X | 1 |
| Ma, C | 1 |
| De la O-Arciniega, M | 2 |
| Déciga-Campos, M | 1 |
| Domínguez-Ramírez, AM | 2 |
| Hewitt, E | 1 |
| Pitcher, T | 1 |
| Rizoska, B | 1 |
| Tunblad, K | 1 |
| Henderson, I | 1 |
| Sahlberg, BL | 1 |
| Grabowska, U | 1 |
| Classon, B | 1 |
| Edenius, C | 1 |
| Malcangio, M | 1 |
| Lindström, E | 1 |
| Kalladka, M | 1 |
| Nasri-Heir, C | 1 |
| Ananthan, S | 1 |
| Viswanath, A | 1 |
| Heir, G | 1 |
| Goel, R | 1 |
| Tyagi, N | 1 |
| Jensen, TS | 5 |
| Semel, D | 1 |
| Li, C | 1 |
| Behar, R | 1 |
| Sadosky, AB | 1 |
| Huang, W | 1 |
| Calvo, M | 1 |
| Pheby, T | 2 |
| Bennett, DLH | 1 |
| Ozbek, Z | 1 |
| Aydin, HE | 1 |
| Kocman, AE | 1 |
| Ozkara, E | 1 |
| Sahin, E | 1 |
| Bektur, E | 1 |
| Vural, M | 1 |
| Kose, A | 1 |
| Arslantas, A | 1 |
| Baycu, C | 1 |
| Mahmood, W | 1 |
| Fawad, K | 2 |
| Kristensen, PJ | 1 |
| Heegaard, AM | 1 |
| Hestehave, S | 1 |
| Jeggo, RD | 1 |
| Munro, G | 2 |
| Kaufmann, D | 1 |
| West, PJ | 1 |
| Smith, MD | 1 |
| Yagen, B | 1 |
| Bialer, M | 1 |
| Devor, M | 1 |
| White, HS | 1 |
| Brennan, KC | 1 |
| Chenaf, C | 1 |
| Libert, F | 1 |
| Courteix, C | 1 |
| Bertrand, M | 1 |
| Gabriel, C | 1 |
| Mocaër, E | 1 |
| Authier, N | 1 |
| Avila-Rojas, SH | 1 |
| Wright, ME | 1 |
| Rizzolo, D | 1 |
| Poucher, M | 1 |
| Cherrier, C | 1 |
| Poucher, AC | 1 |
| Di Patrizio, P | 1 |
| Shanthanna, H | 1 |
| Thabane, L | 1 |
| Devereaux, PJ | 1 |
| Bhandari, M | 1 |
| AlAmri, R | 1 |
| Rajarathinam, M | 1 |
| Kamath, S | 1 |
| Colloca, L | 1 |
| Ludman, T | 1 |
| Bouhassira, D | 2 |
| Baron, R | 4 |
| Yarnitsky, D | 1 |
| Freeman, R | 1 |
| Truini, A | 1 |
| Attal, N | 3 |
| Finnerup, NB | 2 |
| Eccleston, C | 1 |
| Kalso, E | 3 |
| Bennett, DL | 1 |
| Raja, SN | 3 |
| Ding, W | 1 |
| You, Z | 1 |
| Shen, S | 1 |
| Lim, G | 1 |
| Doheny, JT | 1 |
| Zhu, S | 1 |
| Kogure, T | 1 |
| Sumitani, M | 1 |
| Ikegami, K | 1 |
| Abe, H | 1 |
| Hozumi, J | 1 |
| Inoue, R | 1 |
| Kawahara, K | 1 |
| Yamada, Y | 1 |
| Newton, VL | 1 |
| Guck, JD | 1 |
| Cotter, MA | 1 |
| Cameron, NE | 1 |
| Gardiner, NJ | 1 |
| Jacob, S | 1 |
| Saha, A | 1 |
| Rajabally, Y | 1 |
| Taira, T | 1 |
| Roeska, K | 1 |
| Doods, H | 1 |
| Arndt, K | 1 |
| Treede, RD | 2 |
| Tzellos, TG | 1 |
| Papazisis, G | 1 |
| Amaniti, E | 1 |
| Kouvelas, D | 1 |
| Roh, DH | 1 |
| Kim, HW | 1 |
| Yoon, SY | 1 |
| Seo, HS | 1 |
| Kwon, YB | 1 |
| Han, HJ | 1 |
| Beitz, AJ | 1 |
| Tanabe, M | 1 |
| Takasu, K | 2 |
| Takeuchi, Y | 1 |
| Ono, H | 1 |
| Yamamoto, T | 2 |
| Wallace, VC | 1 |
| Segerdahl, AR | 1 |
| Blackbeard, J | 1 |
| Boyd, ST | 1 |
| Mihm, L | 1 |
| Causey, NW | 1 |
| Ho, TW | 1 |
| Backonja, M | 2 |
| Ma, J | 1 |
| Leibensperger, H | 1 |
| Froman, S | 1 |
| Polydefkis, M | 1 |
| Dayioğlu, M | 1 |
| Tuncer, S | 1 |
| Reisli, R | 1 |
| Obata, H | 2 |
| Nakajima, K | 1 |
| Tsavaris, N | 1 |
| Kopterides, P | 1 |
| Kosmas, C | 1 |
| Efthymiou, A | 1 |
| Skopelitis, H | 1 |
| Dimitrakopoulos, A | 1 |
| Pagouni, E | 1 |
| Pikazis, D | 1 |
| Zis, PV | 1 |
| Koufos, C | 1 |
| Hahm, TS | 1 |
| Ahn, HJ | 1 |
| Bae, CD | 1 |
| Lim, SW | 1 |
| Cho, HS | 1 |
| Lee, SM | 1 |
| Sim, WS | 1 |
| Kim, JA | 1 |
| Gwak, MS | 1 |
| Choi, SJ | 1 |
| O'Connor, AB | 3 |
| Díaz-Reval, MI | 1 |
| Cortés-Arroyo, AR | 1 |
| Kruszewski, SP | 1 |
| Paczynski, RP | 1 |
| Kahn, DA | 1 |
| Curros-Criado, MM | 1 |
| Herrero, JF | 1 |
| Piesla, MJ | 1 |
| Leventhal, L | 1 |
| Strassle, BW | 1 |
| Harrison, JE | 1 |
| Cummons, TA | 1 |
| Lu, P | 1 |
| Whiteside, GT | 1 |
| Bailey, JM | 2 |
| Tu, D | 3 |
| Holden, RR | 3 |
| Jackson, AC | 1 |
| Houlden, RL | 2 |
| Blakemore, DC | 1 |
| Bryans, JS | 1 |
| Carnell, P | 1 |
| Carr, CL | 1 |
| Chessum, NE | 1 |
| Field, MJ | 2 |
| Kinsella, N | 1 |
| Osborne, SA | 1 |
| Warren, AN | 1 |
| Williams, SC | 1 |
| Buccafusco, JJ | 1 |
| Terry, AV | 1 |
| Vazdarjanova, A | 1 |
| Snutch, TP | 1 |
| Arneric, SP | 1 |
| da Silva, GF | 1 |
| Antonialli, CS | 1 |
| Rocha, LW | 1 |
| Cechinel Filho, V | 1 |
| Cicció, JF | 1 |
| Audette, J | 1 |
| Gourlay, GK | 1 |
| Haanpää, ML | 1 |
| Kent, JL | 1 |
| Krane, EJ | 1 |
| Lebel, AA | 1 |
| Levy, RM | 1 |
| Mackey, SC | 1 |
| Mayer, J | 1 |
| Miaskowski, C | 1 |
| Schmader, KE | 2 |
| Stacey, B | 2 |
| Stanos, S | 1 |
| Walco, GA | 1 |
| Wells, CD | 1 |
| Bauer, CS | 1 |
| Rahman, W | 1 |
| Tran-van-Minh, A | 1 |
| Lujan, R | 1 |
| Dolphin, AC | 2 |
| Cruccu, G | 2 |
| Hansson, P | 1 |
| Nurmikko, T | 1 |
| Fournier-Charrière, E | 1 |
| Yamama, Y | 1 |
| Nishikawa, K | 1 |
| Funao, T | 1 |
| Mori, T | 1 |
| Asada, A | 1 |
| Folkesson, A | 1 |
| Andersen, LM | 1 |
| Kristensen, P | 1 |
| Yi, H | 1 |
| Kim, MA | 1 |
| Eun, JS | 1 |
| Kusunose, N | 1 |
| Koyanagi, S | 1 |
| Hamamura, K | 1 |
| Matsunaga, N | 1 |
| Yoshida, M | 1 |
| Uchida, T | 1 |
| Tsuda, M | 1 |
| Inoue, K | 1 |
| Ohdo, S | 1 |
| Takemura, Y | 1 |
| Yamashita, A | 1 |
| Horiuchi, H | 1 |
| Furuya, M | 1 |
| Yanase, M | 1 |
| Niikura, K | 1 |
| Imai, S | 1 |
| Hatakeyama, N | 1 |
| Kinoshita, H | 1 |
| Tsukiyama, Y | 1 |
| Senba, E | 1 |
| Matoba, M | 1 |
| Kuzumaki, N | 1 |
| Yamazaki, M | 1 |
| Suzuki, T | 1 |
| Narita, M | 1 |
| Boroujerdi, A | 2 |
| Zeng, J | 1 |
| Sharp, K | 1 |
| Kim, D | 1 |
| Steward, O | 1 |
| Luo, DZ | 1 |
| Faughnan, LG | 1 |
| Relling, MV | 1 |
| Hinds, PS | 1 |
| Hankins, G | 1 |
| Pauley, JL | 1 |
| Schalkwijk, A | 1 |
| Verhagen, CA | 1 |
| Engels, Y | 1 |
| Hekster, YA | 1 |
| Vissers, KC | 1 |
| McQuay, HJ | 3 |
| Tassinari, D | 1 |
| Drudi, F | 1 |
| Carloni, F | 1 |
| Possenti, C | 1 |
| Santelmo, C | 1 |
| Castellani, C | 1 |
| Erdoğan, G | 1 |
| Ceyhan, D | 1 |
| Güleç, S | 1 |
| Irving, GA | 1 |
| Ahl, J | 1 |
| Robinson, MJ | 1 |
| Skljarevski, V | 1 |
| Malcolm, SK | 1 |
| Wu, YT | 1 |
| Lai, MH | 2 |
| Lu, SC | 1 |
| Chang, ST | 2 |
| Heltsley, R | 1 |
| Depriest, A | 1 |
| Black, DL | 1 |
| Robert, T | 1 |
| Caplan, YH | 1 |
| Cone, EJ | 1 |
| Rehman, SU | 1 |
| Khan, MZ | 1 |
| Hussain, R | 1 |
| Jamshed, A | 1 |
| Mishra, S | 1 |
| Bhatnagar, S | 1 |
| Goyal, GN | 1 |
| Rana, SP | 1 |
| Upadhya, SP | 1 |
| Cidral-Filho, FJ | 1 |
| da Silva, MD | 1 |
| Moré, AO | 1 |
| Córdova, MM | 1 |
| Werner, MF | 1 |
| Santos, AR | 2 |
| Gunduz, O | 1 |
| Oltulu, C | 1 |
| Guven, R | 1 |
| Buldum, D | 1 |
| Ulugol, A | 1 |
| Navarro, A | 2 |
| Saldaña, MT | 2 |
| Pérez, C | 2 |
| Masramón, X | 2 |
| Rejas, J | 4 |
| Yeh, CY | 1 |
| Chung, SC | 1 |
| Tseng, FL | 1 |
| Tsai, YC | 1 |
| Liu, YC | 1 |
| Ogawa, K | 1 |
| Shinohara, S | 1 |
| Yoneda, Y | 1 |
| Kato, A | 1 |
| Ma, LL | 1 |
| Liu, W | 1 |
| Huang, YG | 1 |
| Yang, N | 1 |
| Zuo, PP | 1 |
| Storm, A | 1 |
| Hansen, MK | 1 |
| Dyhr, H | 1 |
| Marcher, L | 1 |
| Erichsen, HK | 1 |
| Sheykhzade, M | 1 |
| Miyazaki, R | 1 |
| Morimoto, S | 1 |
| Ito, M | 1 |
| Oda, S | 1 |
| Sugiyama, A | 1 |
| Kuroda, M | 1 |
| Adachi-Akahane, S | 1 |
| Amin, B | 1 |
| Hosseinzadeh, H | 1 |
| Grégoire, S | 1 |
| Michaud, V | 1 |
| Brunton, LM | 1 |
| Laporte, DM | 1 |
| Chaparro, LE | 1 |
| de Biase, S | 1 |
| Merlino, G | 1 |
| Lorenzut, S | 1 |
| Valente, M | 1 |
| Gigli, GL | 1 |
| Ibitoye, RT | 1 |
| Rajbhandari, SM | 1 |
| Smith, BH | 1 |
| Higgins, C | 1 |
| Baldacchino, A | 1 |
| Kidd, B | 1 |
| Bannister, J | 1 |
| Vedula, SS | 1 |
| Goldman, PS | 1 |
| Rona, IJ | 1 |
| Greene, TM | 1 |
| Solak, Y | 1 |
| Biyik, Z | 1 |
| Atalay, H | 1 |
| Gaipov, A | 1 |
| Guney, F | 1 |
| Turk, S | 1 |
| Covic, A | 1 |
| Goldsmith, D | 1 |
| Kanbay, M | 1 |
| Lee, JE | 1 |
| Wang, KC | 1 |
| Chiang, HY | 1 |
| Hsieh, JH | 1 |
| Hsieh, ST | 1 |
| Chen, WH | 1 |
| Li, TH | 1 |
| Lee, LH | 1 |
| Huang, CC | 1 |
| Dias, QM | 1 |
| Silveira, JW | 1 |
| Reis, GM | 1 |
| Costa, KA | 1 |
| Rossaneis, AC | 1 |
| Fais, RS | 1 |
| Prado, WA | 1 |
| Driver, CJ | 1 |
| Chandler, KE | 1 |
| Craig, A | 1 |
| McGonnell, IM | 1 |
| Brodbelt, DC | 1 |
| Taneja, A | 2 |
| Nyberg, J | 2 |
| Danhof, M | 2 |
| de Lange, EC | 1 |
| Arcos, M | 1 |
| Palanca, JM | 1 |
| Montes, F | 1 |
| Barrios, C | 1 |
| Fuzier, R | 1 |
| Serres, I | 1 |
| Guitton, E | 1 |
| Lapeyre-Mestre, M | 1 |
| Montastruc, JL | 1 |
| Murashko, NK | 1 |
| Lee, BS | 2 |
| Jun, IG | 1 |
| Park, JY | 1 |
| Tai, Q | 1 |
| Kirshblum, S | 1 |
| Millis, S | 1 |
| Johnston, M | 1 |
| DeLisa, JA | 1 |
| Benito-Leon, J | 2 |
| Martinez-Salio, A | 1 |
| Berbel, A | 1 |
| Hunt, CH | 1 |
| Dodick, DW | 1 |
| Bosch, EP | 1 |
| Ahn, SH | 1 |
| Park, HW | 1 |
| Moon, HW | 1 |
| Jang, SH | 1 |
| Sakong, J | 1 |
| Bae, JH | 1 |
| Glanzman, RL | 2 |
| Neumeier, S | 1 |
| Brinkschmidt, T | 1 |
| Jensen, U | 1 |
| McCleane, GJ | 1 |
| Scheinfeld, N | 1 |
| Singh, D | 1 |
| Kennedy, DH | 1 |
| Ries, M | 1 |
| Mengel, E | 1 |
| Kutschke, G | 1 |
| Kim, KS | 1 |
| Birklein, F | 1 |
| Krummenauer, F | 1 |
| Beck, M | 1 |
| Fox, A | 2 |
| Gentry, C | 1 |
| Patel, S | 2 |
| Kesingland, A | 2 |
| Bevan, S | 1 |
| Maimone-Baronello, M | 1 |
| Piccoli, F | 1 |
| La Bella, V | 1 |
| Curran, MP | 1 |
| Wagstaff, AJ | 1 |
| Stacey, BR | 2 |
| Junker, U | 1 |
| Brunnmüller, U | 1 |
| Berger, A | 2 |
| Dukes, E | 2 |
| McCarberg, B | 1 |
| Liss, M | 1 |
| Oster, G | 2 |
| White, WT | 1 |
| Patel, N | 1 |
| Drass, M | 1 |
| Nalamachu, S | 1 |
| Nicholson, BD | 1 |
| Levendoglu, F | 1 |
| Ogün, CO | 1 |
| Ozerbil, O | 1 |
| Ogün, TC | 1 |
| Ugurlu, H | 1 |
| Simpson, MA | 1 |
| Rodrigues-Filho, R | 1 |
| Campos, MM | 1 |
| Ferreira, J | 1 |
| Bertelli, JA | 1 |
| Dubinsky, RM | 1 |
| Kabbani, H | 1 |
| El-Chami, Z | 1 |
| Boutwell, C | 1 |
| Ali, H | 1 |
| Hahn, K | 1 |
| Arendt, G | 1 |
| Braun, JS | 1 |
| von Giesen, HJ | 1 |
| Husstedt, IW | 1 |
| Maschke, M | 1 |
| Straube, ME | 1 |
| Schielke, E | 1 |
| Sra, KK | 1 |
| Tyring, SK | 1 |
| Wareham, D | 2 |
| Tive, L | 1 |
| Huang, S | 1 |
| Douglas, MW | 1 |
| Johnson, RW | 1 |
| Cunningham, AL | 1 |
| Criscuolo, S | 1 |
| Auletta, C | 1 |
| Lippi, S | 1 |
| Brogi, F | 1 |
| Brogi, A | 1 |
| Weaver, DF | 1 |
| Walczak, JS | 1 |
| Pichette, V | 1 |
| Leblond, F | 1 |
| Desbiens, K | 1 |
| Beaulieu, P | 1 |
| Baillie, JK | 1 |
| Power, I | 1 |
| Tesfaye, S | 1 |
| Selvarajah, D | 1 |
| Edwards, JE | 1 |
| Jean, WH | 1 |
| Wu, CC | 1 |
| Mok, MS | 1 |
| Misery, L | 1 |
| Weissenbacher, S | 1 |
| Ring, J | 1 |
| Hofmann, H | 1 |
| Coderre, TJ | 1 |
| Kumar, N | 1 |
| Lefebvre, CD | 1 |
| Yu, JS | 1 |
| Mourouzis, C | 1 |
| Saranteas, T | 1 |
| Rallis, G | 1 |
| Anagnostopoulou, S | 1 |
| Tesseromatis, C | 1 |
| Garry, EM | 1 |
| Delaney, A | 1 |
| Anderson, HA | 1 |
| Sirinathsinghji, EC | 1 |
| Clapp, RH | 1 |
| Martin, WJ | 1 |
| Kinchington, PR | 1 |
| Krah, DL | 1 |
| Fleetwood-Walker, SM | 1 |
| Miller, R | 1 |
| Ewy, W | 1 |
| Corrigan, BW | 1 |
| Ouellet, D | 1 |
| Hermann, D | 1 |
| Kowalski, KG | 1 |
| Lockwood, P | 1 |
| Koup, JR | 1 |
| Donevan, S | 1 |
| El-Kattan, A | 1 |
| Li, CS | 1 |
| Werth, JL | 1 |
| Feltner, DE | 1 |
| Lalonde, RL | 1 |
| Cepeda, MS | 1 |
| Butkovic, D | 1 |
| Toljan, S | 1 |
| Mihovilovic-Novak, B | 1 |
| Gálvez, R | 2 |
| Marsal, C | 1 |
| Vidal, J | 1 |
| Cohen, AS | 1 |
| Gantenbein, AR | 1 |
| Goadsby, PJ | 1 |
| Rode, F | 2 |
| Broløs, T | 2 |
| Blackburn-Munro, G | 2 |
| Moulin, D | 1 |
| Xiao, W | 1 |
| Bennett, GJ | 1 |
| Luo, ZD | 1 |
| Keskinbora, K | 2 |
| Pekel, AF | 2 |
| Aydinli, I | 2 |
| Vadalouca, A | 1 |
| Siafaka, I | 1 |
| Argyra, E | 1 |
| Vrachnou, E | 1 |
| Moka, E | 1 |
| Povedano, M | 1 |
| Gascón, J | 1 |
| Barsukov, IN | 1 |
| Kashin, AV | 1 |
| Kostiuk, GP | 1 |
| Bastías A, MJ | 1 |
| Toro C, L | 1 |
| Olmos C, P | 1 |
| Thomsen, M | 1 |
| Jensen, DG | 1 |
| Beyreuther, BK | 1 |
| Callizot, N | 1 |
| Brot, MD | 1 |
| Feldman, R | 1 |
| Bain, SC | 1 |
| Stöhr, T | 1 |
| Davies, A | 1 |
| Hendrich, J | 1 |
| Van Minh, AT | 1 |
| Wratten, J | 1 |
| Douglas, L | 1 |
| Terneus, W | 1 |
| Eisenberg, E | 1 |
| River, Y | 1 |
| Shifrin, A | 1 |
| Krivoy, N | 1 |
| Okada, M | 1 |
| Shinjo, T | 1 |
| Davis, JL | 1 |
| Posner, LP | 1 |
| Elce, Y | 1 |
| Dalal, A | 1 |
| Zhou, L | 1 |
| Wang, TY | 1 |
| Chang, CC | 1 |
| Tsai, KC | 1 |
| Stubhaug, A | 1 |
| Arnèr, S | 1 |
| Biber, B | 1 |
| Boivie, J | 1 |
| Mannheimer, C | 1 |
| Kalliomäki, J | 1 |
| Giannopoulos, S | 1 |
| Kosmidou, M | 1 |
| Kyritsis, AP | 1 |
| Straube, S | 1 |
| Rosner, H | 1 |
| Rubin, L | 1 |
| Kestenbaum, A | 1 |
| Segal, AZ | 1 |
| Rordorf, G | 1 |
| Childers, MK | 1 |
| Holland, D | 1 |
| Sánchez-Valiente, S | 1 |
| Brasseur, L | 1 |
| Parker, F | 1 |
| Chauvin, M | 1 |
| Abdi, S | 1 |
| Lee, DH | 1 |
| Chung, JM | 1 |
| Rowbotham, M | 1 |
| Harden, N | 1 |
| Bernstein, P | 1 |
| Magnus-Miller, L | 1 |
| Low, PA | 1 |
| Dotson, RM | 1 |
| García Callejo, FJ | 1 |
| Marco Algarra, J | 1 |
| Talamantes Escribá, F | 1 |
| Martínez Beneyto, MP | 1 |
| Esparcia Navarro, M | 1 |
| Morant Ventura, A | 1 |
| Colman, E | 1 |
| Stadel, BV | 1 |
| Marples, IL | 1 |
| Murray, P | 1 |
| Hays, H | 1 |
| Woodroffe, MA | 1 |
| Beydoun, A | 1 |
| Magnus, L | 1 |
| Clark, JD | 1 |
| Elliott, J | 1 |
| Fudin, J | 1 |
| Audette, CM | 1 |
| Harden, RN | 1 |
| Laird, MA | 1 |
| Gidal, BE | 1 |
| Carver, A | 1 |
| Payne, R | 1 |
| Foley, K | 1 |
| Hughes, J | 1 |
| Singh, L | 1 |
| Takasaki, I | 1 |
| Andoh, T | 1 |
| Nitta, M | 1 |
| Takahata, H | 1 |
| Nemoto, H | 1 |
| Shiraki, K | 1 |
| Nojima, H | 1 |
| Kuraishi, Y | 1 |
| Graff-Radford, SB | 1 |
| Eckhardt, K | 1 |
| Hufschmidt, A | 1 |
| Feuerstein, TJ | 1 |
| Naeem, S | 1 |
| Froestl, W | 1 |
| Capogna, M | 1 |
| Urban, L | 1 |
| Kamp-Jensen, M | 1 |
| Werner, MU | 1 |
| Rovetta, G | 1 |
| Baratto, L | 1 |
| Farinelli, G | 1 |
| Monteforte, P | 1 |
| Corradini, L | 1 |
| Briscini, L | 1 |
| Ongini, E | 1 |
| Bertorelli, R | 1 |
| Frijns, PD | 1 |
| Maton, S | 1 |
| Picardo, A | 1 |
| Garrido, A | 1 |
| Cuberes, R | 1 |
| Dougherty, JA | 1 |
| Rhoney, DH | 1 |
| Mellegers, MA | 1 |
| Furlan, AD | 1 |
| Mailis, A | 1 |
| Block, F | 1 |
| Chong, MS | 1 |
| Smith, TE | 1 |
| Hanna, M | 1 |
| Bowsher, D | 1 |
| Gehling, M | 1 |
| Tryba, M | 1 |
| Covington, EC | 1 |
| Ross, JR | 1 |
| Waight, C | 1 |
| Riley, J | 1 |
| Broadley, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia[NCT00137111] | Phase 3 | 501 participants (Actual) | Interventional | 2000-07-08 | Completed | ||
| A Double-Blind Randomized Placebo-Controlled Clinical Trial of Preoperative Gabapentin Prior to Vaginal Apical Suspension Prolapse Procedures[NCT05658887] | Phase 4 | 110 participants (Anticipated) | Interventional | 2023-01-01 | Enrolling by invitation | ||
| Evaluation of the Efficacy of Perioperative Administration of Tianeptine Versus Pregabalin on Acute and Chronic Post Mastectomy Pain After Breast Cancer Surgery. A Double-Blinded Randomized Controlled Trial.[NCT05935059] | 90 participants (Anticipated) | Interventional | 2023-06-21 | Recruiting | |||
| Effect of Ultrasound Guided Erector Spinae Plane Block Versus Ultrasound Guided Serratus Anterior Block on the Incidence of Post Mastectomy Pain Syndrome, Randomized Double Blinded Controlled Study[NCT05201963] | 120 participants (Anticipated) | Interventional | 2021-11-01 | Recruiting | |||
| GABA-WHY Study: Deprescription of Gabapentinoids in Medical Inpatients[NCT04855578] | 160 participants (Actual) | Interventional | 2021-05-28 | Completed | |||
| Pain Reduction and Changes in Upper Limb Function Produced by Physiotherapy, Ibuprofen Arginine, Gabapentin and the Absence of Treatment, in Carpal Tunnel Syndrome[NCT04025203] | Phase 4 | 80 participants (Anticipated) | Interventional | 2019-08-01 | Recruiting | ||
| Pain Reduction and Changes in Upper Limb Function Produced by Over the Counter Oral Ibuprofen Versus the Lack of Treatment, in Carpal Tunnel Syndrome.[NCT04328805] | Phase 4 | 45 participants (Anticipated) | Interventional | 2020-09-30 | Not yet recruiting | ||
| Oral Gabapentin Versus Control in the Treatment of Carpal Tunnel Syndrome[NCT04285281] | Phase 4 | 50 participants (Anticipated) | Interventional | 2020-03-31 | Not yet recruiting | ||
| Physical Therapy Versus Control in the Treatment of Carpal Tunnel Syndrome[NCT04329247] | 40 participants (Anticipated) | Interventional | 2020-05-31 | Not yet recruiting | |||
| STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis[NCT05603702] | Phase 1 | 24 participants (Anticipated) | Interventional | 2023-03-17 | Recruiting | ||
| A pRospective, Case-controlled Evaluation of oLIceridine for Moderate or sEVEre Pain in Patients With Acute Burn Injuries. (RELIEVE)[NCT05465226] | Phase 4 | 31 participants (Actual) | Interventional | 2023-04-01 | Completed | ||
| Gabapentin Regimens and Their Effects on Opioid Consumption[NCT03334903] | Phase 4 | 77 participants (Actual) | Interventional | 2018-05-15 | Completed | ||
| Cognitive Changes Associated With Initiation of Gabapentin Treatment in Adults With Chronic Pain[NCT04106011] | 3 participants (Actual) | Observational | 2020-01-10 | Terminated (stopped due to PI request - low enrollment) | |||
| Gabapentin Treatment of Postural Tachycardia Syndrome (PoTS): a Pilot Study[NCT04345432] | 10 participants (Actual) | Interventional | 2014-01-31 | Completed | |||
| Effect of Metformin on Chronic Pain After Thoracic Surgery in Diabetic Patients[NCT04089813] | 200 participants (Anticipated) | Observational | 2019-09-10 | Not yet recruiting | |||
| A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy[NCT00159679] | Phase 4 | 167 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial of Pregabalin Versus Placebo in the Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy[NCT00143156] | Phase 3 | 450 participants | Interventional | 2005-03-31 | Completed | ||
| A 14-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin (150mg-600mg/Day) Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy (DPN).[NCT00156078] | Phase 4 | 450 participants | Interventional | 2005-01-31 | Completed | ||
| Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate Efficacy And Safety Of Pregabalin (CI-1008) In The Treatment For Pain Associated With Diabetic Peripheral Neuropathy[NCT00553475] | Phase 3 | 314 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Randomized, Double-blind, Placebo Controlled, Superiority Phase II Study to Evaluate the Safety, Pharmacokinetic, Efficacy of Gabapentin as add-on to Morphine in Children From 3 Months to Less Than 18 Years[NCT03275012] | Phase 2 | 0 participants (Actual) | Interventional | 2017-04-04 | Withdrawn (stopped due to Study not started) | ||
| Randomized, Double-blind, Double-dummy, Active Controlled, Multicentre, Non-inferiority Phase-III Study to Compare Gabapentin Liquid Formulation to Tramadol in Children Experiencing Moderate to Severe Chronic Neuropathic or Mixed Pain[NCT02722603] | Phase 3 | 2 participants (Actual) | Interventional | 2018-09-12 | Terminated (stopped due to The study was early terminated due to insufficient recruitment) | ||
| Gabapentin Versus Transdermal Fentanyl Matrix (TDF) for Chronic Neuropathic Pain (of Radicular Origin): A Multicenter Randomized, Parallel Group, Rater Blinded, Non-inferiority Trial[NCT01127100] | Phase 4 | 108 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| Cannabidiol for Fibromyalgia -The CANNFIB Trial Protocol for a Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-center Trial[NCT04729179] | Phase 3 | 200 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| Pain Phenotyping of Patients With Bone Cancer Pain[NCT03908853] | 70 participants (Anticipated) | Observational | 2019-02-05 | Recruiting | |||
| Auricular Point Acupressure to Manage Chemotherapy Induced Neuropathy[NCT04920097] | 240 participants (Anticipated) | Interventional | 2021-07-08 | Recruiting | |||
| Intravenous Lidocaine Infusion Versus Oral Duloxetine For The Prevention And Treatment Of Chemotherapy Induced Peripheral Neuropathy Among Breast Cancer Patients[NCT04732455] | 60 participants (Actual) | Interventional | 2021-01-15 | Completed | |||
| The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer[NCT04558034] | 14 participants (Actual) | Interventional | 2020-08-04 | Terminated (stopped due to Principal Investigator retired before study completed.) | |||
| Effect of Cryotherapy in Controlling Peripheral Neuropathy in Cancer Children[NCT04536207] | 60 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | |||
| Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer[NCT02549534] | 29 participants (Actual) | Observational | 2015-09-30 | Completed | |||
| Drug Repurposing for the Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN)[NCT04780854] | Phase 2 | 68 participants (Anticipated) | Interventional | 2020-11-03 | Recruiting | ||
| Effectiveness and Cost-effectiveness of Ozone Therapy in Patients With Pain Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (O3NPIQ)[NCT04299893] | Phase 2/Phase 3 | 42 participants (Anticipated) | Interventional | 2020-11-30 | Recruiting | ||
| Electro-acupuncture for the Prevention and Treatment of Oxaliplatin-induced Neurotoxicity in Colorectal Cancer Patients: a Prospective, Randomized, Sham-controlled, Double-blinded and Multicenter Study[NCT05798884] | 150 participants (Anticipated) | Interventional | 2023-05-31 | Not yet recruiting | |||
| EN20-01: A 24 Week Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Moderate to Severe Knee Osteoarthritis Pain.[NCT05025787] | Phase 2 | 77 participants (Anticipated) | Interventional | 2021-10-25 | Recruiting | ||
| An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients With Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain[NCT00385671] | Phase 4 | 407 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Nabilone Use for Acute Pain in Inflammatory Bowel Disease Patients With Chronic Opioid Use Undergoing Gastrointestinal Surgery: A Single-centered Randomized Controlled Trial[NCT03422861] | 80 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | |||
| Effect of Ambroxol on the Inflammatory Markers and Clinical Outcome of Patients With Diabetic Peripheral Neuropathy[NCT05558878] | 80 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | |||
| A Double-Blind Randomized Placebo-Controlled Trial of the Time to Onset of Pain Relief in Subjects With Post Therapeutic Neuralgia (PHN) Treated With Pregabalin (150 - 600 Mg/Day Flexible Optimized Dose or 300 Mg/Day Fixed Dose) or Placebo[NCT00159666] | Phase 4 | 255 participants | Interventional | 2004-10-31 | Completed | ||
| An 8-Week Multi-Center, Randomized, Double Blind, Placebo-Controlled Study To Evaluate The Efficacy, Safety And Tolerability Of Pregabalin (150mg-600mg/Day) Using A Flexible Dosing Schedule In The Treatment Of Subjects With Symptoms Of Neuropathic Pain[NCT00301223] | Phase 3 | 309 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| A 17-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial Of Pregabalin For The Treatment Of Chronic Central Neuropathic Pain After Spinal Cord Injury[NCT00407745] | Phase 3 | 220 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| BotulInum Toxin Type A for Peripheral Neuropathic Pain in subjEcts With Carpal Tunnel Syndrome: a Multicenter, Randomized, Doubleblind, Placebo-controlled Study[NCT05411900] | Phase 2 | 164 participants (Anticipated) | Interventional | 2022-05-25 | Recruiting | ||
| Hypogastric Plexus Block and Ganglion Impar Block for Cervical and Endometrial Cancer Pain Management: A Randomized Controlled Trial of Efficacy and Safety[NCT05427058] | 36 participants (Anticipated) | Interventional | 2022-08-01 | Not yet recruiting | |||
| Neuropathic Foot and Ankle in Rheumatoid Arthritis : Ultrasound and Nerve Conduction Study[NCT04550884] | 80 participants (Anticipated) | Observational | 2020-10-31 | Not yet recruiting | |||
| NanaBis™ an Oro-buccal Administered Equimolar d9-THC & CBD Formulation as Monotherapy for Management of Opioid Requiring Bone Pain Due to Metastatic Cancer: Phase 3 Multi Centre Blinded Randomized Withdrawal Active & Placebo Controlled Trial[NCT04808531] | Phase 3 | 360 participants (Anticipated) | Interventional | 2023-11-30 | Not yet recruiting | ||
| Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.[NCT06030297] | 301 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | |||
| Nabilone and THC/CBD for the Treatment of FBSS Refractory Pain[NCT03210766] | 20 participants (Actual) | Observational | 2014-09-01 | Completed | |||
| Erenumab as a Therapeutic Approach for the Management of Trigeminal Neuropathic Pain (TNP)[NCT05142228] | Phase 2 | 5 participants (Actual) | Interventional | 2022-04-01 | Terminated (stopped due to Low enrollment rate) | ||
| Effects of Intra-Operative Ropivaciane Epidural Injection on Post-Operative Outcomes Following Elective Lumbar Fusion[NCT03035656] | Phase 4 | 228 participants (Anticipated) | Interventional | 2019-03-01 | Not yet recruiting | ||
| Efficacy of Pregabalin and Duloxetine in Patients With Painful Diabetic Peripheral Neuropathy (PDPN): the Effect of Pain on Cognitive Function, Sleep and Quality of Life (BLOSSOM)[NCT04246619] | Phase 4 | 254 participants (Actual) | Interventional | 2019-11-12 | Terminated (stopped due to The statistical analysis will still provide relevant results with the same statistical power as initially planned.COVID-19 pandemic prolonged the recruiting period and consequently affected the costs of the clinical trial.) | ||
| Topical Compounded Pain Creams And Pain Perception (TOPCAPP)[NCT01862848] | 285 participants (Actual) | Observational [Patient Registry] | 2012-11-30 | Completed | |||
| Hypoalgesic Effect of Median Nerve Neural Mobilization in Cervicobrachial Pain Compared to a Controlled Group[NCT02596815] | 51 participants (Actual) | Interventional | 2015-07-31 | Completed | |||
| Hypoalgesic Effect of Neural Mobilization in Cervicobrachial Pain Compared to a Controlled Group[NCT02595294] | 52 participants (Actual) | Interventional | 2015-07-31 | Completed | |||
| Hypoalgesic Effect of Median Nerve Neural Mobilization Versus Ibuprofen Pharmacologic Treatment in Patients With Cervicobrachial Pain[NCT02593721] | Phase 2/Phase 3 | 50 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Randomized Controlled Trial Comparing Two Different Bladder Instillation Treatments for Interstitial Cystitis/Bladder Pain Syndrome[NCT03463915] | Phase 3 | 90 participants (Actual) | Interventional | 2019-01-25 | Completed | ||
| Subcutaneous Injection of Botulinum Toxin A for At--Level Back Pain in Patients With Spinal Cord Injury[NCT02736890] | Phase 2 | 8 participants (Actual) | Interventional | 2016-03-31 | Terminated (stopped due to funding not available to continue) | ||
| Effects of Transverse Abdominis Plane Block Guided by Ultrasound on the Postoperative Analgesia and Quality of Lives Among the Patients Undergo Inguinal Hernia Repair[NCT02292095] | Phase 4 | 260 participants (Anticipated) | Interventional | 2016-01-31 | Not yet recruiting | ||
| Analgesic Effect of Pregabalin in Patients Undergoing Total Abdominal Hysterectomy[NCT01466101] | 0 participants (Actual) | Interventional | 2011-01-31 | Withdrawn (stopped due to PI left the institution. No subjects screened or enrolled.) | |||
| Effect of Preoperative Pregabalin on Propofol Induction Dose[NCT01158859] | Phase 4 | 50 participants (Anticipated) | Interventional | 2010-04-30 | Completed | ||
| Perioperative Administration of Pregabalin in Laparoscopic Living Donor Nephrectomy (L-LDN) - an Adjuvance to Peroral Analgetic Treatment - a Randomized Controlled Study[NCT01059331] | Phase 4 | 80 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| Persistent Postoperative Pain Incidence With Long Term Perioperative Gabapentin Used[NCT02693821] | Phase 4 | 122 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"White blood cell (leukocytes) counts in peripheral blood by Complete Blood Count~Measurement: Percentage change of leukemia cells from baseline" (NCT00137111)
Timeframe: Immediately before the methotrexate infusion and three days after subsequent infusion
| Intervention | Percent change (Mean) |
|---|---|
| 4 hr | -44 |
| 24 hr | -50 |
CCR was measured from end of week 56 therapy to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow up time (range) 4.5 (1 to 7.8) years
| Intervention | Percentage of participants (Number) |
|---|---|
| Patients With High Risk of CNS Relapse | 92.2 |
Children were randomly assigned to receive initial single-agent treatment with HDMTX (1g/m^2) as either a 24-hour infusion or a 4-hour infusion and the outcome measure was the accumulation of MTXPG in leukemia cells. (NCT00137111)
Timeframe: 42 hours after start of high dose methotrexate infusion (HDMTX)
| Intervention | pmol/1,000,000,000 cells (Mean) |
|---|---|
| 4 hr | 1688 |
| 24 hr | 2521 |
EFS was measured from the start of on-study to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Failure to enter remission was considered an event at time zero. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow-up time (range) 5.6 (1.3 to 8.9) years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Total Therapy | 87.3 |
Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of CASP1 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment
| Intervention | arbitrary units (Median) | |
|---|---|---|
| Prednisolone-sensitive cells | Prednisolone-resistant cells | |
| Total Therapy | 341.3 | 447.9 |
Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of NLRP3 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment
| Intervention | arbitrary units (Median) | |
|---|---|---|
| Prednisolone-sensitive cells | Prednisolone-resistant cells | |
| Total Therapy | 41.2 | 110.7 |
Detection of MRD at end of induction where positive MRD was defined as one or more leukemic cell per 10,000 mononuclear bone-marrow cells (>=0.01%). (NCT00137111)
Timeframe: End of Induction (Day 46 MRD measurement)
| Intervention | participants (Number) | |
|---|---|---|
| Negative <0.01% | Positive >= 0.01% | |
| Total Therapy | 390 | 102 |
Surgical site pain. Scale 0-10, with 0 best and 10 worst (NCT03334903)
Timeframe: 2-3 months after surgery (at 2nd postoperative appointment)
| Intervention | score on 10-point scale (Mean) |
|---|---|
| Standard of Care | 2.26 |
| Postoperative Gabapentin Regimen | 2.46 |
Surgical site pain. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 3.84 |
| Postoperative Gabapentin Regimen | 3.54 |
Sleep quality. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 5.73 |
| Postoperative Gabapentin Regimen | 6.38 |
Nausea. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 0.36 |
| Postoperative Gabapentin Regimen | 0.17 |
Satisfaction. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 7.83 |
| Postoperative Gabapentin Regimen | 8.48 |
Number of days until patients are finished consuming opioid medications after discharge. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | days (Mean) |
|---|---|
| Standard of Care | 14.8 |
| Postoperative Gabapentin Regimen | 18.7 |
Mean opioid consumption, measured in mg of morphine equivalents. (NCT03334903)
Timeframe: 2-3 months following surgery (total amount measured at second postoperative appointment; means assessed afterwards).
| Intervention | morphine equivalents (Mean) |
|---|---|
| Standard of Care | 287.0 |
| Postoperative Gabapentin Regimen | 281.1 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 1.~Change from baseline: Score at Week 1 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 1
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.39 |
| Pregabalin 300 mg/Day | -0.82 |
| Pregabalin 600 mg/Day | -1.14 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 10.~Change from baseline: Score at Week 10 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 10
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.23 |
| Pregabalin 300 mg/Day | -1.93 |
| Pregabalin 600 mg/Day | -2.10 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 11.~Change from baseline: Score at Week 11 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 11
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.32 |
| Pregabalin 300 mg/Day | -1.95 |
| Pregabalin 600 mg/Day | -2.09 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 12.~Change from baseline: Score at Week 12 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 12
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.36 |
| Pregabalin 300 mg/Day | -2.01 |
| Pregabalin 600 mg/Day | -2.13 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 13.~Change from baseline: Score at Week 13 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 13
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.38 |
| Pregabalin 300 mg/Day | -2.04 |
| Pregabalin 600 mg/Day | -2.12 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 2.~Change from baseline: Score at Week 2 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 2
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.57 |
| Pregabalin 300 mg/Day | -1.17 |
| Pregabalin 600 mg/Day | -1.80 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 3.~Change from baseline: Score at Week 3 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 3
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.80 |
| Pregabalin 300 mg/Day | -1.40 |
| Pregabalin 600 mg/Day | -1.93 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 4.~Change from baseline: Score at Week 4 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 4
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.89 |
| Pregabalin 300 mg/Day | -1.53 |
| Pregabalin 600 mg/Day | -2.00 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 5.~Change from baseline: Score at Week 5 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 5
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.91 |
| Pregabalin 300 mg/Day | -1.57 |
| Pregabalin 600 mg/Day | -2.07 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 6.~Change from baseline: Score at Week 6 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 6
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.94 |
| Pregabalin 300 mg/Day | -1.72 |
| Pregabalin 600 mg/Day | -2.06 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 7.~Change from baseline: Score at Week 7 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 7
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.04 |
| Pregabalin 300 mg/Day | -1.76 |
| Pregabalin 600 mg/Day | -2.13 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 8.~Change from baseline: Score at Week 8 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 8
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.18 |
| Pregabalin 300 mg/Day | -1.85 |
| Pregabalin 600 mg/Day | -2.12 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 9.~Change from baseline: Score at Week 9 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 9
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.20 |
| Pregabalin 300 mg/Day | -1.93 |
| Pregabalin 600 mg/Day | -2.06 |
The mean change from baseline in the weekly mean sleep interference score at study endpoint. Score range is from 0-10. Higher scores indicate more severe interference with sleep. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.74 |
| Pregabalin 300 mg/Day | -1.59 |
| Pregabalin 600 mg/Day | -1.36 |
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for overall sleep problems index ranges from 0-100. Higher scores indicate more of the attribute. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -7.91 |
| Pregabalin 300 mg/Day | -11.45 |
| Pregabalin 600 mg/Day | -9.73 |
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for quantity of sleep ranges from 0-24. Higher scores indicate more of the attribute named in the subscale. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 0.37 |
| Pregabalin 300 mg/Day | 0.69 |
| Pregabalin 600 mg/Day | 0.54 |
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep adequacy ranges from 0-100. Higher scores indicate more of the attribute. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 12.08 |
| Pregabalin 300 mg/Day | 17.69 |
| Pregabalin 600 mg/Day | 21.73 |
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep disturbance ranges from 0-100. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -9.03 |
| Pregabalin 300 mg/Day | -15.40 |
| Pregabalin 600 mg/Day | -12.81 |
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep shortness of breath or headache ranges from 0-100. Higher scores indicate more of the attribute. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.63 |
| Pregabalin 300 mg/Day | -3.02 |
| Pregabalin 600 mg/Day | -4.47 |
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for snoring ranges from 0-100. Higher scores indicate more of the attribute. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -6.00 |
| Pregabalin 300 mg/Day | -5.96 |
| Pregabalin 600 mg/Day | -1.56 |
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for somnolence ranges from 0-100. Higher scores indicate more of the attribute. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -2.96 |
| Pregabalin 300 mg/Day | 0.83 |
| Pregabalin 600 mg/Day | 4.83 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 10.34 |
| Pregabalin 300 mg/Day | 11.84 |
| Pregabalin 600 mg/Day | 12.89 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 2.31 |
| Pregabalin 300 mg/Day | 3.29 |
| Pregabalin 600 mg/Day | 4.40 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 3.84 |
| Pregabalin 300 mg/Day | 5.33 |
| Pregabalin 600 mg/Day | 7.81 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 2.70 |
| Pregabalin 300 mg/Day | 2.43 |
| Pregabalin 600 mg/Day | 3.86 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 4.13 |
| Pregabalin 300 mg/Day | 5.05 |
| Pregabalin 600 mg/Day | 6.35 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 4.38 |
| Pregabalin 300 mg/Day | 2.28 |
| Pregabalin 600 mg/Day | 3.97 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 3.00 |
| Pregabalin 300 mg/Day | 8.06 |
| Pregabalin 600 mg/Day | 11.16 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 5.28 |
| Pregabalin 300 mg/Day | 4.20 |
| Pregabalin 600 mg/Day | 12.87 |
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Affective score ranges from 0-12. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.83 |
| Pregabalin 300 mg/Day | -1.43 |
| Pregabalin 600 mg/Day | -1.39 |
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Present pain intensity score ranges from 0-5. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.59 |
| Pregabalin 300 mg/Day | -0.80 |
| Pregabalin 600 mg/Day | -0.96 |
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Sensory score ranges from 0-33. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -2.82 |
| Pregabalin 300 mg/Day | -4.60 |
| Pregabalin 600 mg/Day | -4.95 |
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Total score ranges from 0-45. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -3.68 |
| Pregabalin 300 mg/Day | -6.03 |
| Pregabalin 600 mg/Day | -6.36 |
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Visual Analogue Scale Score ranges from 0-100 mm. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | mm (Least Squares Mean) |
|---|---|
| Placebo | -16.92 |
| Pregabalin 300 mg/Day | -24.19 |
| Pregabalin 600 mg/Day | -24.41 |
Change from baseline: Score at study endpoint minus score at baseline. Study endpoint is defined as the mean of the last seven entries of the daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) while on study medication up to and including day after last dose. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.20 |
| Pregabalin 300 mg/Day | -1.82 |
| Pregabalin 600 mg/Day | -1.94 |
Change from baseline: Score at study endpoint minus score at baseline. Study endpoint is defined as the mean of the last seven entries of the daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) while on study medication up to and including day after last dose. Subjects are classified by exposure to pregabalin, which is estimated by creatinine clearance (CLcr). (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.27 |
| Expected Exposure Pregabalin 300 mg/Day | -1.93 |
| Expected Exposure Pregabalin 600 mg/Day | -1.90 |
Clinical Global Impression of Change is a clinician-rated instrument that measures change in patient's overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). (NCT00553475)
Timeframe: Week 13 or up to discontinuation
| Intervention | score on scale (Mean) |
|---|---|
| Placebo | 3.3 |
| Pregabalin 300 mg/Day | 2.9 |
| Pregabalin 600 mg/Day | 2.7 |
A responder is defined as a subject with a 50% reduction in weekly mean pain score from baseline to study endpoint. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | participants (Number) |
|---|---|
| Placebo | 29 |
| Pregabalin 300 mg/Day | 39 |
| Pregabalin 600 mg/Day | 16 |
The Patient Global Impression of Change is a patient-rated instrument that measures change in patient's overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). (NCT00553475)
Timeframe: Week 13 or up to discontinuation
| Intervention | score on scale (Mean) |
|---|---|
| Placebo | 3.4 |
| Pregabalin 300 mg/Day | 3.2 |
| Pregabalin 600 mg/Day | 2.8 |
A 21-item, patient-completed questionnaire to assess characteristics of depression. Each of the 21 items corresponding to a symptom of depression is summed to give a single score. There is a four-point scale for each item ranging from 0 to 3. Total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Pregabalin | -2.57 |
| Duloxetine | -3.13 |
| Gabapentin + Duloxetine | -2.54 |
Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | kilogram (Least Squares Mean) |
|---|---|
| Pregabalin | 1.00 |
| Duloxetine | -2.39 |
| Gabapentin + Duloxetine | -1.06 |
Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | beats per minute (Least Squares Mean) |
|---|---|
| Pregabalin | -1.30 |
| Duloxetine | 0.80 |
| Gabapentin + Duloxetine | 1.05 |
This is an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Data presented represent the weekly mean of the scores of the average pain severity over the last 24 hours. Scores are based on daily assessments recorded by patients in their diaries. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Gabapentin + Duloxetine | -2.39 |
| Duloxetine | -2.62 |
This is an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Data presented represent the weekly mean of the scores of the average pain severity over the last 24 hours. Scores are based on daily assessments recorded by patients in their diaries. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Pregabalin | -2.12 |
| Duloxetine | -2.62 |
This is an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Data presented represent the weekly mean of the scores of the daily nighttime pain severity over the last 24 hours. Scores are based on daily assessments recorded by patients in their diaries. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Pregabalin | -2.30 |
| Duloxetine | -2.71 |
| Gabapentin + Duloxetine | -2.49 |
This is an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Data presented represent the weekly mean of the scores of the daily worst pain severity over the last 24 hours. Scores are based on daily assessments recorded by patients in their diaries. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Pregabalin | -2.59 |
| Duloxetine | -3.08 |
| Gabapentin + Duloxetine | -2.86 |
This is a nominal outcome reflecting whether or not a clinically-important efficacy outcome was achieved at endpoint. It is based on a comparison between baseline and endpoint scores on an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Used were the weekly mean of the scores of the average pain severity over the last 24 hours. The weekly averages were based on daily assessments recorded by patients in their diaries. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 65 |
| Duloxetine | 68 |
| Gabapentin + Duloxetine | 72 |
This is a nominal outcome reflecting whether or not a clinically-important efficacy outcome was achieved at endpoint. It is based on a comparison between baseline and endpoint scores on an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Used were the weekly mean of the scores of the average pain severity over the last 24 hours. The weekly averages were based on daily assessments recorded by patients in their diaries. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 59 |
| Duloxetine | 64 |
| Gabapentin + Duloxetine | 68 |
Elevated heart rate: >=100 beats per minute (bpm) + an increase of >=10 bpm if baseline <100 bpm. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 2 |
| Duloxetine | 9 |
| Gabapentin + Duloxetine | 6 |
This is a nominal outcome reflecting whether or not a clinically-important efficacy outcome was achieved at endpoint. It is based on a comparison between baseline and endpoint scores on an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Used were the weekly mean of the scores of the average pain severity over the last 24 hours. The weekly averages were based on daily assessments recorded by patients in their diaries. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 48 |
| Duloxetine | 50 |
| Gabapentin + Duloxetine | 47 |
A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse). (NCT00385671)
Timeframe: 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin | 3.03 |
| Duloxetine | 3.01 |
| Gabapentin + Duloxetine | 2.83 |
Number of participants who discontinued. The reasons for discontinuation are presented in the participant flow. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 38 |
| Duloxetine | 51 |
| Gabapentin + Duloxetine | 36 |
This is the number of days required to first achieve a nominal outcome reflecting whether or not a clinically-important efficacy outcome was achieved. It is based on a comparison between baseline and post-baseline scores on an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Used were the weekly mean of the scores of the average pain severity over the last 24 hours. The weekly averages were based on daily assessments recorded by patients in their diaries. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | days (Median) |
|---|---|
| Pregabalin | 56.0 |
| Duloxetine | 35.0 |
| Gabapentin + Duloxetine | 28.0 |
This is the number of days required to first achieve a nominal outcome reflecting whether or not a clinically-important efficacy outcome was achieved. It is based on a comparison between baseline and post-baseline scores on an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Used were the weekly mean of the scores of the average pain severity over the last 24 hours. The weekly averages were based on daily assessments recorded by patients in their diaries. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | days (Median) |
|---|---|
| Pregabalin | 35.0 |
| Duloxetine | 28.0 |
| Gabapentin + Duloxetine | 28.0 |
The Portland Neurotoxicity Scale is a 15-item, patient-completed questionnaire designed to assess the degree of impact of anti-epileptic drug therapy on a number of cognitive and somatomotor parameters. Categories: better=negative change in score; same=no change in score; worse=positive change in score. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| better, total; n=122, n=126, n=128 | same, total; n=122, n=126, n=128 | worse, total; n=122, n=126, n=128 | better, cognitive toxicity; n=126, n=129, n=128 | same, cognitive toxicity; n=126, n=129, n=128 | worse, cognitive toxicity; n=126, n=129, n=128 | better, somatomotor toxicity; n=122, n=126, n=129 | same, somatomotor toxicity; n=122, n=126, n=129 | worse, somatomotor toxicity; n=122, n=126, n=129 | |
| Duloxetine | 84 | 5 | 37 | 80 | 6 | 43 | 74 | 19 | 33 |
| Gabapentin + Duloxetine | 86 | 4 | 38 | 82 | 5 | 41 | 74 | 19 | 36 |
| Pregabalin | 68 | 8 | 46 | 75 | 9 | 42 | 60 | 15 | 47 |
The Resource Utilization Scale measures direct and indirect costs (collected only for US sites). Direct costs include inpatient and outpatient costs, while indirect costs include lost days of work and caregiver time spent with patients. Inpatient costs include costs associated with hospitalizations and time spent in emergency rooms and psychiatric rooms. Outpatient costs include costs associated with visits to various health care providers, home health care by health care providers, and partial care. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| hours worked, greater, n=86, n=90, n=83 | hours worked, same, n=86, n=90, n=83 | hours worked, lower, n=86, n=90, n=83 | hours volunteered, greater, n=86, n=91, n=82 | hours volunteered, same, n=86, n=91, n=82 | hours volunteered, lower, n=86, n=91, n=82 | psychiatric visits, greater, n=92, n=93, n=90 | psychiatric visits, same, n=92, n=93, n=90 | psychiatric visits, lower, n=92, n=93, n=90 | outpatient group visits, greater, n=91, n=92, n=91 | outpatient group visits, same, n=91, n=92, n=91 | outpatient group visits, lower, n=91, n=92, n=91 | outpatient ind. visits, greater, n=91, n=88, n=90 | outpatient ind. visits, same, n=91, n=88, n=90 | outpatient ind. visits, lower, n=91, n=88, n=90 | days of partial care, greater, n=93, n=95, n=90 | days of partial care, same, n=93, n=95, n=90 | days of partial care, lower, n=93, n=95, n=90 | nights of partial care, greater, n=92, n=95, n=91 | nights of partial care, same, n=92, n=95, n=91 | nights of partial care, lower, n=92, n=95, n=91 | ER visits-psychiatric, greater, n=93, n=94, n=91 | ER visits-psychiatric, same, n=93, n=94, n=91 | ER visits-psychiatric, lower, n=93, n=94, n=91 | ER visits-nonpsychiatric, greater,n=91, n=95, n=88 | ER visits-nonpsychiatric, same,n=91, n=95, n=88 | ER visits-nonpsychiatric, lower,n=91, n=95, n=88 | phone mental health, greater,n=94, n=95, n=90 | phone mental health, same,n=94, n=95, n=90 | phone mental health, lower,n=94, n=95, n=90 | nonpsychiatric visits, greater, n=89, n=94, n=83 | nonpsychiatric visits, same, n=89, n=94, n=83 | nonpsychiatric visits, lower, n=89, n=94, n=83 | unpaid care, greater, n=84, n=87, n=86 | unpaid care, same, n=84, n=87, n=86 | unpaid care, lower, n=84, n=87, n=86 | missed work caregiver, greater, n=6, n=9, n=5 | missed work caregiver, same, n=6, n=9, n=5 | missed work caregiver, lower, n=6, n=9, n=5 | paid care, greater, n=60, n=58, n=58 | paid care, same, n=60, n=58, n=58 | paid care, less, n=60, n=58, n=58 | |
| Duloxetine | 12 | 66 | 12 | 8 | 77 | 6 | 0 | 91 | 2 | 0 | 92 | 0 | 1 | 84 | 3 | 1 | 94 | 0 | 1 | 94 | 0 | 0 | 94 | 0 | 4 | 85 | 6 | 1 | 93 | 1 | 20 | 46 | 28 | 0 | 87 | 0 | 0 | 8 | 1 | 0 | 58 | 0 |
| Gabapentin + Duloxetine | 13 | 59 | 11 | 10 | 66 | 6 | 2 | 84 | 4 | 1 | 89 | 1 | 4 | 81 | 5 | 2 | 87 | 1 | 2 | 89 | 0 | 0 | 91 | 0 | 4 | 78 | 6 | 2 | 87 | 1 | 18 | 45 | 20 | 0 | 85 | 1 | 0 | 5 | 0 | 0 | 58 | 0 |
| Pregabalin | 10 | 65 | 11 | 7 | 66 | 13 | 2 | 88 | 2 | 0 | 90 | 1 | 3 | 84 | 4 | 2 | 91 | 0 | 1 | 91 | 0 | 0 | 91 | 2 | 3 | 83 | 5 | 1 | 92 | 1 | 24 | 44 | 21 | 2 | 82 | 0 | 0 | 6 | 0 | 0 | 60 | 0 |
14-item subject-rated scale assessing changes in sexual activity and functioning; structured interview/questionnaire, designed to measure medication related changes in sexual functioning. 5 dimensions of sexual behavior: pleasure; desire/frequency; desire/interest; arousal; orgasm. Total score: obtained across all 5 dimensions, ranges from 14 to 70. Subscale scores: desire/frequency=2-10; desire/interest=3-15; pleasure=1-5; arousal=3-15; orgasm=3-15. Higher scores = better sexual functioning. Categories: better=positive change in score; same=no change in score; worse=negative change in score. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| male, total, better; n=62, n=67, n=66 | male, total, same; n=62, n=67, n=66 | male, total, worse; n=62, n=67, n=66 | female, total, better; n=39, n=42, n=43 | female, total, same; n=39, n=42, n=43 | female, total, worse; n=39, n=42, n=43 | male, pleasure, better; n=64, n=67, n=69 | male, pleasure, same; n=64, n=67, n=69 | male, pleasure, worse; n=64, n=67, n=69 | female, pleasure, better; n=40, n=42, n=43 | female, pleasure, same; n=40, n=42, n=43 | female, pleasure, worse; n=40, n=42, n=43 | male, desire/frequency, better; n=65, n=67, n=69 | male, desire/frequency, same; n=65, n=67, n=69 | male, desire/frequency, worse; n=65, n=67, n=69 | female, desire/frequency, better; n=42, n=42, n=43 | female, desire/frequency, same; n=42, n=42, n=43 | female, desire/frequency, worse; n=42, n=42, n=43 | male, desire/interest, better; n=65, n=67, n=70 | male, desire/interest, same; n=65, n=67, n=70 | male, desire/interest, worse; n=65, n=67, n=70 | female, desire/interest, better; n=42, n=42, n=45 | female, desire/interest, same; n=42, n=42, n=45 | female, desire/interest, worse; n=42, n=42, n=45 | male, arousal, better; n=65, n=67, n=70 | male, arousal, same; n=65, n=67, n=70 | male, arousal, worse; n=65, n=67, n=70 | female, arousal, better; n=40, n=42, n=45 | female, arousal, same; n=40, n=42, n=45 | female, arousal, worse; n=40, n=42, n=45 | male, orgasm, better; n=64, n=67, n=69 | male, orgasm, same; n=64, n=67, n=69 | male, orgasm, worse; n=64, n=67, n=69 | female, orgasm, better; n=40, n=42, n=43 | female, orgasm, same; n=40, n=42, n=43 | female, orgasm, worse; n=40, n=42, n=43 | |
| Duloxetine | 26 | 9 | 32 | 23 | 5 | 14 | 11 | 40 | 16 | 16 | 21 | 5 | 20 | 29 | 18 | 12 | 21 | 9 | 18 | 19 | 30 | 18 | 14 | 10 | 24 | 29 | 14 | 18 | 10 | 14 | 18 | 31 | 18 | 17 | 13 | 12 |
| Gabapentin + Duloxetine | 31 | 11 | 24 | 18 | 7 | 18 | 21 | 32 | 16 | 6 | 32 | 5 | 24 | 23 | 22 | 12 | 24 | 7 | 26 | 17 | 27 | 16 | 17 | 12 | 23 | 33 | 14 | 15 | 16 | 14 | 17 | 29 | 23 | 11 | 16 | 16 |
| Pregabalin | 24 | 9 | 29 | 13 | 5 | 21 | 13 | 39 | 12 | 10 | 23 | 7 | 12 | 36 | 17 | 11 | 21 | 10 | 20 | 19 | 26 | 13 | 12 | 17 | 20 | 28 | 17 | 11 | 14 | 15 | 12 | 29 | 23 | 15 | 13 | 12 |
Presented are numbers of participants who discontinued due to a change from baseline in laboratory analytes or vital signs. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | participants (Number) | |
|---|---|---|
| Increased blood creatinine | Increased blood glucose | |
| Duloxetine | 0 | 0 |
| Gabapentin + Duloxetine | 1 | 0 |
| Pregabalin | 0 | 1 |
Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | millimeter mercury (Least Squares Mean) | |
|---|---|---|
| Diastolic | Systolic | |
| Duloxetine | 2.24 | -3.08 |
| Gabapentin + Duloxetine | -0.79 | -2.08 |
| Pregabalin | 0.18 | -3.31 |
A self-reported scale that measures the interference of pain in the past 24 hours on enjoyment of life. The Interference scores range from 0 (does not interfere) to 10 (completely interferes). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 4.63 | -2.09 |
| Gabapentin + Duloxetine | 5.02 | -2.33 |
| Pregabalin | 4.38 | -1.82 |
A self-reported scale that measures the interference of pain in the past 24 hours on mood. The Interference scores range from 0 (does not interfere) to 10 (completely interferes). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 4.08 | -1.85 |
| Gabapentin + Duloxetine | 4.10 | -1.43 |
| Pregabalin | 3.42 | -1.46 |
A self-reported scale that measures the interference of pain in the past 24 hours on normal work. The Interference scores range from 0 (does not interfere) to 10 (completely interferes). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 4.98 | -1.86 |
| Gabapentin + Duloxetine | 5.15 | -1.88 |
| Pregabalin | 4.61 | -1.63 |
A self-reported scale that measures the interference of pain in the past 24 hours on relations with other people. The Interference scores range from 0 (does not interfere) to 10 (completely interferes). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 3.08 | -1.27 |
| Gabapentin + Duloxetine | 3.29 | -1.17 |
| Pregabalin | 2.96 | -0.97 |
A self-reported scale that measures the interference of pain in the past 24 hours on sleep. The Interference scores range from 0 (does not interfere) to 10 (completely interferes). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 4.97 | -2.12 |
| Gabapentin + Duloxetine | 5.40 | -2.50 |
| Pregabalin | 4.91 | -2.29 |
A self-reported scale that measures the interference of pain in the past 24 hours on walking ability. The Interference scores range from 0 (does not interfere) to 10 (completely interferes). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 5.52 | -2.56 |
| Gabapentin + Duloxetine | 5.79 | -2.09 |
| Pregabalin | 5.25 | -1.88 |
A self-reported scale that measures the interference of pain in the past 24 hours on general activity. The Interference scores range from 0 (does not interfere) to 10 (completely interferes). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 5.03 | -2.38 |
| Gabapentin + Duloxetine | 5.03 | -1.86 |
| Pregabalin | 4.24 | -1.51 |
The Interference scores range from 0 (does not interfere) to 10 (completely interferes). There are 7 questions assessing the interference of pain in the past 24 hours for general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 4.61 | -2.00 |
| Gabapentin + Duloxetine | 4.83 | -1.90 |
| Pregabalin | 4.25 | -1.62 |
A self-reported scale that measures the severity of pain based on the average pain over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 5.65 | -2.44 |
| Gabapentin + Duloxetine | 5.75 | -2.29 |
| Pregabalin | 5.53 | -1.80 |
A self-reported scale that measures the severity of pain based on the least pain experienced over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 4.18 | -1.55 |
| Gabapentin + Duloxetine | 4.07 | -1.54 |
| Pregabalin | 4.23 | -1.27 |
A self-reported scale that measures the severity of pain based on the pain right now. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 5.03 | -2.24 |
| Gabapentin + Duloxetine | 5.36 | -2.19 |
| Pregabalin | 4.98 | -1.77 |
A self-reported scale that measures the severity of pain based on the worst pain experienced over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 Weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 6.87 | -3.02 |
| Gabapentin + Duloxetine | 7.00 | -2.64 |
| Pregabalin | 6.73 | -2.34 |
Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 4.47 | -1.16 |
| Gabapentin + Duloxetine | 4.40 | -1.13 |
| Pregabalin | 4.27 | -1.06 |
(NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | millimole/liter (Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 8.45 | 0.19 |
| Gabapentin + Duloxetine | 7.99 | 0.67 |
| Pregabalin | 8.24 | 0.16 |
(NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | percent (Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 7.51 | -0.01 |
| Gabapentin + Duloxetine | 7.16 | 0.07 |
| Pregabalin | 7.57 | -0.12 |
Aspartate aminotransferase = AST Alanine aminotransferase = ALT Gamma glutamyl transferase = GGT Alkaline phosphatase = AlkPhos (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units/liter (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| baseline, AST, n=119, n=121, n=118 | change, AST, n=119, n=121, n=118 | baseline, ALT, n=120, n=122, n=120 | change, ALT, n=120, n=122, n=120 | baseline, GGT, n=121, n=123, n=120 | change, GGT, n=121, n=123, n=120 | baseline, AlkPhos, n=121, n=123, n=120 | change, AlkPhos, n=121, n=123, n=120 | |
| Duloxetine | 22.84 | -0.52 | 25.04 | -0.16 | 34.29 | -3.03 | 83.74 | 0.55 |
| Gabapentin + Duloxetine | 23.42 | -0.48 | 24.39 | 0.03 | 43.93 | -2.55 | 82.18 | 1.78 |
| Pregabalin | 22.55 | 1.12 | 23.88 | -0.13 | 40.80 | 1.17 | 84.97 | 2.80 |
The LSEQ assesses the effects of psychoactive compounds on sleep and early morning behavior. Participants mark a series of 100 mm line analogue scales, indicating the direction and magnitude of any changes in behavioral state they experience following administration of the drug. Scores are represented in millimeters, higher scores indicate better sleep and better early morning behavior. Subscale score ranges: GTS=0-300, QOS=0-200, AFS=0-200, BFW=0-300. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |||
|---|---|---|---|---|
| GTS, n=122, n=119, n=118 | QOS, n=121, n=118, n=118 | AFS, n=122, n=118, n=118 | BFW, n=124, n=115, n=118 | |
| Duloxetine | 17.40 | 7.39 | 8.14 | 21.04 |
| Gabapentin + Duloxetine | 14.75 | 9.64 | 11.86 | 14.33 |
| Pregabalin | 10.96 | 9.32 | 10.02 | 19.67 |
The Portland Neurotoxicity Scale is a 15-item, patient-completed questionnaire designed to assess the degree of impact of anti-epileptic drug therapy on a number of cognitive and somatomotor parameters. The total score ranges from 15-135 with higher scores indicating more toxicity. The cognitive toxicity score ranges from 10-90 and the somatomotor toxicity score ranges from 5-45, for both higher scores indicate more toxicity. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | ||
|---|---|---|---|
| total, n=122, n=126, n=128 | cognitive toxicity, n=126, n=129, n=128 | somatomotor toxicity, n=122, n=126, n=129 | |
| Duloxetine | -8.92 | -6.23 | -2.58 |
| Gabapentin + Duloxetine | -7.29 | -5.29 | -1.91 |
| Pregabalin | -6.27 | -5.12 | -1.36 |
14-item subject-rated scale assessing medication related changes in sexual activity + functioning. Structured interview/questionnaire. It measures five dimensions of sexual behavior: pleasure; desire/frequency; desire/interest; arousal; and orgasm. The total score is obtained across all 5 dimensions, ranging from 14 to 70. Subscale score ranges: desire/frequency=2-10; desire/interest=3-15; pleasure=1-5; arousal=3-15; orgasm=3-15. Higher scores = better sexual functioning. Least-squares means: adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| male, total; n=62, n=67, n=66 | female, total; n=39; n=42, n=43 | male, pleasure; n=64, n=67, n=69 | female, pleasure; n=40, n=42, n=43 | male, desire/frequency; n=65, n=67, n=69 | female, desire/frequency; n=42, n=42, n=43 | male, desire/interest; n=65, n=67, n=70 | female, desire/interest; n=42, n=42, n=45 | male, arousal; n=65, n=67, n=70 | female, arousal; n=40, n=42, n=45 | male, orgasm; n=64, n=67, n=69 | female, orgasm; n=40, n=42, n=43 | |
| Duloxetine | 0.48 | 1.12 | -0.06 | 0.47 | 0.06 | 0.26 | -0.19 | 0.34 | 0.52 | 0.07 | 0.18 | -0.05 |
| Gabapentin + Duloxetine | 1.29 | -0.61 | 0.13 | -0.09 | 0.16 | 0.30 | 0.05 | 0.01 | 0.52 | -0.30 | 0.17 | -0.85 |
| Pregabalin | -0.53 | -0.01 | 0.08 | 0.15 | -0.02 | 0.21 | -0.27 | -0.17 | 0.17 | -0.11 | -0.39 | 0.31 |
The SDS is completed by the patient and is used to assess the effect of the patient's symptoms on their work/social/family life. Total scores range from 0 to 30, higher values indicate greater disruption in the patient's life. Item 1 assesses the effect of the patient's symptoms on their work/school schedule, Item 2 on their social life/leisure activities, and Item 3 on their family life/home responsibilities. Subscales scores range: 0-10, higher values indicate greater disruption in the patient's life. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |||
|---|---|---|---|---|
| Total | Item 1 | Item 2 | Item 3 | |
| Duloxetine | -3.47 | -1.21 | -1.12 | -1.17 |
| Gabapentin + Duloxetine | -4.54 | -1.95 | -1.53 | -1.54 |
| Pregabalin | -4.96 | -1.96 | -1.64 | -1.70 |
(NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | micromole/liter (Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 8.07 | -0.28 |
| Gabapentin + Duloxetine | 8.23 | -0.42 |
| Pregabalin | 8.43 | -0.51 |
"Treatment-emergent high body weight: weight at last visit >=107% of baseline weight.~Treatment-emergent low body weight: weight at last visit <=93% of baseline weight." (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | participants (Number) | |
|---|---|---|
| high | low | |
| Duloxetine | 1 | 10 |
| Gabapentin + Duloxetine | 3 | 8 |
| Pregabalin | 6 | 2 |
"Elevated systolic blood pressure: >=130 millimeter mercury (mm Hg) + an increase of >=10 mm Hg if baseline <130 mm Hg.~Elevated diastolic blood pressure: >=85 mm Hg + an increase of >=10 mm Hg if baseline <85 mm Hg." (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | participants (Number) | |
|---|---|---|
| diastolic, n=94, n=98, n=100 | systolic, n=42, n=39, n=56 | |
| Duloxetine | 12 | 15 |
| Gabapentin + Duloxetine | 13 | 16 |
| Pregabalin | 11 | 20 |
Treatment-emergent: within range at baseline, out of range after baseline. Ranges in Units/Liter (U/L). Aspartate Aminotransferase (AST): female (f): >34, male (m): >36. Alanine Aminotransferase (ALT): f:<69 years (yr) >34, ≥69yr >32; m: <69yr >43, ≥69yr >35. Total Bilirubin (TBili): >21. Gamma Glutamyl Transferase (GGT): f: <59yr >49, ≥59yr >50; m: <59yr >61, ≥59yr >50. Fasting Plasma Glucose (FPG): <59yr >6.4, ≥59yr >6.7. Hemoglobin A1C (HbA1C) >6%. Alkaline Phosphatase (AlkPhos): f: 18-50yr >106, 50-70yr >123, 70-80yr >164, ≥80yr >221; m: 18-50yr >129, 50-70yr >131, 70-80yr >156, ≥80yr >187 (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| AST, n=113, n=116, n=109 | ALT, n=111, n=104, n=110 | TBili, n=119, n=121, n=116 | GGT, n=102, n=105, n=96 | FPG, n=33, n=30, n=36 | HbA1C, n=17, n=18, n=29 | AlkPhos, n=112, n=114, n=113 | |
| Duloxetine | 6 | 6 | 0 | 6 | 11 | 2 | 3 |
| Gabapentin + Duloxetine | 4 | 10 | 0 | 6 | 18 | 10 | 4 |
| Pregabalin | 4 | 3 | 2 | 2 | 7 | 6 | 4 |
Contribution to reduction in pain directly by treatment and indirectly by treatment through the reduction of depressive symptoms using path analysis. The direct treatment effect estimates the mean drug difference in pain reduction directly through treatment; the indirect treatment effect estimates the contribution that treatment plays to the mean drug difference in pain reduction indirectly through the reduction in mood symptoms; the total effect estimates the drug difference in reducing pain in sum through the specified path of direct and indirect treatment effects. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | coefficient (Number) | ||
|---|---|---|---|
| Direct Treatment Effect | Indirect Treatment Effect | Total Treatment Effect | |
| Ordinary Coefficient | -0.449 | 0.014 | -0.435 |
(NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | participants (Number) | ||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nausea | Peripheral Oedema | Insomnia | Somnolence | Anxiety | Dizziness | Dysuria | Headache | Hyperhidrosis | Sedation | Allergic Oedema | Anorgasmia | Increased Blood Creatine | Increased Blood Glucose | Bruxism | Cerebrovascular Accident | Chest Discomfort | Depression | Dermatitis | Diarrhoea | Dry mouth | Enterovirus Infection | Fatigue | Generalized Oedema | Facial Hypoaesthesia | Lacunar Infarction | Loss of Consciousness | Lymphoma | Mental Impairment | Muscular Weakness | Myoclonus | Pollakiuria | Pulomnary Embolism | Rash | Sleep Disorder | Urticaria | Vomiting | |
| Duloxetine | 4 | 0 | 4 | 2 | 1 | 0 | 2 | 2 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 |
| Gabapentin + Duloxetine | 4 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| Pregabalin | 0 | 5 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Ordinal scale: 0=no pain, 10=worst possible pain. Data=weekly mean of scores of average pain severity over last 24 hours (h). Scores: daily assessments recorded by patients in diaries. Only patients adhering to key protocol criteria included: baseline Weekly Mean 24h Average Pain Score ≥4; 80-120% compliant with study Drug, each visit; baseline Michigan Neuropathy Screening Instrument Physical Assessment Total Score ≥3; gabapentin taper ≤14 days, no HbA1c ≥12% post randomization; no contraindicated medications used. Least-squares means=adjustment due to baseline severity + investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 6.02 | -2.58 |
| Gabapentin + Duloxetine | 5.74 | -2.40 |
| Pregabalin | 5.74 | -2.12 |
This is an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Data presented represent the weekly mean of the scores of the average pain severity over the last 24 hours. Scores are based on daily assessments recorded by patients in their diaries. De novo: use of gabapentin for <56 contiguous days prior to randomization. Prior use: use of gabapentin for >=56 contiguous days prior to randomization. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| de novo, baseline | de novo, week 1 | de novo, week 2 | de novo, week 3 | de novo, week 4 | de novo, week 5 | de novo, week 6 | de novo, week 7 | de novo, week 8 | de novo, week 9 | de novo, week 10 | de novo, week 11 | de novo, week 12 | prior use, baseline | prior use, week 1 | prior use, week 2 | prior use, week 3 | prior use, week 4 | prior use, week 5 | prior use, week 6 | prior use, week 7 | prior use, week 8 | prior use, week 9 | prior use, week 10 | prior use, week 11 | prior use, week 12 | |
| Duloxetine | 5.39 | -0.71 | -1.22 | -1.83 | -2.35 | -2.65 | -2.64 | -2.73 | -2.78 | -2.89 | -2.86 | -2.98 | -3.08 | 5.99 | -0.48 | -0.99 | -1.32 | -1.61 | -1.95 | -2.03 | -2.14 | -2.16 | -2.38 | -2.45 | -2.46 | -2.46 |
| Gabapentin + Duloxetine | 5.49 | -0.38 | -1.10 | -1.62 | -1.67 | -1.81 | -1.88 | -2.07 | -2.06 | -2.10 | -1.92 | -2.09 | -2.10 | 5.92 | -0.65 | -1.28 | -1.68 | -1.75 | -1.96 | -1.98 | -2.17 | -2.31 | -2.37 | -2.44 | -2.41 | -2.53 |
| Pregabalin | 5.24 | -0.22 | -0.39 | -0.71 | -0.84 | -0.95 | -1.09 | -1.08 | -1.26 | -1.21 | -1.42 | -1.48 | -1.62 | 5.91 | -0.30 | -0.70 | -1.18 | -1.64 | -1.72 | -1.92 | -1.93 | -1.89 | -2.04 | -2.14 | -2.27 | -2.39 |
DAAC was derived from participant's daily pain diary, where pain was measured on an 11-point Numerical Rating Scale (NRS-Pain)ranging from 0 (did not interfere with sleep) to 10 (completely interfered [unable to sleep due to pain]). The DAAC was calculated as the mean of all daily pain diary rating post baseline minus the baseline score then multiplied by the proportion of the planned study duration completed by the participant. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Pregabalin | -1.66 |
| Placebo | -1.07 |
Participant rated questionnaire to assess sleep quality and quantity. Consists of a 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); 7 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath (SOB) or with a headache, somnolence adequacy, and sleep quantity. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range multiplied by 100); total score range = 0 to 100; higher score indicates greater intensity of attribute. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 49 |
| Placebo | 30 |
Mean weekly score was calculated as the average of the available daily diary pain score values for the week. Pain score was measured on an 11-point numeric rating scale (NRS): 0 (no pain) to 10 (worst possible pain). (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 48 |
| Placebo | 33 |
Mean weekly score was calculated as the average of the available daily diary pain score values for the week. Pain score was measured on an 11-point numeric rating scale (NRS): 0 (no pain) to 10 (worst possible pain). (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 31 |
| Placebo | 16 |
NPSI - Temporal item which assesses the duration (number of hours during the last 24 hours) of spontaneous ongoing pain. Improved duration would be a decrease in the number of hours of spontaneous ongoing pain during the last 24 hours compared to baseline. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 39 |
| Placebo | 28 |
NPSI - Temporal item which assesses the paroxysmal pain (number of pain attacks during the last 24 hours). Improvement in the number of attacks would be a decrease in the number of paroxysms during the last 24 hours compared to baseline. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 48 |
| Placebo | 38 |
HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline | Change from baseline at endpoint (n = 100, 99) | |
| Placebo | 6.9 | -0.8 |
| Pregabalin | 6.7 | -1.4 |
HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline | Change from baseline at endpoint (n = 100, 99) | |
| Placebo | 6.3 | -0.5 |
| Pregabalin | 5.2 | -1.0 |
Participant rated questionnaire to assess sleep quality and quantity. Consists of a 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); 7 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath (SOB) or with a headache, somnolence adequacy, and sleep quantity. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range multiplied by 100); total score range = 0 to 100; higher score indicates greater intensity of attribute. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n = 105, 105) | Change from baseline at endpoint (n = 100, 98) | |
| Placebo | 12.8 | -0.2 |
| Pregabalin | 15.0 | -6.2 |
Participant rated questionnaire to assess sleep quality and quantity. Consists of a 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); 7 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath (SOB) or with a headache, somnolence adequacy, and sleep quantity. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range multiplied by 100); total score range = 0 to 100; higher score indicates greater intensity of attribute. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n = 105, 104) | Change from baseline at endpoint (n = 100, 97) | |
| Placebo | 43.8 | 5.7 |
| Pregabalin | 42.3 | 11.6 |
Participant rated questionnaire to assess sleep quality and quantity. Consists of a 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); 7 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath (SOB) or with a headache, somnolence adequacy, and sleep quantity. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range multiplied by 100); total score range = 0 to 100; higher score indicates greater intensity of attribute. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n = 105, 104) | Change from baseline at endpoint (n = 100, 97) | |
| Placebo | 51.2 | -8.0 |
| Pregabalin | 51.9 | -17.3 |
Participant rated questionnaire to assess sleep quality and quantity. Consists of a 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); 7 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath (SOB) or with a headache, somnolence adequacy, and sleep quantity. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range multiplied by 100); total score range = 0 to 100; higher score indicates greater intensity of attribute. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n = 104,105) | Change from baseline at endpoint (n = 100, 98) | |
| Placebo | 6.2 | 0.2 |
| Pregabalin | 5.9 | 0.6 |
Participant rated questionnaire to assess sleep quality and quantity. Consists of a 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); 7 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath (SOB) or with a headache, somnolence adequacy, and sleep quantity. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range multiplied by 100); total score range = 0 to 100; higher score indicates greater intensity of attribute. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n = 105, 104) | Change from baseline at endpoint (n = 100, 97) | |
| Placebo | 35.6 | -4.7 |
| Pregabalin | 31.2 | 2.2 |
Participant rated questionnaire to assess sleep quality and quantity. Consists of a 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); 7 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath (SOB) or with a headache, somnolence adequacy, and sleep quantity. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range multiplied by 100); total score range = 0 to 100; higher score indicates greater intensity of attribute. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n = 105, 105) | Change from baseline at endpoint (n = 100, 97) | |
| Placebo | 39.7 | -4.9 |
| Pregabalin | 36.3 | -0.8 |
Participant rated questionnaire to assess sleep quality and quantity. Consists of a 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); 7 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath (SOB) or with a headache, somnolence adequacy, and sleep quantity. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range multiplied by 100); total score range = 0 to 100; higher score indicates greater intensity of attribute. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n = 105, 103) | Change from baseline at endpoint (n = 100, 95) | |
| Placebo | 45.9 | -5.8 |
| Pregabalin | 45.7 | -10.8 |
"The Modified Brief Pain Inventory (mBPI-10) Interference Scale is a self administered questionnaire that assessed pain interference with functional activities over the past week. The items were measured on an 11 point scale, ranging from does not interfere (0) to completely interferes (10). A composite score, the pain interference index, was calculated by averaging the 10 items that comprised the scale." (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline | Change from baseline at endpoint (n = 100, 99) | |
| Placebo | 4.9 | -1.1 |
| Pregabalin | 4.7 | -1.6 |
Participant rated questionnaire used to evaluate different symptoms of neuropathic pain (dimensions: burning [superficial] spontaneous pain, pressing [deep] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia [P/D]). Includes 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each of the relevant dimensions and a total score of 0-100. Higher score indicates a greater intensity of pain. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n = 104, 106) | Change from baseline at endpoint (n = 99, 99) | |
| Placebo | 0.4 | -0.1 |
| Pregabalin | 0.4 | -0.1 |
Participant rated questionnaire used to evaluate different symptoms of neuropathic pain (dimensions: burning [superficial] spontaneous pain, pressing [deep] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia [P/D]). Includes 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each of the relevant dimensions and a total score of 0-100. Higher score indicates a greater intensity of pain. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline | Change from baseline at endpoint (n = 100, 99) | |
| Placebo | 0.5 | -0.1 |
| Pregabalin | 0.5 | -0.1 |
Participant rated questionnaire used to evaluate different symptoms of neuropathic pain (dimensions: burning [superficial] spontaneous pain, pressing [deep] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia [P/D]). Includes 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each of the relevant dimensions and a total score of 0-100. Higher score indicates a greater intensity of pain. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline | Change from baseline at endpoint (n = 100, 99) | |
| Placebo | 0.4 | -0.1 |
| Pregabalin | 0.4 | -0.1 |
Participant rated questionnaire used to evaluate different symptoms of neuropathic pain (dimensions: burning [superficial] spontaneous pain, pressing [deep] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia [P/D]). Includes 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each of the relevant dimensions and a total score of 0-100. Higher score indicates a greater intensity of pain. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1- Burning pain (n = 100, 99) | 2- Squeezing pain (n = 100, 99) | 3- Pain like pressure (n = 100, 99) | 5- Electric shocks (n = 100, 99) | 6- Stabbing pain (n = 100, 99) | 8- By light touching (n = 100, 99) | 9- By pressure (n = 100, 99) | 10- By something cold (n = 100, 99) | 11- Pins and needles (n = 99, 99) | 12- Tingling (n = 99, 99) | |
| Placebo | -1.00 | -0.41 | -0.20 | -0.68 | -0.52 | -0.94 | -1.10 | -0.52 | -0.62 | -0.83 |
| Pregabalin | -1.39 | -1.04 | -0.73 | -1.77 | -1.13 | -0.78 | -1.22 | -0.89 | -1.01 | -0.99 |
Participant rated questionnaire used to evaluate different symptoms of neuropathic pain (dimensions: burning [superficial] spontaneous pain, pressing [deep] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia [P/D]). Includes 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each of the relevant dimensions and a total score of 0-100. Higher score indicates a greater intensity of pain. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n = 104, 106) | Change from baseline at endpoint (n = 99, 99) | |
| Placebo | 0.5 | -0.1 |
| Pregabalin | 0.5 | -0.1 |
Participant rated questionnaire used to evaluate different symptoms of neuropathic pain (dimensions: burning [superficial] spontaneous pain, pressing [deep] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia [P/D]). Includes 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each of the relevant dimensions and a total score of 0-100. Higher score indicates a greater intensity of pain. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline | Change from baseline at endpoint (n = 100, 99) | |
| Placebo | 0.3 | -0.1 |
| Pregabalin | 0.4 | -0.1 |
Participant rated questionnaire used to evaluate different symptoms of neuropathic pain (dimensions: burning [superficial] spontaneous pain, pressing [deep] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia [P/D]). Includes 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each of the relevant dimensions and a total score of 0-100. Higher score indicates a greater intensity of pain. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline | Change from baseline at endpoint (n = 100, 99) | |
| Placebo | 0.4 | -0.0 |
| Pregabalin | 0.4 | -0.1 |
Participant rated pain scale. The pain produced by the applied stimulus (dynamic mechanical allodynia - gentle stroking with foam brush) was rated on an 11 point numerical rating scale (0=no pain, 10=worst possible pain). (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n = 83, 82) | Change from baseline at endpoint (n = 79, 75) | |
| Placebo | 2.3 | -0.3 |
| Pregabalin | 2.7 | -0.6 |
Participant rated pain scale. The pain produced by the applied stimulus (static mechanical allodynia - gentle constant mechanical pressure) was rated on an 11 point numerical rating scale (0=no pain, 10=worst possible pain). (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n = 83, 82) | Change from baseline at endpoint (n = 79, 75) | |
| Placebo | 2.6 | -0.3 |
| Pregabalin | 2.9 | -1.0 |
Participant rated pain scale. The pain produced by the applied stimulus (Cold allodynia - touch with cool metal rod 13-17 degrees celsius was rated on an 11 point numerical rating scale (0=no pain, 10=worst possible pain). (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n = 83, 82) | Change from baseline at endpoint (n = 79, 72) | |
| Placebo | 2.7 | 0.4 |
| Pregabalin | 2.5 | -0.1 |
Participant rated pain scale. The pain produced by the applied stimulus (Cold hyperalgesia - touch with cold metal rod 4 degrees celsius) was rated on an 11 point numerical rating scale (0=no pain, 10=worst possible pain). (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n = 83, 82) | Change from baseline at endpoint (n = 79, 72) | |
| Placebo | 2.8 | 0.4 |
| Pregabalin | 2.8 | -0.1 |
Participant rated pain scale. The pain produced by the applied stimulus (Punctata hyperalgesia - pinprick) was rated on an 11 point numerical rating scale (0=no pain, 10=worst possible pain). (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n=83,82) | Change from baseline at endpoint (n=79,75) | |
| Placebo | 3.4 | -0.4 |
| Pregabalin | 3.9 | -1.0 |
Participant rated pain scale. The pain produced by the applied stimulus (Temporal summation to tactile stimuli - repeated touching/tapping) was rated on an 11 point numerical rating scale (0=no pain, 10=worst possible pain). (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n = 83, 82) | Change from baseline at endpoint (n = 79, 75) | |
| Placebo | 3.9 | -0.8 |
| Pregabalin | 4.1 | -0.5 |
Mean weekly score was calculated as the average of the available daily diary pain score values for the week. Pain score was measured on an 11-point numeric rating scale (NRS): 0 (no pain) to 10 (worst possible pain). (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline | Change from baseline at endpoint | |
| Placebo | 6.5 | -1.2 |
| Pregabalin | 6.5 | -1.9 |
Mean weekly score was calculated as the average of the available daily diary pain score values for the week. Pain score was measured on an 11-point numeric rating scale (NRS): 0 (no pain) to 10 (worst possible pain). (NCT00407745)
Timeframe: Baseline, Week 1 through16
| Intervention | score on scale (Mean) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (n = 111, 108) | Change at Week 1 (n = 111, 107) | Change at Week 2 (n = 110, 105) | Change at Week 3 (n = 107, 105) | Change at Week 4 (n = 107, 103) | Change at Week 5 (n = 105, 101) | Change at Week 6 (n = 105, 99) | Change at Week 7 (n = 103, 98) | Change at Week 8 (n = 101, 97) | Change at Week 9 (n = 98, 97) | Change at Week 10 (n = 97, 91) | Change at Week 11 (n = 96, 90) | Change at Week 12 (n = 96, 91) | Change at Week 13 (n = 93, 91) | Change at Week 14 (n = 93, 92) | Change at Week 15 (n = 93, 92) | Change at Week 16 (n = 89, 90) | |
| Placebo | 6.51 | -0.38 | -0.62 | -0.86 | -1.03 | -1.07 | -1.22 | -1.34 | -1.32 | -1.37 | -1.32 | -1.43 | -1.44 | -1.39 | -1.34 | -1.41 | -1.36 |
| Pregabalin | 6.44 | -0.85 | -1.26 | -1.35 | -1.64 | -1.87 | -1.89 | -2.02 | -1.96 | -1.99 | -2.03 | -2.04 | -1.90 | -2.02 | -2.00 | -2.09 | -2.17 |
Pain-related sleep interference was assessed on an 11-point numerical rating scale ranging from 0 (did not interfere with sleep) to 10 (completely interfered [unable to sleep due to pain]). (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n = 105, 105) | Change from baseline at endpoint (n = 105, 104) | |
| Placebo | 5.2 | -1.0 |
| Pregabalin | 4.9 | -2.0 |
Pain related sleep interference was assessed on an 11 point numerical rating scale ranging from 0 (did not interfere with sleep) to 10 (completely interfered [unable to sleep due to pain]). (NCT00407745)
Timeframe: Baseline, Week 1 through 16
| Intervention | score on scale (Mean) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (n = 111, 107) | Change at Week 1 (n = 111, 106) | Change at Week 2 (n = 110, 104) | Change at Week 3 (n = 107, 104) | Change at Week 4 (n = 107, 102) | Change at Week 5 (n = 105, 100) | Change at Week 6 (n = 105, 98) | Change at Week 7 (n = 103, 97) | Change at Week 8 (n = 101, 96) | Change at Week 9 (n = 98, 96) | Change at Week 10 (n = 97, 90) | Change at Week 11 (n = 96, 89) | Change at Week 12 (n = 96, 90) | Change at Week 13 (n = 93, 90) | Change at Week 14 (n = 93, 91) | Change at Week 15 (n = 93, 91) | Change at Week 16 (n = 89, 89) | |
| Placebo | 5.18 | -0.26 | -0.49 | -0.61 | -0.90 | -0.91 | -0.99 | -1.10 | -1.11 | -1.11 | -1.12 | -1.20 | -1.20 | -1.19 | -1.18 | -1.11 | -1.17 |
| Pregabalin | 4.86 | -0.96 | -1.29 | -1.36 | -1.59 | -1.81 | -1.86 | -1.98 | -1.97 | -2.03 | -2.18 | -2.08 | -2.07 | -2.08 | -2.09 | -2.15 | -2.25 |
The PGIC is a participant-rated instrument measuring change in the participant's overall status on a 7-point scale: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| 1-Very much improved | 2-Much improved | 3-Minimally improved | 4-No change | 5-Minimally worse | 6-Much worse | 7-Very much worse | |
| Placebo | 2 | 25 | 24 | 40 | 5 | 3 | 0 |
| Pregabalin | 7 | 33 | 38 | 19 | 2 | 0 | 1 |
Total scores range: 0-36 (0= no symptoms to 36= the most severe symptoms) (NCT03463915)
Timeframe: Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported
| Intervention | scores on a scale (Mean) |
|---|---|
| Bladder Instillation WITH Triamcinolone Acetonide | -6.7 |
| Bladder Instillation WITHOUT Triamcinolone Acetonide | -5.8 |
VAS is measured on marking on a 10-centimeter (cm) ruler (measured in cm, 0= no pain and 10= most severe pain possible) (NCT03463915)
Timeframe: Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported
| Intervention | score on a scale (Mean) |
|---|---|
| Bladder Instillation WITH Triamcinolone Acetonide | -1.9 |
| Bladder Instillation WITHOUT Triamcinolone Acetonide | -1.8 |
Adverse events will only be those determined to be related to the study drug (NCT03463915)
Timeframe: End of study (6 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Bladder Instillation WITH Triamcinolone Acetonide | 1 |
| Bladder Instillation WITHOUT Triamcinolone Acetonide | 5 |
Total scores range: 0-100 (higher scores on the symptom-severity scale suggestive of greater severity of symptoms and higher scores on the quality-of-life scale suggestive of better quality of life) (NCT03463915)
Timeframe: Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported
| Intervention | score on a scale (Mean) |
|---|---|
| Bladder Instillation WITH Triamcinolone Acetonide | -24.2 |
| Bladder Instillation WITHOUT Triamcinolone Acetonide | -18.8 |
20 question self-administered questionnaire on the presence and absence of pelvic floor symptoms. Score ranges from 0 (least distress) to 300 (most distress). (NCT03463915)
Timeframe: Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported
| Intervention | score on a scale (Mean) |
|---|---|
| Bladder Instillation WITH Triamcinolone Acetonide | -5.3 |
| Bladder Instillation WITHOUT Triamcinolone Acetonide | -6.4 |
Total scores range: 0-35 (0= no symptoms to 35= the most severe symptoms) (NCT03463915)
Timeframe: Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported
| Intervention | score on a scale (Mean) |
|---|---|
| Bladder Instillation WITH Triamcinolone Acetonide | -5.3 |
| Bladder Instillation WITHOUT Triamcinolone Acetonide | -2.7 |
Measures sexual function in women with pelvic floor disorders. Queries about arousal, orgasm, partner-related issues, sexual quality, and desire. The tool also takes into account those who are not sexually active. The questionnaire was used in the study solely to determine if patients had improved dyspareunia (as a categorical variable). (NCT03463915)
Timeframe: Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported
| Intervention | participants (Number) |
|---|---|
| Bladder Instillation WITH Triamcinolone Acetonide | 4 |
| Bladder Instillation WITHOUT Triamcinolone Acetonide | 4 |
"Mean change from baseline. Participants are asked Taking into account your pain level and how it affects your life, are you feeling better, the same or worse than when you started treatment? and then to quantify the magnitude of the change. with the 7-Point guy Farrar which measures the global treatment effect from with scale from 0 to 6, higher score indicates worse outcomes." (NCT02736890)
Timeframe: up to 12 weeks post-injection, for a total of 24 weeks from baseline
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 2 week post injection | 4 week post injection | 8 week post injection | 12 week post injection | crossover 2 week follow up | crossover 4 week follow up | crossover 8 week follow up | crossover 12 week follow up | |
| Botulinum Toxin A Then Placebo | 2.2 | 2.4 | 2 | 2 | 0 | 0 | 0 | 0 |
| Placebo Then Botulinum Toxin A | 0.3 | 0.3 | 0 | 0 | 5 | 5 | 3 | 1 |
The International Basic Pain Dataset is an assessment tool which includes several components including: location of pain, temporal qualities of the pain, type of pain, pain interference measures of activity, sleep, and mood. It has been shown to be valid in an interview/self -report format. The pain affecting day-to-day activities subset of the dataset is scored is from 0 to 10, with higher score indicating less favorable outcomes. (NCT02736890)
Timeframe: up to 12 weeks post-injection, for a total of 24 weeks from baseline
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 2 week post injection | 4 week post injection | 8 week post injection | 12 week post injection | crossover 2 week follow up | crossover 4 week follow up | crossover 8 week follow up | crossover 12 week follow up | |
| Botulinum Toxin A Then Placebo | 4.2 | 5.4 | 5 | 5 | 4.8 | 7 | 6.7 | 7 | 6.7 |
| Placebo Then Botulinum Toxin A | 5.3 | 2.7 | 2.7 | 2.7 | 2.7 | 2 | 3 | 4 | 5 |
The International Basic Pain Dataset is an assessment tool which includes several components including: location of pain, temporal qualities of the pain, type of pain, pain interference measures of activity, sleep, and mood. It has been shown to be valid in an interview/self -report format. The pain affecting mood subset of the dataset is scored is from 0 to 10, with higher score indicating less favorable outcomes. (NCT02736890)
Timeframe: up to 12 weeks post-injection, for a total of 24 weeks from baseline
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 2 week post injection | 4 week post injection | 8 week post injection | 12 week post injection | crossover 2 week follow up | crossover 4 week follow up | crossover 8 week follow up | crossover 12 week follow up | |
| Botulinum Toxin A Then Placebo | 5.6 | 6.6 | 5.8 | 5.2 | 5.6 | 7 | 7 | 7.3 | 6.7 |
| Placebo Then Botulinum Toxin A | 5.7 | 2.7 | 2.7 | 4.3 | 5.7 | 2 | 3 | 4 | 7 |
The International Basic Pain Dataset is an assessment tool which includes several components including: location of pain, temporal qualities of the pain, type of pain, pain interference measures of activity, sleep, and mood. It has been shown to be valid in an interview/self -report format. The pain affecting sleep subset of the dataset is scored is from 0 to 10, with higher score indicating less favorable outcomes. (NCT02736890)
Timeframe: up to 12 weeks post-injection, for a total of 24 weeks from baseline
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 2 week post injection | 4 week post injection | 8 week post injection | 12 week post injection | crossover 2 week follow up | crossover 4 week follow up | crossover 8 week follow up | crossover 12 week follow up | |
| Botulinum Toxin A Then Placebo | 5.8 | 4.6 | 5 | 6 | 6.2 | 8 | 8 | 8 | 7.3 |
| Placebo Then Botulinum Toxin A | 6.7 | 4.7 | 3.3 | 6 | 6.7 | 1 | 3 | 4 | 5 |
Participant rated pain intensity from 0-10, with higher score indicating more pain (NCT02736890)
Timeframe: up to 12 weeks post-injection, for a total of 24 weeks from baseline
| Intervention | score on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| baseline | 2 week post injection | 4 week post injection | 8 week post injection | 12 week post injection | crossover 2 week follow up | crossover 4 week follow up | crossover 8 week follow up | crossover 12 week follow up | |
| Botulinum Toxin A Then Placebo | 7.6 | 6.4 | 5.6 | 5.6 | 5.6 | 8 | 8 | 6.7 | 8 |
| Placebo Then Botulinum Toxin A | 8 | 8 | 8 | 8 | 8 | 5 | 5 | 6 | 7 |
PGI measures activity affected by pain. Full score is 0 to 10000, with higher score indicating better function (NCT02736890)
Timeframe: up to 12 weeks post-injection, for a total of 24 weeks from baseline
| Intervention | score on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 2 week post injection | 4 week post injection | 8 week post injection | 12 week post injection | crossover 2 week follow up | crossover 4 week follow up | crossover 8 week follow up | crossover 12 week follow up | |
| Botulinum Toxin A Then Placebo | 4250 | 5240 | 5219 | 3725 | 4330 | 3333.3 | 3333.3 | 3333.3 | 3333.3 |
| Placebo Then Botulinum Toxin A | 1500 | 1550 | 1825 | 2800 | 1800 | 3500 | 3750 | 3000 | 1500 |
102 reviews available for gabapentin and Nerve Pain
| Article | Year |
|---|---|
Non-drug pain relievers active on non-opioid pain mechanisms.
Topics: Acetaminophen; Analgesics; Gabapentin; Humans; Neuralgia; Pain, Postoperative | 2022 |
Is gabapentin a safe and effective treatment for nonneuropathic pain?
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Neural | 2021 |
Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients.
Topics: Analgesics; Antibodies, Monoclonal; Gabapentin; Gangliosides; Humans; Morphine; Neoplasm Metastasis; | 2021 |
Comparison of the Efficacy and Safety of Duloxetine and Gabapentin in Diabetic Peripheral Neuropathic Pain: A Meta-Analysis.
Topics: Analgesics; Chronic Disease; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Duloxetine Hydrochlor | 2022 |
[Pharmacological approach to neuropathic pain: past, present and future].
Topics: Amitriptyline; Analgesics; Animals; Antidepressive Agents, Tricyclic; Gabapentin; Humans; Neuralgia; | 2022 |
Pharmacotherapy for Spine-Related Pain in Older Adults.
Topics: Acetaminophen; Aged; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Gabapentin; Humans | 2022 |
An Update On Proficiency of Voltage-gated Ion Channel Blockers in the Treatment of Inflammation-associated Diseases.
Topics: Calcium Channels; Gabapentin; Humans; Inflammation; Neuralgia; Sodium | 2022 |
Avellis syndrome with ipsilateral prosopalgia, glossopharyngeal neuralgia, and central post-stroke pain: A case report and literature review.
Topics: Aspirin; Carbamazepine; Deglutition Disorders; Dizziness; Female; Gabapentin; Glossopharyngeal Nerve | 2022 |
Efficacy and safety of different antidepressants and anticonvulsants in central poststroke pain: A network meta-analysis and systematic review.
Topics: Amitriptyline; Anticonvulsants; Antidepressive Agents; Carbamazepine; Duloxetine Hydrochloride; Fluo | 2022 |
Gabapentin-Induced Overflow Urinary Incontinence: A Case Report and Review of the Literature.
Topics: Amines; Analgesics; Carcinoma, Non-Small-Cell Lung; Cyclohexanecarboxylic Acids; Gabapentin; gamma-A | 2023 |
The safety and efficacy of gabapentinoids in the management of neuropathic pain: a systematic review with meta-analysis of randomised controlled trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; | 2023 |
Pharmacologic Management of Cancer-Related Pain in Pregnant Patients.
Topics: Analgesics; Analgesics, Opioid; Cancer Pain; Duloxetine Hydrochloride; Female; Gabapentin; Humans; N | 2023 |
Efficacy of gabapentin in the treatment of trigeminal neuralgia: A systematic review of randomized controlled trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; | 2019 |
Evaluating the impact of gabapentinoids on sleep health in patients with chronic neuropathic pain: a systematic review and meta-analysis.
Topics: Analgesics; Chronic Pain; Clinical Trials as Topic; Gabapentin; Humans; Neuralgia; Pain Measurement; | 2020 |
Gabapentin for chronic neuropathic pain in adults.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Chronic Pain; Female; Gabapentin; Humans; Male; Middle A | 2019 |
The mirogabalin ALDAY phase 3 program in pain associated with fibromyalgia: the lessons learned.
Topics: Bridged Bicyclo Compounds; Clinical Trials, Phase III as Topic; Double-Blind Method; Fibromyalgia; G | 2020 |
Can Gabapentin Alleviate Chronic Neuropathic Pain in Adults?: A Cochrane Review Summary With Commentary.
Topics: Analgesics; Chronic Pain; Dose-Response Relationship, Drug; Gabapentin; Humans; Neuralgia | 2020 |
Pregabalin and gabapentin for pain.
Topics: Analgesics; Diabetic Neuropathies; Evidence-Based Medicine; Fibromyalgia; Gabapentin; Humans; Neural | 2020 |
Beneficial "Pharmaceutical Pleiotropy" of Gabapentinoids in Spinal Cord Injury: A Case for Refining Standard-of-Care.
Topics: Analgesics; Animals; Gabapentin; Humans; Neuralgia; Pregabalin; Spinal Cord Injuries | 2020 |
A Comprehensive Review of the Diagnosis, Treatment, and Management of Postmastectomy Pain Syndrome.
Topics: Acetylcholine Release Inhibitors; Analgesics; Anesthesia, Conduction; Anesthetics, Local; Antidepres | 2020 |
A Comprehensive Review of the Diagnosis, Treatment, and Management of Postmastectomy Pain Syndrome.
Topics: Acetylcholine Release Inhibitors; Analgesics; Anesthesia, Conduction; Anesthetics, Local; Antidepres | 2020 |
A Comprehensive Review of the Diagnosis, Treatment, and Management of Postmastectomy Pain Syndrome.
Topics: Acetylcholine Release Inhibitors; Analgesics; Anesthesia, Conduction; Anesthetics, Local; Antidepres | 2020 |
A Comprehensive Review of the Diagnosis, Treatment, and Management of Postmastectomy Pain Syndrome.
Topics: Acetylcholine Release Inhibitors; Analgesics; Anesthesia, Conduction; Anesthetics, Local; Antidepres | 2020 |
Distal Symmetric Polyneuropathy in 2020.
Topics: Antidepressive Agents, Tricyclic; Cognitive Behavioral Therapy; Diabetic Neuropathies; Gabapentin; H | 2020 |
The use of antineuropathic medications for the treatment of chronic pain.
Topics: Anticonvulsants; Antidepressive Agents, Tricyclic; Chronic Pain; Gabapentin; Humans; Neuralgia; Pain | 2020 |
HIV Neuropathy-a Review of Mechanisms, Diagnosis, and Treatment of Pain.
Topics: Anesthetics, Local; Gabapentin; HIV Infections; Humans; Neuralgia; Neurologic Examination; Pregabali | 2021 |
Multiple outcomes and analyses in clinical trials create challenges for interpretation and research synthesis.
Topics: Amines; Analgesics; Antipsychotic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Gabapentin; | 2017 |
Gabapentin for chronic neuropathic pain in adults.
Topics: Adult; Amines; Analgesics; Chronic Disease; Chronic Pain; Cyclohexanecarboxylic Acids; Diabetic Neur | 2017 |
Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal.
Topics: Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Fructose; Gabapentin; gamm | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Antidepressants for chronic non-cancer pain in children and adolescents.
Topics: Abdominal Pain; Adolescent; Amines; Amitriptyline; Analgesics; Antidepressive Agents; Child; Chronic | 2017 |
Antiepileptic drugs for chronic non-cancer pain in children and adolescents.
Topics: Adolescent; Amines; Amitriptyline; Anticonvulsants; Child; Chronic Pain; Complex Regional Pain Syndr | 2017 |
Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy.
Topics: Amines; Bias; Bipolar Disorder; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Hu | 2017 |
Is there a role for combined use of gabapentin and pregabalin in pain control? Too good to be true?
Topics: Analgesics; Drug Therapy, Combination; Gabapentin; Humans; Neuralgia; Pregabalin | 2018 |
Pharmacotherapy for Neuropathic Pain in Japan.
Topics: Aged; Algorithms; Amines; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents; Cyclohexanecar | 2017 |
Etiology and Pharmacology of Neuropathic Pain.
Topics: Analgesics; Analgesics, Opioid; Animals; Gabapentin; Humans; Ion Channels; Molecular Targeted Therap | 2018 |
Analgesic mechanisms of gabapentinoids and effects in experimental pain models: a narrative review.
Topics: Analgesics; Animals; Calcium Channels; Disease Models, Animal; Gabapentin; gamma-Aminobutyric Acid; | 2018 |
A Clinical Overview of Off-label Use of Gabapentinoid Drugs.
Topics: Analgesics; Diabetic Neuropathies; Drug Approval; Fibromyalgia; Gabapentin; Humans; Low Back Pain; M | 2019 |
Harms are assessed inconsistently and reported inadequately part 1: systematic adverse events.
Topics: Bipolar Disorder; Data Accuracy; Drug-Related Side Effects and Adverse Reactions; Gabapentin; Humans | 2019 |
Harms are assessed inconsistently and reported inadequately Part 2: nonsystematic adverse events.
Topics: Bipolar Disorder; Data Accuracy; Drug-Related Side Effects and Adverse Reactions; Gabapentin; Humans | 2019 |
Implications and mechanism of action of gabapentin in neuropathic pain.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Human | 2013 |
Update on neuropathic pain treatment: ion channel blockers and gabapentinoids.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Human | 2013 |
Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews.
Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Fibromyalgia; Gabapentin; gamma-Aminobutyric A | 2013 |
Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews.
Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Fibromyalgia; Gabapentin; gamma-Aminobutyric A | 2013 |
Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews.
Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Fibromyalgia; Gabapentin; gamma-Aminobutyric A | 2013 |
Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews.
Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Fibromyalgia; Gabapentin; gamma-Aminobutyric A | 2013 |
Anticonvulsant medication use for the management of pain following spinal cord injury: systematic review and effectiveness analysis.
Topics: Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci | 2014 |
Managing difficult pain conditions in the cancer patient.
Topics: Amines; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Breakthrough Pain; Cyclohexanec | 2014 |
Analgesia for the cirrhotic patient: a literature review and recommendations.
Topics: Acetaminophen; Amines; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Anti | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Gabapentin for chronic neuropathic pain and fibromyalgia in adults.
Topics: Adult; Amines; Analgesics; Chronic Disease; Chronic Pain; Cyclohexanecarboxylic Acids; Fibromyalgia; | 2014 |
A systematic review of pharmacoeconomic studies for pregabalin.
Topics: Amines; Analgesics; Anticonvulsants; Chronic Disease; Cost-Benefit Analysis; Cyclohexanecarboxylic A | 2015 |
Gabapentinoids are effective in decreasing neuropathic pain and other secondary outcomes after spinal cord injury: a meta-analysis.
Topics: Amines; Analgesics; Anxiety; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Depression; Gaba | 2014 |
Nortriptyline for neuropathic pain in adults.
Topics: Amines; Amitriptyline; Analgesics; Antidepressive Agents, Tricyclic; Clomipramine; Cyclohexanecarbox | 2015 |
[DRUG THERAPY OF NEUROPATHIC PAIN BASED ON THE LATEST RECOMMENDATIONS].
Topics: Amines; Amitriptyline; Analgesics, Non-Narcotic; Analgesics, Opioid; Anticonvulsants; Antidepressive | 2015 |
Pregabalin and gabapentin for the treatment of sciatica.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Neural | 2016 |
Gabapentin for Chronic Neuropathic Pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Neural | 2015 |
Pain management strategies for neuropathic pain in Fabry disease--a systematic review.
Topics: Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Fabry Disease; Gabapentin; gamm | 2016 |
Continuous neuropathic pain secondary to endoscopic procedures: report of two cases and review of the literature.
Topics: Adult; Amines; Analgesics; Clonazepam; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; GABA | 2016 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
An update on the pharmacologic management and treatment of neuropathic pain.
Topics: Amines; Analgesics; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Cannabinoids; Cyclohexanec | 2017 |
Gabapentinoids for chronic low back pain: a protocol for systematic review and meta-analysis of randomised controlled trials.
Topics: Amines; Chronic Pain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Low | 2016 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
[Chronic intrathecal drug administration for the control of intractable pain].
Topics: Amines; Analgesics, Opioid; Anesthetics, Local; Baclofen; Calcium Channel Blockers; Clonidine; Cyclo | 2008 |
Efficacy of pregabalin and gabapentin for neuropathic pain in spinal-cord injury: an evidence-based evaluation of the literature.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Evidence-Based Medicine; Gabapentin; gamma-Aminobut | 2008 |
Pain relief by gabapentin and pregabalin via supraspinal mechanisms after peripheral nerve injury.
Topics: Amines; Analgesics; Animals; Brain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid | 2008 |
[Mechanisms of the development of neuropathic pain and its treatment].
Topics: Amines; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Calcium Channel Block | 2008 |
Treatment of neuropathic pain: an overview of recent guidelines.
Topics: Amines; Analgesics; Analgesics, Opioid; Anesthetics, Local; Antidepressive Agents; Canada; Cyclohexa | 2009 |
Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.
Topics: Acetamides; Amines; Analgesics; Analgesics, Opioid; Anesthetics, Local; Antidepressive Agents; Cyclo | 2010 |
Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.
Topics: Acetamides; Amines; Analgesics; Analgesics, Opioid; Anesthetics, Local; Antidepressive Agents; Cyclo | 2010 |
Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.
Topics: Acetamides; Amines; Analgesics; Analgesics, Opioid; Anesthetics, Local; Antidepressive Agents; Cyclo | 2010 |
Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.
Topics: Acetamides; Amines; Analgesics; Analgesics, Opioid; Anesthetics, Local; Antidepressive Agents; Cyclo | 2010 |
The anti-allodynic alpha(2)delta ligand pregabalin inhibits the trafficking of the calcium channel alpha(2)delta-1 subunit to presynaptic terminals in vivo.
Topics: Amines; Analgesics; Animals; Calcium Channels; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminob | 2010 |
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.
Topics: Amines; Analgesia; Analgesics; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Cyclohexanecarb | 2010 |
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.
Topics: Amines; Analgesia; Analgesics; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Cyclohexanecarb | 2010 |
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.
Topics: Amines; Analgesia; Analgesics; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Cyclohexanecarb | 2010 |
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.
Topics: Amines; Analgesia; Analgesics; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Cyclohexanecarb | 2010 |
Gabapentin for chronic neuropathic pain and fibromyalgia in adults.
Topics: Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Fibromyalgia; Gabapentin; gamma-Am | 2011 |
[Neuropathic pain in oncology. Novel evidence for clinical practice].
Topics: Amines; Amitriptyline; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Anti | 2011 |
Use of gabapentin and pregabalin for hand surgery patients.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Hand; Humans; | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
ADMET considerations for restless leg syndrome drug treatments.
Topics: Amines; Anticonvulsants; Benzothiazoles; Carbamates; Cyclohexanecarboxylic Acids; Dopamine Agents; D | 2012 |
Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials.
Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Anticonvu | 2003 |
Treatment and prevention of postherpetic neuralgia.
Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Drug Therapy, Combina | 2003 |
The role of gabapentin in treating diseases with cutaneous manifestations and pain.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Herp | 2003 |
The use of gabapentin for the treatment of postherpetic neuralgia.
Topics: Acetates; Amines; Analgesics; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Drug Interactio | 2003 |
Gabapentin: in postherpetic neuralgia.
Topics: Acetates; Amines; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Herpes | 2003 |
Gabapentin: a viewpoint by Brett R. Stacey.
Topics: Acetates; Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Herpes Zoster; H | 2003 |
Use of gabapentin for postherpetic neuralgia: results of two randomized, placebo-controlled studies.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Herp | 2003 |
Diagnosis and management of neuropathic pain: a balanced approach to treatment.
Topics: Acetates; Amines; Antidepressive Agents; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapentin; g | 2003 |
Post-herpetic neuralgia case study: optimizing pain control.
Topics: Acetates; Aged; Amines; Amitriptyline; Analgesics; Antidepressive Agents, Tricyclic; Cyclohexanecarb | 2004 |
Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology.
Topics: Acupuncture Analgesia; Administration, Cutaneous; Amines; Analgesics; Analgesics, Opioid; Anti-Infla | 2004 |
Postherpetic neuralgia.
Topics: 2-Aminopurine; Acyclovir; Adrenal Cortex Hormones; Adult; Amines; Amitriptyline; Analgesics, Non-Nar | 2003 |
Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia.
Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Dizziness; Dose-Response Relationship, Drug; | 2004 |
Tolerability of treatments for postherpetic neuralgia.
Topics: Amines; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexanecarboxylic Acids; Gabapentin; | 2004 |
Postherpetic neuralgia.
Topics: 2-Aminopurine; Acyclovir; Amines; Antidepressive Agents, Tricyclic; Antiviral Agents; Arabinofuranos | 2004 |
Gabapentin for acute and chronic pain.
Topics: Acute Disease; Amines; Analgesics; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids; Ga | 2005 |
How modeling and simulation have enhanced decision making in new drug development.
Topics: Alzheimer Disease; Amines; Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III a | 2005 |
Therapeutic management of chronic neuropathic pain: an examination of pharmacologic treatment.
Topics: Amines; Analgesics; Antidepressive Agents, Tricyclic; Chronic Disease; Cyclohexanecarboxylic Acids; | 2006 |
Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels.
Topics: Amines; Animals; Calcium Channel Blockers; Calcium Channels; Cell Membrane; Cerebellar Ataxia; Cyclo | 2007 |
Antiepileptic drugs in the treatment of neuropathic pain.
Topics: Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Fructose; Gabapentin; gamma-Ami | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Treatment of painful neuropathy.
Topics: Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gaba | 2007 |
[Alpha2-adrenergic receptors in the dorsal horn of the spinal cord--their function and the descending inhibitory systems].
Topics: Acetylcholine; Adrenergic alpha-2 Receptor Agonists; Amines; Analgesics; Animals; Brain-Derived Neur | 2007 |
Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Gabapentin; gamma | 2008 |
Postherpetic neuralgia: role of gabapentin and other treatment modalities.
Topics: Acetates; Administration, Topical; Age Factors; Aged; Ambulatory Care; Amines; Analgesics; Anticonvu | 1999 |
Nonepileptic uses of gabapentin.
Topics: Acetates; Amines; Analgesics; Antimanic Agents; Antiparkinson Agents; Bipolar Disorder; Clinical Tri | 1999 |
Gabapentin: a new tool in the treatment of neuropathic pain.
Topics: Acetates; Amines; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Dose-Response Relationship, | 1999 |
Use of gabapentin in the treatment of neuropathic pain.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Huma | 2000 |
[Gabapentin--yet another antiepileptic agent for the treatment of neuropathic pain?].
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Clinical Trials as Topic; Controlled Clinical Trials | 2001 |
Gabapentin: a unique anti-epileptic agent.
Topics: Acetates; Adult; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Epilepsy, Complex Part | 2001 |
Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature.
Topics: Acetates; Amines; Analgesics; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Dose-Response R | 2001 |
Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature.
Topics: Acetates; Amines; Analgesics; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Dose-Response R | 2001 |
Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature.
Topics: Acetates; Amines; Analgesics; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Dose-Response R | 2001 |
Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature.
Topics: Acetates; Amines; Analgesics; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Dose-Response R | 2001 |
[Gabapentin for therapy of neuropathic pain].
Topics: Acetates; Amines; Animals; Biological Availability; Brain; Clinical Trials as Topic; Cyclohexanecarb | 2001 |
Anticonvulsants for neuropathic pain and detoxification.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Clonazepam; Cyclohexanecarboxylic Acids; Gabapenti | 1998 |
42 trials available for gabapentin and Nerve Pain
| Article | Year |
|---|---|
Neuropathic pain and neurocognitive functioning in children treated for acute lymphoblastic leukemia.
Topics: Analgesics, Opioid; Child; Female; Gabapentin; Humans; Male; Neuralgia; Neuropsychological Tests; Pr | 2022 |
Effectiveness of oral clonidine and gabapentin on peripheral neuropathy in diabetic patients in southwestern Iran: a randomized clinical trial.
Topics: Amines; Analgesics; Clonidine; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type 2; Diabetic Neur | 2023 |
Prospective randomized trial of interventions for vincristine-related neuropathic pain.
Topics: Adolescent; Analgesics; Analgesics, Opioid; Antineoplastic Agents, Phytogenic; Child; Child, Prescho | 2020 |
A randomized controlled trial of amitriptyline versus gabapentin for complex regional pain syndrome type I and neuropathic pain in children.
Topics: Adolescent; Amines; Amitriptyline; Analgesics; Child; Cyclohexanecarboxylic Acids; Female; Gabapenti | 2016 |
Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study.
Topics: Adult; Aged; Amines; Analgesics; Analgesics, Opioid; Cancer Pain; Cyclohexanecarboxylic Acids; Doubl | 2017 |
Efficacy and safety of oxycodone/naloxone as add-on therapy to gabapentin or pregabalin for the management of chemotherapy-induced peripheral neuropathy in Korea.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Agents; Female; Gabapentin; Humans; Male; | 2018 |
Gabapentin dose and the 30-day risk of altered mental status in older adults: A retrospective population-based study.
Topics: Aged; Aged, 80 and over; Amines; Confusion; Cyclohexanecarboxylic Acids; Disease-Free Survival; Dizz | 2018 |
Gabapentin as add-on to morphine for severe neuropathic or mixed pain in children from age 3 months to 18 years - evaluation of the safety, pharmacokinetics, and efficacy of a new gabapentin liquid formulation: study protocol for a randomized controlled t
Topics: Administration, Oral; Adolescent; Age Factors; Analgesics; Analgesics, Opioid; Child; Child, Prescho | 2019 |
Non-inferiority double-blind randomised controlled trial comparing gabapentin versus tramadol for the treatment of chronic neuropathic or mixed pain in children and adolescents: the GABA-1 trial-a study protocol.
Topics: Adolescent; Analgesics; Analgesics, Opioid; Child; Child, Preschool; Chronic Pain; Double-Blind Meth | 2019 |
Gabapentin versus Transdermal Fentanyl Matrix for the Alleviation of Chronic Neuropathic Pain of Radicular Origin: A Randomized Blind Multicentered Parallel-Group Noninferiority Trial.
Topics: Administration, Cutaneous; Adult; Analgesics; Double-Blind Method; Female; Fentanyl; Gabapentin; Hum | 2019 |
Donepezil provides positive effects to patients treated with gabapentin for neuropathic pain: an exploratory study.
Topics: Adult; Aged; Algorithms; Amines; Analgesics; Cyclohexanecarboxylic Acids; Cyclohexanols; Donepezil; | 2014 |
Comparative safety and tolerability of duloxetine vs. pregabalin vs. duloxetine plus gabapentin in patients with diabetic peripheral neuropathic pain.
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combi | 2014 |
Gabapentin versus pregabalin in relieving early post-surgical neuropathic pain in patients after lumbar disc herniation surgery: a prospective clinical trial.
Topics: Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diskectomy; Female; Follow-Up Studies; | 2014 |
Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Dronabinol; Female; Gab | 2015 |
Comparison of gabapentin versus topiramate on clinically affected dogs with Chiari-like malformation and syringomyelia.
Topics: Amines; Analgesics; Animals; Arnold-Chiari Malformation; Cross-Over Studies; Cyclohexanecarboxylic A | 2015 |
Efficient assessment of neuropathic pain drugs in patients with small fiber sensory neuropathies.
Topics: Adolescent; Adult; Amines; Analgesics; Cross-Over Studies; Cyclohexanecarboxylic Acids; Diphenhydram | 2009 |
Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial.
Topics: Administration, Oral; Aged; Amines; Analgesics; Antidepressive Agents, Tricyclic; Canada; Cross-Over | 2009 |
Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison.
Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Drug Therapy, Combinat | 2011 |
A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study.
Topics: Adult; Amines; Amitriptyline; Analgesics; Analysis of Variance; Cyclohexanecarboxylic Acids; Double- | 2012 |
Costs and health resources utilization following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain: a post hoc analysis.
Topics: Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric | 2012 |
Sensory and affective pain descriptors respond differentially to pharmacological interventions in neuropathic conditions.
Topics: Amines; Analgesics; Case-Control Studies; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Fe | 2013 |
Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study.
Topics: Adult; Aged; Amines; Analgesics; Antipruritics; Chi-Square Distribution; Cross-Over Studies; Cyclohe | 2012 |
[Neuropathy pain: tactic of treatment].
Topics: Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Administration Schedule; Drug The | 2012 |
Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double-blind, crossover trial.
Topics: Acetates; Adult; Amines; Analgesics; Cross-Over Studies; Cyclohexanecarboxylic Acids; Dose-Response | 2002 |
Gabapentin effect on neuropathic pain compared among patients with spinal cord injury and different durations of symptoms.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Ac | 2003 |
Use of gabapentin to reduce chronic neuropathic pain in Fabry disease.
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Fabry Disease; Ga | 2003 |
Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain.
Topics: Acetates; Activities of Daily Living; Aged; Aged, 80 and over; Amines; Analgesics; Anesthetics, Loca | 2003 |
Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury.
Topics: Acetates; Adult; Aged; Amines; Analgesics; Cross-Over Studies; Cyclohexanecarboxylic Acids; Disabili | 2004 |
A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2004 |
Morphine, gabapentin, or their combination for neuropathic pain.
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Analgesics, Opioid; Cross-Over Studies; Cyclohex | 2005 |
Morphine, gabapentin, or their combination for neuropathic pain.
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Analgesics, Opioid; Cross-Over Studies; Cyclohex | 2005 |
Morphine, gabapentin, or their combination for neuropathic pain.
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Analgesics, Opioid; Cross-Over Studies; Cyclohex | 2005 |
Morphine, gabapentin, or their combination for neuropathic pain.
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Analgesics, Opioid; Cross-Over Studies; Cyclohex | 2005 |
Starting dose of gabapentin for patients with post-herpetic neuralgia--a dose-response study.
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relat | 2005 |
Gabapentin for the symptomatic treatment of chronic neuropathic pain in patients with late-stage lyme borreliosis: a pilot study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amines; Chronic Disease; Cyclohexanecarboxylic Acids; | 2005 |
Cross-sectional evaluation of patient functioning and health-related quality of life in patients with neuropathic pain under standard care conditions.
Topics: Adult; Age Distribution; Aged; Amines; Analgesics; Cohort Studies; Cross-Sectional Studies; Cyclohex | 2007 |
[Comparison of efficacy of gabapentin and amitriptyline in the management of peripheral neuropathic pain].
Topics: Amines; Amitriptyline; Anticonvulsants; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Ga | 2006 |
[The tebantin use in the complex therapy of pain syndrome during the mixed forms of alcoholic polyneuropathy].
Topics: Alcoholic Neuropathy; Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Fe | 2006 |
Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: a randomized open trial.
Topics: Adult; Aged; Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Drug Therapy, Comb | 2007 |
Gabapentin in traumatic nerve injury pain: a randomized, double-blind, placebo-controlled, cross-over, multi-center study.
Topics: Adult; Aged; Aged, 80 and over; Amines; Cross-Over Studies; Cyclohexanecarboxylic Acids; Double-Blin | 2008 |
Gabapentin adjunctive therapy in neuropathic pain states.
Topics: Acetates; Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Facial Pain; Female; Gabapen | 1996 |
Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: a pilot study.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Central Nervous System Diseases; Cyclohexanecarboxyli | 1998 |
Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic | 1998 |
Postherpetic neuralgia: role of gabapentin and other treatment modalities.
Topics: Acetates; Administration, Topical; Age Factors; Aged; Ambulatory Care; Amines; Analgesics; Anticonvu | 1999 |
Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Bl | 2001 |
328 other studies available for gabapentin and Nerve Pain
| Article | Year |
|---|---|
Synthesis and biological evaluation of novel dimiracetam derivatives useful for the treatment of neuropathic pain.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Imidazoles; Neuralgia; Pain Threshold; Pyrroles; | 2008 |
Sulfamoyl benzamides as novel CB2 cannabinoid receptor ligands.
Topics: Animals; Benzamides; Binding Sites; Dose-Response Relationship, Drug; Ligands; Mice; Models, Animal; | 2008 |
Novel KCNQ2/Q3 agonists as potential therapeutics for epilepsy and neuropathic pain.
Topics: Adamantane; Animals; Azides; Epilepsy; KCNQ2 Potassium Channel; KCNQ3 Potassium Channel; Mice; Neura | 2010 |
Synthesis and T-type calcium channel blocking activity of novel diphenylpiperazine compounds, and evaluation of in vivo analgesic activity.
Topics: Analgesics; Animals; Calcium Channels, T-Type; Humans; Neuralgia; Pain Measurement; Piperazines; Rat | 2010 |
Discovery of molecules for the treatment of neuropathic pain: synthesis, antiallodynic and antihyperalgesic activities of 5-(4-nitrophenyl)furoic-2-acid hydrazones.
Topics: Analgesics; Animals; Disease Models, Animal; Drug Discovery; Female; Furans; Humans; Hydrazones; Hyp | 2011 |
Synthesis and biological evaluation of 4-piperidinecarboxylate and 4-piperidinecyanide derivatives for T-type calcium channel blockers.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, T-Type; Disease Models, Animal; Drug Design; Dr | 2011 |
Synthesis and biological evaluation of a fluorescent analog of phenytoin as a potential inhibitor of neuropathic pain and imaging agent.
Topics: Animals; Disease Models, Animal; Drug Design; Female; Fluorescence; Fluorescent Dyes; Models, Molecu | 2012 |
Aminopiperidine sulfonamide Cav2.2 channel inhibitors for the treatment of chronic pain.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, N-Type; Cells, Cultured; Chronic Pain; Dogs; Hu | 2012 |
Synthesis and biological evaluation of 2-(arylethynyl)quinoline derivatives as mGluR5 antagonists for the treatment of neuropathic pain.
Topics: Acetylene; HEK293 Cells; Humans; Neuralgia; Quinolines; Receptor, Metabotropic Glutamate 5 | 2013 |
A novel benzazepinone sodium channel blocker with oral efficacy in a rat model of neuropathic pain.
Topics: Animals; Benzazepines; Disease Models, Animal; Neuralgia; Rats; Sodium Channel Blockers | 2013 |
Discovery of novel tetrahydro-pyrazolo [4,3-c] pyridines for the treatment of neuropathic pain: synthesis and neuropharmacology.
Topics: Animals; Chemistry Techniques, Synthetic; Drug Discovery; Female; Hyperalgesia; Male; Mice; Neuralgi | 2013 |
Discovery of (S,E)-3-(2-fluorophenyl)-N-(1-(3-(pyridin-3-yloxy)phenyl)ethyl)-acrylamide as a potent and efficacious KCNQ2 (Kv7.2) opener for the treatment of neuropathic pain.
Topics: Acrylamides; Animals; KCNQ2 Potassium Channel; Male; Neuralgia; Patch-Clamp Techniques; Rats; Rats, | 2013 |
Synthesis and biological evaluation of aryl isoxazole derivatives as metabotropic glutamate receptor 1 antagonists: a potential treatment for neuropathic pain.
Topics: Administration, Oral; Analgesics; Animals; Disease Models, Animal; Isoxazoles; Neuralgia; Protein Bi | 2015 |
Discovery and biological evaluation of tetrahydrothieno[2,3-c]pyridine derivatives as selective metabotropic glutamate receptor 1 antagonists for the potential treatment of neuropathic pain.
Topics: Administration, Oral; Analgesics; Animals; Cells, Cultured; Disease Models, Animal; Drug Discovery; | 2015 |
Gram Scale Syntheses of (-)-Incarvillateine and Its Analogs. Discovery of Potent Analgesics for Neuropathic Pain.
Topics: Alkaloids; Animals; Drug Discovery; Male; Mice; Mice, Inbred ICR; Monoterpenes; Neuralgia; Structure | 2016 |
Synthesis and T-type calcium channel-blocking effects of aryl(1,5-disubstituted-pyrazol-3-yl)methyl sulfonamides for neuropathic pain treatment.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, T-Type; Chemistry Techniques, Synthetic; Drug S | 2016 |
Synthesis and evaluation of 6-pyrazoylamido-3N-substituted azabicyclo[3,1,0]hexane derivatives as T-type calcium channel inhibitors for treatment of neuropathic pain.
Topics: Administration, Oral; Animals; Azabicyclo Compounds; Calcium Channel Blockers; Calcium Channels, T-T | 2016 |
Synthesis and diabetic neuropathic pain-alleviating effects of 2N-(pyrazol-3-yl)methylbenzo[d]isothiazole-1,1-dioxide derivatives.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, T-Type; Diabetic Neuropathies; Disease Models, | 2017 |
Neuropathic pain-alleviating effects of pyrazole-conjugated arylsulfonamides as 5-HT
Topics: Animals; Cytochrome P-450 Enzyme System; Disease Models, Animal; Dose-Response Relationship, Drug; E | 2017 |
Discovery of a para-Acetoxy-benzyl Ester Prodrug of a Hydroxamate-Based Glutamate Carboxypeptidase II Inhibitor as Oral Therapy for Neuropathic Pain.
Topics: Administration, Oral; Analgesics; Animals; Drug Discovery; Enzyme Inhibitors; Esterification; Glutam | 2017 |
Structural hybridization of pyrrolidine-based T-type calcium channel inhibitors and exploration of their analgesic effects in a neuropathic pain model.
Topics: Analgesics; Animals; Calcium Channel Blockers; Calcium Channels, T-Type; Calcium Signaling; Disease | 2019 |
Discovery of Nonpungent Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist as Strong Topical Analgesic.
Topics: Analgesics; Animals; Capsaicin; CHO Cells; Cricetulus; Drug Discovery; Hyperalgesia; Mice, Inbred IC | 2020 |
Discovery of Potent, Selective, and State-Dependent Na
Topics: Animals; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Disease Models, Animal; Drug Des | 2020 |
Novel Sigma 1 Receptor Antagonists as Potential Therapeutics for Pain Management.
Topics: Animals; Binding Sites; Blood-Brain Barrier; Drug Design; Guinea Pigs; Half-Life; Humans; Microsomes | 2021 |
Alkyne-Bridged α-Conotoxin Vc1.1 Potently Reverses Mechanical Allodynia in Neuropathic Pain Models.
Topics: Alkynes; Analgesics; Animals; Cells, Cultured; Conotoxins; Conus Snail; Disease Models, Animal; Fema | 2021 |
Discovery, Structure-Activity Relationships, and In Vivo Evaluation of Novel Aryl Amides as Brain Penetrant Adaptor Protein 2-Associated Kinase 1 (AAK1) Inhibitors for the Treatment of Neuropathic Pain.
Topics: Amides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Caco-2 Cells; Dose-Response Relatio | 2021 |
Synthesis and evaluation of dual fatty acid amide hydrolase-monoacylglycerol lipase inhibition and antinociceptive activities of 4-methylsulfonylaniline-derived semicarbazones.
Topics: Amidohydrolases; Analgesics; Enzyme Inhibitors; Humans; Molecular Docking Simulation; Monoacylglycer | 2022 |
Anti-nociceptive effects of ECa 233 a standardized extract of Centella asiatica (L.) Urban on chronic neuropathic orofacial pain in mice.
Topics: Analgesics; Animals; Calcitonin Gene-Related Peptide; Chronic Pain; Disease Models, Animal; Dose-Res | 2022 |
Heme oxygenase-1 in the spinal cord plays crucial roles in the analgesic effects of pregabalin and gabapentin in a spared nerve-injury mouse model.
Topics: Analgesics; Animals; Disease Models, Animal; Gabapentin; Heme Oxygenase-1; Male; Mice; Mice, Inbred | 2022 |
Risk of Pregabalin-Induced Hypoglycemia: Analysis of the Japanese Adverse Drug Event Report Database.
Topics: Aged; Drug-Related Side Effects and Adverse Reactions; Duloxetine Hydrochloride; Gabapentin; Humans; | 2022 |
Asprosin, a novel therapeutic candidate for painful neuropathy: an experimental study in mice.
Topics: Analgesics; Animals; Disease Models, Animal; Fibrillin-1; Gabapentin; Hyperalgesia; Male; Mice; Mice | 2022 |
The impact of regulatory restrictions on pregabalin use in Saudi Arabia: An interrupted time series analysis.
Topics: Analgesics; Gabapentin; Humans; Interrupted Time Series Analysis; Neuralgia; Pregabalin; Saudi Arabi | 2022 |
Misuse of gabapentinoids (pregabalin and gabapentin) in patients with neuropathic pain related to spinal cord injury.
Topics: Amines; Analgesics; Cross-Sectional Studies; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobut | 2023 |
Gabapentin initiation in the inpatient setting: A characterization of prescribing.
Topics: Adult; Analgesics, Opioid; Female; Gabapentin; Humans; Inpatients; Male; Middle Aged; Neuralgia; Pai | 2022 |
Does gabapentin impact response to anticholinergics for overactive bladder?
Topics: Cholinergic Antagonists; Chronic Pain; Female; Gabapentin; Humans; Neuralgia; Urinary Bladder, Overa | 2022 |
Antagonistic Effect and Mechanism of Gabapentin on Neuropathic Pain in Rats through P38 MAPK Signaling Pathway.
Topics: Animals; Female; Gabapentin; Humans; MAP Kinase Signaling System; Neuralgia; p38 Mitogen-Activated P | 2022 |
Gabapentin inhibits the analgesic effects and nerve regeneration process induced by hepatocyte growth factor (HGF) in a peripheral nerve injury model: Implication for the use of VM202 and gabapentinoids for peripheral neuropathy.
Topics: Analgesics; Animals; Axons; Disease Models, Animal; DNA; Gabapentin; Genetic Therapy; Hepatocyte Gro | 2022 |
Development of a PET radioligand for α2δ-1 subunit of calcium channels for imaging neuropathic pain.
Topics: Animals; Calcium Channels, L-Type; Gabapentin; Ligands; Neuralgia; Positron-Emission Tomography; Rat | 2022 |
Comparing the Value of Data Visualization Methods for Communicating Harms in Clinical Trials.
Topics: Data Visualization; Gabapentin; Humans; Neuralgia | 2022 |
Efficacy of 2-Hydroxyflavanone in Rodent Models of Pain and Inflammation: Involvement of Opioidergic and GABAergic Anti-Nociceptive Mechanisms.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Cisplatin; Disease Models, Animal; Edema; Flavanones; | 2022 |
Small Synthetic Hyaluronan Disaccharide BIS014 Mitigates Neuropathic Pain in Mice.
Topics: Animals; Capsaicin; Gabapentin; Hyaluronic Acid; Hyperalgesia; Mice; Neuralgia; TRPV Cation Channels | 2023 |
HDAC2 in Primary Sensory Neurons Constitutively Restrains Chronic Pain by Repressing α2δ-1 Expression and Associated NMDA Receptor Activity.
Topics: Acute Pain; Animals; Chronic Pain; Female; Gabapentin; Ganglia, Spinal; Histone Deacetylase 2; Histo | 2022 |
Effect of Repeated High-voltage Long-duration Pulsed Radiofrequency on Herpetic Neuralgia.
Topics: Gabapentin; Galectin 3; Herpes Zoster; Humans; Interleukin-6; Morphine Derivatives; Neuralgia; Neura | 2022 |
[Efficacy analysis of lidocaine plaster combined with gabapentin in the treatment of herpes zoster neuralgia].
Topics: Aged; Female; Gabapentin; Herpes Zoster; Humans; Lidocaine; Male; Middle Aged; Neuralgia; Quality of | 2022 |
Effective treatment of high-voltage pulsed radiofrequency combined with oxygen-ozone injection in acute zoster neuralgia.
Topics: Gabapentin; Herpes Zoster; Humans; Neuralgia; Neuralgia, Postherpetic; Oxygen; Ozone; Pulsed Radiofr | 2022 |
Does gabapentin provide benefit for patients with knee OA? A benefit-harm and cost-effectiveness analysis.
Topics: Cost-Benefit Analysis; Cost-Effectiveness Analysis; Gabapentin; Humans; Neuralgia; Osteoarthritis, K | 2023 |
Does gabapentin provide benefit for patients with knee OA? A benefit-harm and cost-effectiveness analysis.
Topics: Cost-Benefit Analysis; Cost-Effectiveness Analysis; Gabapentin; Humans; Neuralgia; Osteoarthritis, K | 2023 |
Does gabapentin provide benefit for patients with knee OA? A benefit-harm and cost-effectiveness analysis.
Topics: Cost-Benefit Analysis; Cost-Effectiveness Analysis; Gabapentin; Humans; Neuralgia; Osteoarthritis, K | 2023 |
Does gabapentin provide benefit for patients with knee OA? A benefit-harm and cost-effectiveness analysis.
Topics: Cost-Benefit Analysis; Cost-Effectiveness Analysis; Gabapentin; Humans; Neuralgia; Osteoarthritis, K | 2023 |
Does gabapentin provide benefit for patients with knee OA? A benefit-harm and cost-effectiveness analysis.
Topics: Cost-Benefit Analysis; Cost-Effectiveness Analysis; Gabapentin; Humans; Neuralgia; Osteoarthritis, K | 2023 |
Does gabapentin provide benefit for patients with knee OA? A benefit-harm and cost-effectiveness analysis.
Topics: Cost-Benefit Analysis; Cost-Effectiveness Analysis; Gabapentin; Humans; Neuralgia; Osteoarthritis, K | 2023 |
Does gabapentin provide benefit for patients with knee OA? A benefit-harm and cost-effectiveness analysis.
Topics: Cost-Benefit Analysis; Cost-Effectiveness Analysis; Gabapentin; Humans; Neuralgia; Osteoarthritis, K | 2023 |
Does gabapentin provide benefit for patients with knee OA? A benefit-harm and cost-effectiveness analysis.
Topics: Cost-Benefit Analysis; Cost-Effectiveness Analysis; Gabapentin; Humans; Neuralgia; Osteoarthritis, K | 2023 |
Does gabapentin provide benefit for patients with knee OA? A benefit-harm and cost-effectiveness analysis.
Topics: Cost-Benefit Analysis; Cost-Effectiveness Analysis; Gabapentin; Humans; Neuralgia; Osteoarthritis, K | 2023 |
Chronic pain inhibits autophagy in hippocampus while the analgetic drug, Gabapentin reverts this SNI-driven action.
Topics: Autophagy; Chronic Pain; Gabapentin; Hippocampus; Humans; Neuralgia | 2022 |
Chronic pain inhibits autophagy in hippocampus while the analgetic drug, Gabapentin reverts this SNI-driven action.
Topics: Autophagy; Chronic Pain; Gabapentin; Hippocampus; Humans; Neuralgia | 2022 |
Chronic pain inhibits autophagy in hippocampus while the analgetic drug, Gabapentin reverts this SNI-driven action.
Topics: Autophagy; Chronic Pain; Gabapentin; Hippocampus; Humans; Neuralgia | 2022 |
Chronic pain inhibits autophagy in hippocampus while the analgetic drug, Gabapentin reverts this SNI-driven action.
Topics: Autophagy; Chronic Pain; Gabapentin; Hippocampus; Humans; Neuralgia | 2022 |
Case Series: Synergistic Effect of Gabapentin and Adjuvant Pregabalin in Neuropathic Pain.
Topics: Amines; Analgesics; Animals; Calcium Channels; Cyclohexanecarboxylic Acids; Gabapentin; Humans; Neur | 2023 |
Case Series: Synergistic Effect of Gabapentin and Adjuvant Pregabalin in Neuropathic Pain.
Topics: Amines; Analgesics; Animals; Calcium Channels; Cyclohexanecarboxylic Acids; Gabapentin; Humans; Neur | 2023 |
Case Series: Synergistic Effect of Gabapentin and Adjuvant Pregabalin in Neuropathic Pain.
Topics: Amines; Analgesics; Animals; Calcium Channels; Cyclohexanecarboxylic Acids; Gabapentin; Humans; Neur | 2023 |
Case Series: Synergistic Effect of Gabapentin and Adjuvant Pregabalin in Neuropathic Pain.
Topics: Amines; Analgesics; Animals; Calcium Channels; Cyclohexanecarboxylic Acids; Gabapentin; Humans; Neur | 2023 |
PK/PD analysis of trazodone and gabapentin in neuropathic pain rodent models: Translational PK-PD modeling from nonclinical to clinical development.
Topics: Acetic Acid; Analgesics; Animals; Gabapentin; Humans; Mice; Models, Biological; Neuralgia; Rodentia; | 2023 |
Synergistic effect of ellagic acid and gabapentin in a rat model of neuropathic pain.
Topics: Animals; Ellagic Acid; Gabapentin; Hyperalgesia; Neuralgia; Rats; Rats, Sprague-Dawley; Spinal Cord; | 2023 |
Ketoprofen, lysine and gabapentin co-crystal magnifies synergistic efficacy and tolerability of the constituent drugs: Pre-clinical evidences towards an innovative therapeutic approach for neuroinflammatory pain.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Chronic Pain; Gabapentin; Ketoprofen; Lysine; Neur | 2023 |
Inhibition of T-Type Calcium Channels With TTA-P2 Reduces Chronic Neuropathic Pain Following Spinal Cord Injury in Rats.
Topics: Animals; Calcium Channels, T-Type; Female; Gabapentin; Male; Neuralgia; Quality of Life; Rats; Rats, | 2023 |
Abuse and addiction in gabapentinoid drug users for neuropathic pain.
Topics: Adult; Aged; Amines; Cyclohexanecarboxylic Acids; Drug Users; Female; Gabapentin; gamma-Aminobutyric | 2023 |
Evaluation of
Topics: Animals; Brain; Gabapentin; Macaca mulatta; Neuralgia; Positron-Emission Tomography | 2023 |
Efficacy of a topical gabapentin gel in a cisplatin paradigm of chemotherapy-induced peripheral neuropathy.
Topics: Administration, Topical; Animals; Antineoplastic Agents; Cisplatin; Gabapentin; Hyperalgesia; Male; | 2019 |
Opportunities for selective reporting of harms in randomized clinical trials: Selection criteria for non-systematic adverse events.
Topics: Adverse Drug Reaction Reporting Systems; Bipolar Disorder; Gabapentin; Humans; Information Dissemina | 2019 |
Management of neuropathic pain following traumatic brachial plexus injury with neurolysis and oral gabapentin: A case report.
Topics: Adult; Aged; Analgesics; Brachial Plexus; Brachial Plexus Neuropathies; Bupivacaine; Gabapentin; Hum | 2019 |
Management of neuropathic pain: A graph theory-based presentation of literature review.
Topics: Breast Neoplasms; Gabapentin; Humans; Neuralgia; Paclitaxel | 2020 |
Is gabapentin effective in dry eye disease and neuropathic ocular pain?
Topics: Dry Eye Syndromes; Eye; Gabapentin; Humans; Neuralgia | 2020 |
Application of gabapentin after stapled hemorrhoidopexy may prevent age-related complication.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Female; Gabapentin; Hemorrhoidectomy; Human | 2020 |
Effects of gabapentinoids on responses of primary cultures from rat dorsal root ganglia to inflammatory or somatosensory stimuli.
Topics: Analgesics; Animals; Capsaicin; Female; Gabapentin; Ganglia, Spinal; Inflammation; Lipopolysaccharid | 2020 |
Recurrent Henoch-Schönlein Purpura with bullous rash and pulmonary nodules.
Topics: Biopsy, Fine-Needle; Bronchoalveolar Lavage Fluid; Chest Pain; Child; Complement C3; Cough; Female; | 2020 |
The protective effect of modafinil on vincristine-induced peripheral neuropathy in rats: A possible role for TRPA1 receptors.
Topics: Animals; Cytokines; Gabapentin; Hyperalgesia; Interleukin-1beta; Modafinil; Neural Conduction; Neura | 2020 |
Beneficial effect of gabapentin in two children with Noonan syndrome and early-onset neuropathic pain.
Topics: Adolescent; Adult; Age of Onset; Aged; Child; Female; Gabapentin; Humans; Male; Middle Aged; Neuralg | 2020 |
Chronic Neuropathic Pain Following Hand Burns: Etiology, Treatment, and Long-Term Outcomes.
Topics: Burns; Gabapentin; Hand Injuries; Humans; Neuralgia; Pain Management | 2021 |
Comparing Effectiveness of Gabapentin and Pregabalin in Treatment of Neuropathic Pain: A Retrospective Cohort of Palliative Care Outpatients.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; Humans; Neuralgia; Outpatients; Palliat | 2020 |
[Whether or not to use gabapentinoids in adults with chronic neuropathic pain].
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Chronic Pain; Diabetic Neuropathies; Female; Gabapentin; | 2020 |
The neuropathic phenotype of the K/BxN transgenic mouse with spontaneous arthritis: pain, nerve sprouting and joint remodeling.
Topics: Analgesics; Animals; Arthritis, Experimental; Female; Gabapentin; Ganglia, Spinal; Hyperalgesia; Kne | 2020 |
Population pharmacokinetics of gabapentin in patients with neuropathic pain: Lack of effect of diabetes or glycaemic control.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type 2; Gabapentin; Glycemic Con | 2021 |
Influence of single nucleotide polymorphism of LAT1 on therapeutic response to gabapentinoids in Pakistani patients with neuropathic pain.
Topics: Adult; Female; Gabapentin; Genotype; Humans; Large Neutral Amino Acid-Transporter 1; Male; Middle Ag | 2021 |
Involvement of selective GABA-A receptor subtypes in amelioration of cisplatin-induced neuropathic pain by 2'-chloro-6-methyl flavone (2'-Cl-6MF).
Topics: Analgesics; Animals; Antineoplastic Agents; Benzodiazepines; Cisplatin; Disease Models, Animal; Dose | 2021 |
Pain burden, sensory profile and inflammatory cytokines of dogs with naturally-occurring neuropathic pain treated with gabapentin alone or with meloxicam.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Cytokines; Dog Diseases; Dogs; Fe | 2020 |
Role of the endocannabinoid system on the antihyperalgesic action of gabapentin in animal model of neuropathic pain induced by partial sciatic nerve ligation.
Topics: Analgesics; Animals; Disease Models, Animal; Endocannabinoids; Gabapentin; Hyperalgesia; Male; Mice; | 2020 |
Treatment-induced diabetes neuropathy: description of singular clinical signs to reach a prompt diagnosis.
Topics: Diabetes Mellitus, Type 1; Diabetic Neuropathies; Dibenzazepines; Drug Therapy, Combination; Electro | 2020 |
Synergistic interaction between trazodone and gabapentin in rodent models of neuropathic pain.
Topics: Analgesics; Animals; Anti-Anxiety Agents; Depressive Disorder, Major; Disease Models, Animal; Drug S | 2021 |
Prevalence of and Factors Associated with Gabapentinoid Use and Misuse Among Texas Medicaid Recipients.
Topics: Adolescent; Adult; Analgesics, Opioid; Female; Gabapentin; Humans; Male; Medicaid; Middle Aged; Neur | 2021 |
In-Silico Validation and Fabrication of Matrix Diffusion-Based Polymeric Transdermal Patches for Repurposing Gabapentin Hydrochloride in Neuropathic Pain.
Topics: Analgesics; Computer Simulation; Diabetic Neuropathies; Drug Repositioning; Gabapentin; Humans; Mole | 2021 |
A novel gabapentin analogue assuages neuropathic pain response in chronic sciatic nerve constriction model in rats.
Topics: Analgesics; Animals; Behavior, Animal; Chronic Disease; Constriction; Disease Models, Animal; Excita | 2021 |
Chemotherapeutic Agent-Induced Vulvodynia, an Experimental Model.
Topics: Analgesics; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Disease Models, Anima | 2021 |
Restoring invisible and abandoned trials of gabapentin for neuropathic pain: a clinical and methodological investigation.
Topics: Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Neuralgia | 2021 |
Dynamic Change of Endocannabinoid Signaling in the Medial Prefrontal Cortex Controls the Development of Depression After Neuropathic Pain.
Topics: Animals; Brain Mapping; Chronic Pain; Depression; Endocannabinoids; Feeding Behavior; Female; GABAer | 2021 |
[
Topics: Amines; Animals; Autoradiography; Brain; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-R | 2017 |
Neuropathic pain-induced enhancement of spontaneous and pain-evoked neuronal activity in the periaqueductal gray that is attenuated by gabapentin.
Topics: Action Potentials; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Amino | 2017 |
Gabapentin-induced aquagenic wrinkling of the palms.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Hand De | 2017 |
The Potential for Gabapentinoid Abuse in Pain Management.
Topics: Analgesics; Gabapentin; Humans; Neuralgia; Pain Management; Pregabalin; Substance-Related Disorders | 2017 |
Murine model and mechanisms of treatment-induced painful diabetic neuropathy.
Topics: Amines; Animals; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Disease Models, Animal; Enzyme | 2017 |
ANTI-NOCICEPTIVE EFFECT OF AGRIMONIA EUPATORIA EXTRACT ON A CISPLATIN-INDUCED NEUROPATHIC MODEL.
Topics: Agrimonia; Amines; Analgesics; Animals; Cisplatin; Cyclohexanecarboxylic Acids; Foot; Gabapentin; ga | 2016 |
Characteristics, resource utilization and safety profile of patients prescribed with neuropathic pain treatments: a real-world evidence study on general practices in Europe - the role of the lidocaine 5% medicated plaster.
Topics: Aged; Aged, 80 and over; Amines; Anesthetics, Local; Cyclohexanecarboxylic Acids; Duloxetine Hydroch | 2017 |
Radiologic Findings in Gabapentin-Induced Myositis.
Topics: Adult; Amines; Analgesics; Biomarkers; Computed Tomography Angiography; Contrast Media; Cyclohexanec | 2017 |
Very-Low-Dose Methadone To Treat Refractory Neuropathic Pain in Children with Cancer.
Topics: Amines; Analgesics; Analgesics, Opioid; Cancer Pain; Child; Child, Preschool; Chronic Pain; Cyclohex | 2017 |
Sigma 2 Receptor/Tmem97 Agonists Produce Long Lasting Antineuropathic Pain Effects in Mice.
Topics: Amines; Analgesics, Opioid; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Gabapentin | 2017 |
Haloperidol Decreases Hyperalgesia and Allodynia Induced by Chronic Constriction Injury.
Topics: Amines; Analgesics; Animals; Antipsychotic Agents; Chronic Disease; Constriction, Pathologic; Cycloh | 2017 |
Intervertebral Foramen Injection of Ozone Relieves Mechanical Allodynia and Enhances Analgesic Effect of Gabapentin in Animal Model of Neuropathic Pain.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Follow-Up Studies; | 2017 |
Investigation of spinal nerve ligation-mediated functional activation of the rat brain using manganese-enhanced MRI.
Topics: Amines; Animals; Brain; Cyclohexanecarboxylic Acids; Disease Models, Animal; Gabapentin; gamma-Amino | 2018 |
Gabapentin and Pregabalin for Pain - Is Increased Prescribing a Cause for Concern?
Topics: Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Drug Approval; Drug Utilization; Gaba | 2017 |
Use of gabapentin and pregabalin for pruritus and neuropathic pain associated with major burn injury: A retrospective chart review.
Topics: Adolescent; Analgesics; Burns; Child; Child, Preschool; Female; Gabapentin; Humans; Infant; Male; Ne | 2018 |
Multiple sites and actions of gabapentin-induced relief of ongoing experimental neuropathic pain.
Topics: Amines; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Gabapentin; gamma-Aminobutyric | 2017 |
Gabapentin and its salicylaldehyde derivative alleviate allodynia and hypoalgesia in a cisplatin-induced neuropathic pain model.
Topics: Aldehydes; Amines; Animals; Cisplatin; Cyclohexanecarboxylic Acids; Drug Interactions; Female; Gabap | 2017 |
Effects of S 38093, an antagonist/inverse agonist of histamine H3 receptors, in models of neuropathic pain in rats.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Gabapentin; gamma- | 2018 |
A neuropathic pain syndrome associated with hantavirus infection.
Topics: Adult; Amines; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Cyclohexanecarboxylic Acids; Gab | 2017 |
The flavonoid 6-methoxyflavone allays cisplatin-induced neuropathic allodynia and hypoalgesia.
Topics: Amines; Analgesics; Animals; Antineoplastic Agents; Behavior, Animal; Cisplatin; Cyclohexanecarboxyl | 2017 |
The monoacylglycerol lipase inhibitor KML29 with gabapentin synergistically produces analgesia in mice.
Topics: Amines; Analgesics; Animals; Benzodioxoles; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dos | 2017 |
Practical guidance for using multiple data sources in systematic reviews and meta-analyses (with examples from the MUDS study).
Topics: Amines; Bipolar Disorder; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Data Collection; Ga | 2018 |
Pharmacological validation of voluntary gait and mechanical sensitivity assays associated with inflammatory and neuropathic pain in mice.
Topics: Analgesics; Animals; Buprenorphine; Carbazoles; Disease Models, Animal; Female; Freund's Adjuvant; G | 2018 |
Intercostobrachial Neuralgia After Axillary Surgery for Hidradenitis Suppurativa.
Topics: Adult; Axilla; Excitatory Amino Acid Antagonists; Female; Gabapentin; Hidradenitis Suppurativa; Huma | 2018 |
Evaluating the effectiveness of antidepressant therapy adjuvant to gabapentin and pregabalin for treatment of SCI-related neuropathic pain.
Topics: Adult; Analgesics; Antidepressive Agents; Chemotherapy, Adjuvant; Cohort Studies; Drug Therapy, Comb | 2018 |
Effects of ralfinamide in models of nerve injury and chemotherapy-induced neuropathic pain.
Topics: Amines; Analgesics; Animals; Antineoplastic Agents; Blood Pressure; Cyclohexanecarboxylic Acids; Dis | 2018 |
Effect of cold pack therapy for management of burn scar pruritus: A pilot study.
Topics: Adult; Burns; Cicatrix; Cryotherapy; Excitatory Amino Acid Antagonists; Female; Gabapentin; Histamin | 2018 |
Efficacy and safety of combined low doses of either diclofenac or celecoxib with gabapentin versus their single high dose in treatment of neuropathic pain in rats.
Topics: Amines; Analgesics; Animals; Behavior, Animal; Celecoxib; Cyclohexanecarboxylic Acids; Diclofenac; D | 2018 |
Evaluation of the neonatal streptozotocin model of diabetes in rats: Evidence for a model of neuropathic pain.
Topics: Activating Transcription Factor 3; Amines; Animals; Animals, Newborn; Astrocytes; Cyclohexanecarboxy | 2018 |
The α2δ-1-NMDA Receptor Complex Is Critically Involved in Neuropathic Pain Development and Gabapentin Therapeutic Actions.
Topics: Animals; Calcium Channels; Calcium Channels, L-Type; Gabapentin; HEK293 Cells; Humans; Male; Mice, K | 2018 |
Patterns of pain medication use in older individuals with cardiovascular disease.
Topics: Acetaminophen; Aged; Aged, 80 and over; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, No | 2018 |
Cost of treating peripheral neuropathic pain with pregabalin or gabapentin at therapeutic doses in routine practice.
Topics: Adult; Amines; Analgesics; Electronic Health Records; Female; Gabapentin; Health Resources; Humans; | 2018 |
An Evaluation of Efficacy and Safety of Commonly Prescribed Drugs and Effect of These Drugs on Quality of Sleep in Patients Suffering From Zoster-Associated Pain.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amitriptyline; Anti-Inflammatory Agents, Non-Steroidal; | 2018 |
A voxel-based analysis of neurobiological mechanisms in placebo analgesia in rats.
Topics: Analgesia; Analgesics; Animals; Brain Mapping; Conditioning, Classical; Gabapentin; Humans; Image Pr | 2018 |
[Effects of HCN2 in the development of peripheral neuropathic pain in rats].
Topics: Amines; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Ganglia, Spinal; | 2017 |
Gabapentin and NMDA receptor antagonists interacts synergistically to alleviate allodynia in two rat models of neuropathic pain.
Topics: Animals; Behavior, Animal; Dextromethorphan; Dizocilpine Maleate; Dose-Response Relationship, Drug; | 2018 |
Evaluation of composite responder outcomes of pain intensity and physical function in neuropathic pain clinical trials: an ACTTION individual patient data analysis.
Topics: Aged; Aged, 80 and over; Analgesics; Clinical Trials as Topic; Double-Blind Method; Duloxetine Hydro | 2018 |
Neuropathic Pain Creates an Enduring Prefrontal Cortex Dysfunction Corrected by the Type II Diabetic Drug Metformin But Not by Gabapentin.
Topics: Analgesics; Animals; Attention; Axons; Clonidine; Cognition Disorders; Discrimination, Psychological | 2018 |
Synergism between gabapentin-tramadol in experimental diabetic neuropathic pain.
Topics: Analgesics, Opioid; Animals; Diabetic Neuropathies; Drug Synergism; Drug Therapy, Combination; Gabap | 2018 |
THC and gabapentin interactions in a mouse neuropathic pain model.
Topics: Analgesics; Animals; Cold Temperature; Disease Models, Animal; Dose-Response Relationship, Drug; Dro | 2019 |
Interleukin-1beta in synergism gabapentin with tramadol in murine model of diabetic neuropathy.
Topics: Analgesics; Animals; Diabetic Neuropathies; Disease Models, Animal; Drug Synergism; Drug Therapy, Co | 2019 |
Comparison of ex vivo and in vitro actions of gabapentin in superficial dorsal horn and the role of extra-spinal sites of drug action.
Topics: Analgesics; Animals; Excitatory Postsynaptic Potentials; Gabapentin; Hyperalgesia; Male; Neural Inhi | 2019 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Actigraphy-based evaluation of sleep quality and physical activity in individuals with spinal cord injury.
Topics: Actigraphy; Adult; Analgesics; Benzodiazepines; Case-Control Studies; Exercise; Female; Gabapentin; | 2019 |
Clinical Pharmacology Considerations in Pain Management in Patients with Advanced Kidney Failure.
Topics: Acetaminophen; Acute Pain; Analgesics, Non-Narcotic; Analgesics, Opioid; Carbamazepine; Chronic Pain | 2019 |
Switching from gabapentin to pregabalin.
Topics: Analgesics; Anticonvulsants; Drug Substitution; Gabapentin; Humans; Neuralgia; New Zealand; Pregabal | 2019 |
The Effects of Early Neuropathic Pain Control With Gabapentin on Long-Term Chronic Pain and Itch in Burn Patients.
Topics: Adolescent; Adult; Analgesics; Burns; Female; Gabapentin; Humans; Male; Middle Aged; Neuralgia; Pain | 2019 |
Prescribing practice of pregabalin/gabapentin in pain therapy: an evaluation of German claim data.
Topics: Adult; Aged; Analgesics; Chronic Pain; Female; Gabapentin; Germany; Humans; Infant; Insurance Claim | 2019 |
Sinomenine facilitates the efficacy of gabapentin or ligustrazine hydrochloride in animal models of neuropathic pain.
Topics: Analgesics; Animals; Disease Models, Animal; Drug Synergism; Gabapentin; Male; Mice; Mice, Inbred C5 | 2019 |
Attenuation of vincristine-induced neuropathy by synthetic cyclohexenone-functionalized derivative in mice model.
Topics: Analgesics; Animals; Antineoplastic Agents, Phytogenic; Antioxidants; Behavior, Animal; Disease Mode | 2019 |
Multiple foraminal compression in a child with sialidosis type 2.
Topics: Analgesics; Child; Female; Gabapentin; Ganglia, Sympathetic; Humans; Hyperalgesia; Mucolipidoses; Ne | 2019 |
Pharmacodynamic effects of a D-amino acid oxidase inhibitor indicate a spinal site of action in rat models of neuropathic pain.
Topics: Amines; Analgesics; Anesthesia; Animals; Behavior, Animal; Constriction, Pathologic; Cyclohexanecarb | 2013 |
Topical medications for the effective management of neuropathic orofacial pain.
Topics: Administration, Topical; Amines; Analgesics, Non-Narcotic; Anesthetics, Local; Anti-Inflammatory Age | 2013 |
Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting.
Topics: Amines; Analgesics; Cost-Benefit Analysis; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Femal | 2013 |
Treatment of neuropathic pain in acute intermittent porphyria with gabapentin.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; | 2013 |
Gabapentin-induced pharmacodynamic effects in the spinal nerve ligation model of neuropathic pain.
Topics: Amines; Analgesics; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Disease Models, Animal; | 2014 |
Effects of gabapentin on thermal sensitivity following spinal nerve ligation or spinal cord compression.
Topics: Amines; Analgesics; Animals; Behavior, Animal; Conditioning, Operant; Cyclohexanecarboxylic Acids; D | 2013 |
[Occipital neuralgia: clinical and therapeutic characteristics of a series of 14 patients].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Amitriptyline; Analgesics; Cyclohexanecarboxylic | 2013 |
Neuropathic pain following sagittal split ramus osteotomy of the mandible: prevalence, risk factors, and clinical course.
Topics: Adult; Age Factors; Amines; Anticonvulsants; Antidepressive Agents, Tricyclic; Cohort Studies; Cyclo | 2013 |
[Lacosamide as an alternative in the treatment of post-surgery neuropathic pain in an allergic patient].
Topics: Acetamides; Adult; Amines; Analgesics; Anticonvulsants; Brachial Plexus Neuropathies; Contraindicati | 2013 |
Oral gabapentin treatment accentuates nerve and peripheral inflammatory responses following experimental nerve constriction in Wistar rats.
Topics: Administration, Oral; Amines; Analgesics; Animals; Cell Movement; Constriction, Pathologic; Cyclohex | 2013 |
The role of keratinocyte-derived chemokine (KC) on hyperalgesia caused by peripheral nerve injury in mice.
Topics: Amines; Analgesics; Animals; Antibodies; Chemokines; Cyclohexanecarboxylic Acids; Cyclooxygenase Inh | 2014 |
Spinal morphine but not ziconotide or gabapentin analgesia is affected by alternative splicing of voltage-gated calcium channel CaV2.2 pre-mRNA.
Topics: Alternative Splicing; Amines; Analgesia; Animals; Calcium Channels, N-Type; Cyclohexanecarboxylic Ac | 2013 |
The anticonvulsant enaminone E139 attenuates paclitaxel-induced neuropathic pain in rodents.
Topics: Amines; Amitriptyline; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Cyclohexanes; Female; | 2013 |
Antinociceptive effects of mirtazapine, pregabalin, and gabapentin after chronic constriction injury of the infraorbital nerve in rats.
Topics: Adrenergic alpha-Antagonists; Amines; Analgesics; Animals; Cranial Nerve Injuries; Cyclohexanecarbox | 2014 |
Gabapentin increases extracellular glutamatergic level in the locus coeruleus via astroglial glutamate transporter-dependent mechanisms.
Topics: Amines; Amino Acid Transport System X-AG; Animals; Astrocytes; Cyclohexanecarboxylic Acids; Disease | 2014 |
Gabapentin enhances the morphine anti-nociceptive effect in neuropathic pain via the interleukin-10-heme oxygenase-1 signalling pathway in rats.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Heme | 2014 |
Ligation of mouse L4 and L5 spinal nerves produces robust allodynia without major motor function deficit.
Topics: Amines; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Female; Gabapentin; gamma-Amin | 2015 |
Anti-allodynic and neuroprotective effects of koumine, a Benth alkaloid, in a rat model of diabetic neuropathy.
Topics: Amines; Animals; Blood Glucose; Body Weight; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Experim | 2014 |
Nummular headache in a patient with ipsilateral occipital neuralgia--a case report.
Topics: Amines; Analgesics; Anesthetics, Local; Bupivacaine; Comorbidity; Cyclohexanecarboxylic Acids; Femal | 2014 |
Effect of variability in the 7-day baseline pain diary on the assay sensitivity of neuropathic pain randomized clinical trials: an ACTTION study.
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathi | 2014 |
Activation of mesocorticolimbic reward circuits for assessment of relief of ongoing pain: a potential biomarker of efficacy.
Topics: Amines; Analgesics; Animals; Biomarkers; Cyclohexanecarboxylic Acids; Dopamine; Gabapentin; gamma-Am | 2014 |
Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy.
Topics: Amines; Analgesics; Animals; Benzoates; Chronic Pain; Conditioning, Psychological; Cyclohexanecarbox | 2014 |
Evidence, regulation and 'rational' prescribing: the case of gabapentin for neuropathic pain.
Topics: Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci | 2015 |
Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy.
Topics: Administration, Oral; Amines; Analgesics; Animals; Biological Availability; Chemistry Techniques, Sy | 2014 |
Effect of histone deacetylase inhibitor JNJ-26481585 in pain.
Topics: Amines; Animals; Antineoplastic Agents; Calcium Channels; Cyclohexanecarboxylic Acids; Gabapentin; g | 2015 |
Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods.
Topics: Amines; Amitriptyline; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Cyclohexanecarboxyli | 2014 |
Gabapentin reverses central hypersensitivity and suppresses medial prefrontal cortical glucose metabolism in rats with neuropathic pain.
Topics: Amines; Animals; Brain; Cyclohexanecarboxylic Acids; Disease Models, Animal; Fluorodeoxyglucose F18; | 2014 |
Pharmacovigilance in hospice/palliative care: net effect of gabapentin for neuropathic pain.
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; | 2015 |
Severe postherpetic neuralgia and other neuropathic pain syndromes alleviated by topical gabapentin.
Topics: Aged; Aged, 80 and over; Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Female; Gaba | 2015 |
Antinociceptive synergism of gabapentin and nortriptyline in mice with partial sciatic nerve ligation.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Drug Synergism; Drug Therapy, Combination; | 2015 |
Differences in cisplatin-induced mechanical allodynia in male and female mice.
Topics: Amines; Analgesics; Animals; Antineoplastic Agents; Cisplatin; Cyclohexanecarboxylic Acids; Disease | 2015 |
Experience from therapeutic drug monitoring and gender aspects of gabapentin and pregabalin in clinical practice.
Topics: Adult; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; | 2015 |
Peripheral neuropathies: new recommendations for neuropathic pain pharmacotherapy.
Topics: Amines; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents; Cyclohexanecarboxylic Acids; Gab | 2015 |
Increased expression of HCN2 channel protein in L4 dorsal root ganglion neurons following axotomy of L5- and inflammation of L4-spinal nerves in rats.
Topics: Amines; Animals; Axotomy; Cyclohexanecarboxylic Acids; Disease Models, Animal; Excitatory Amino Acid | 2015 |
Antinociceptive and hypnotic activities of pregabalin in a neuropathic pain-like model in mice.
Topics: Amines; Analgesics; Animals; Cerebral Cortex; Cyclohexanecarboxylic Acids; Electroencephalography; G | 2015 |
Gabapentin alleviates affective pain after traumatic nerve injury.
Topics: Affect; Amines; Analgesics; Animals; Conditioning, Psychological; Cyclohexanecarboxylic Acids; Gabap | 2015 |
Psychotic and depressive symptoms after gabapentin treatment.
Topics: Amines; Cyclohexanecarboxylic Acids; Depression; Excitatory Amino Acid Antagonists; Female; Gabapent | 2015 |
Suboptimal Treatment of Diabetic Peripheral Neuropathic Pain in the United States.
Topics: Adult; Aged; Amines; Antidepressive Agents; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Dulo | 2015 |
A streptozotocin-induced diabetic neuropathic pain model for static or dynamic mechanical allodynia and vulvodynia: validation using topical and systemic gabapentin.
Topics: Administration, Topical; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Diabetes Mellitus | 2015 |
Routine prescribing of gabapentin or pregabalin in supportive and palliative care: what are the comparative performances of the medications in a palliative care population?
Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Prescriptions; Female; Gabapentin; gamma | 2015 |
Effect of a Novel, Orally Active Matrix Metalloproteinase-2 and -9 Inhibitor in Spinal and Trigeminal Rat Models of Neuropathic Pain.
Topics: Administration, Oral; Amines; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Gabapent | 2015 |
Gabapentin, an Analgesic Used Against Cancer-Associated Neuropathic Pain: Effects on Prostate Cancer Progression in an In Vivo Rat Model.
Topics: Amines; Analgesics; Animals; Carcinogenesis; Cells, Cultured; Cyclohexanecarboxylic Acids; Disease M | 2016 |
Gabapentin attenuates neuropathic pain and improves nerve myelination after chronic sciatic constriction in rats.
Topics: Amines; Animals; Anticonvulsants; Constriction, Pathologic; Cyclohexanecarboxylic Acids; Gabapentin; | 2015 |
5-HT6 receptor antagonist attenuates the memory deficits associated with neuropathic pain and improves the efficacy of gabapentinoids.
Topics: Amines; Animals; Cognition; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; Gabapent | 2015 |
A Medication Combination for the Treatment of Central Poststroke Pain via the Adjuvant Use of Prednisone With Gabapentin: A Case Report.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Drug Thera | 2016 |
Peripheral Neuritis Trauma in Pigs: A Neuropathic Pain Model.
Topics: Amines; Analgesics; Animals; Behavior, Animal; Brain-Derived Neurotrophic Factor; Calcitonin Gene-Re | 2016 |
Trigeminal neuropathic pain as a complication of anterior temporal lobectomy: report of 2 cases.
Topics: Amines; Analgesics; Anterior Temporal Lobectomy; Cyclohexanecarboxylic Acids; Drug Resistant Epileps | 2016 |
Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: a protocol.
Topics: Amines; Analgesics; Antipsychotic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Data Interp | 2015 |
Topical ambroxol for the treatment of neuropathic pain. An initial clinical observation.
Topics: Administration, Topical; Adult; Aged; Ambroxol; Amines; Anesthetics, Local; Cyclohexanecarboxylic Ac | 2015 |
Gabapentinoid Insensitivity after Repeated Administration is Associated with Down-Regulation of the α(2)δ-1 Subunit in Rats with Central Post-Stroke Pain Hypersensitivity.
Topics: Amines; Analgesics; Animals; Blotting, Western; Calcium Channels; Cyclohexanecarboxylic Acids; Disea | 2016 |
Antinociceptive Interaction of Tramadol with Gabapentin in Experimental Mononeuropathic Pain.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Response Rela | 2016 |
Auriculotemporal Neuralgia: Eight New Cases Report.
Topics: Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Facial Pain; Female; Gabapentin; gamma | 2016 |
[Postmastectomy pain syndrome in our region: characteristics, treatment, and experience with gabapentin].
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Humans | 2016 |
Antinociceptive Interactions Between Meloxicam and Gabapentin in Neuropathic Pain Depend on the Ratio used in Combination in Rats.
Topics: Amines; Analgesics; Animals; Area Under Curve; Cyclohexanecarboxylic Acids; Disease Models, Animal; | 2016 |
Macular Edema after Gabapentin.
Topics: Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Fluorescein Angiography; Gabapentin; gam | 2016 |
Effects of Adjuvant Analgesics on Cerebral Ischemia-Induced Mechanical Allodynia.
Topics: Amines; Analgesics; Animals; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Antico | 2016 |
Medial plantar nerve ligation as a novel model of neuropathic pain in mice: pharmacological and molecular characterization.
Topics: Activating Transcription Factor 3; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease | 2016 |
Vitamin C enhances the analgesic effect of gabapentin on rats with neuropathic pain.
Topics: Amines; Analgesics; Animals; Ascorbic Acid; Cyclohexanecarboxylic Acids; Drug Synergism; Gabapentin; | 2016 |
The Antinociceptive Effects of Tramadol and/or Gabapentin on Rat Neuropathic Pain Induced by a Chronic Constriction Injury.
Topics: Amines; Analgesics; Analgesics, Opioid; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal | 2016 |
Clinical and economic consequences of treating patients with peripheral neuropathic pain with brand name or generic drugs in routine clinical practice: The effects of age and sex.
Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Drugs, Generic; Female; Gabapentin; gamma-Ami | 2018 |
Selective Cathepsin S Inhibition with MIV-247 Attenuates Mechanical Allodynia and Enhances the Antiallodynic Effects of Gabapentin and Pregabalin in a Mouse Model of Neuropathic Pain.
Topics: Amines; Animals; Behavior, Animal; Cathepsins; Cyclohexanecarboxylic Acids; Dipeptides; Disease Mode | 2016 |
Potential Contribution of Antioxidant Mechanism in the Defensive Effect of Lycopene Against Partial Sciatic Nerve Ligation Induced Behavioral, Biochemical and Histopathological Modification in Wistar Rats.
Topics: Amines; Animals; Antioxidants; Carotenoids; Catalase; Cyclohexanecarboxylic Acids; Gabapentin; gamma | 2016 |
Cost of treatment of peripheral neuropathic pain with pregabalin or gabapentin in routine clinical practice: impact of their loss of exclusivity.
Topics: Adult; Aged; Amines; Analgesics; Comoros; Cyclohexanecarboxylic Acids; Electronic Health Records; Fe | 2017 |
A rodent model of HIV protease inhibitor indinavir induced peripheral neuropathy.
Topics: Amines; Analgesics; Animals; Calcitonin Gene-Related Peptide; Calcium-Binding Proteins; Cyclohexanec | 2017 |
Neuroprotective Effect of Genistein in Peripheral Nerve Injury.
Topics: Amines; Animals; Anti-Inflammatory Agents; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyr | 2017 |
6-Methoxyflavanone attenuates mechanical allodynia and vulvodynia in the streptozotocin-induced diabetic neuropathic pain.
Topics: Amines; Animals; Computer Simulation; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Fl | 2016 |
Vendor-derived differences in injury-induced pain phenotype and pharmacology of Sprague-Dawley rats: Does it matter?
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Freund's Adjuvant; Gabapentin; gamma-Amino | 2017 |
Topical gabapentin gel alleviates allodynia and hyperalgesia in the chronic sciatic nerve constriction injury neuropathic pain model.
Topics: Administration, Topical; Amines; Analgesics; Animals; Constriction, Pathologic; Cyclohexanecarboxyli | 2017 |
sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain.
Topics: Amides; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Gabapentin | 2017 |
Agomelatine: a new opportunity to reduce neuropathic pain-preclinical evidence.
Topics: Acetamides; Adrenergic alpha-2 Receptor Antagonists; Amines; Animals; Antineoplastic Agents; Constri | 2017 |
Formalin injection produces long-lasting hypersensitivity with characteristics of neuropathic pain.
Topics: Activating Transcription Factor 3; Amines; Animals; Cyclohexanecarboxylic Acids; Female; Formaldehyd | 2017 |
Changing general medical practices in the management of neuropathic pain
Topics: Adult; Aged; Amines; Cyclohexanecarboxylic Acids; Duloxetine Hydrochloride; Female; Gabapentin; gamm | 2016 |
An Improved Rodent Model of Trigeminal Neuropathic Pain by Unilateral Chronic Constriction Injury of Distal Infraorbital Nerve.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Functional Lateral | 2017 |
Donepezil, an Acetylcholinesterase Inhibitor, Can Attenuate Gabapentinoid-Induced Somnolence in Patients with Neuropathic Pain: A Retrospective Chart Review.
Topics: Adult; Aged; Aged, 80 and over; Amines; Cholinesterase Inhibitors; Cyclohexanecarboxylic Acids; Diso | 2017 |
Neutrophils Infiltrate the Spinal Cord Parenchyma of Rats with Experimental Diabetic Neuropathy.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Experimental; Diabetic | 2017 |
Post-traumatic short-lasting unilateral headache with cranial autonomic symptoms (SUNA).
Topics: Accidents, Traffic; Adult; Amines; Carbamazepine; Conjunctiva; Cyclohexanecarboxylic Acids; Facial P | 2008 |
Anxiety-like behaviour in rats with mononeuropathy is reduced by the analgesic drugs morphine and gabapentin.
Topics: Amines; Analgesics; Animals; Anxiety; Cyclohexanecarboxylic Acids; Disease Models, Animal; Gabapenti | 2008 |
Intrathecal clonidine suppresses phosphorylation of the N-methyl-D-aspartate receptor NR1 subunit in spinal dorsal horn neurons of rats with neuropathic pain.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Amines; Analgesics; Animals; Anticonvulsant | 2008 |
Anxiety-like behaviour is attenuated by gabapentin, morphine and diazepam in a rodent model of HIV anti-retroviral-associated neuropathic pain.
Topics: Amines; Analgesics; Animal Diseases; Animals; Anxiety; Behavior, Animal; Cyclohexanecarboxylic Acids | 2008 |
Improvement in psoriasis following treatment with gabapentin and pregabalin.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Male; | 2008 |
[Gabapentin for neurophatic pain in children: a case report].
Topics: Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; Gaba | 2008 |
Gabapentin acts within the locus coeruleus to alleviate neuropathic pain.
Topics: Amines; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Locus Coeruleus; | 2008 |
Gabapentin monotherapy for the treatment of chemotherapy-induced neuropathic pain: a pilot study.
Topics: Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug-Related Side Effects and Adverse | 2008 |
Protective effects of gabapentin on allodynia and alpha 2 delta 1-subunit of voltage-dependent calcium channel in spinal nerve-ligated rats.
Topics: Amines; Analgesics; Animals; Calcium Channels; Calcium Channels, L-Type; Cyclohexanecarboxylic Acids | 2009 |
Gabapentin versus tricyclics for neuropathic pain.
Topics: Amines; Antidepressive Agents, Tricyclic; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyri | 2009 |
Anti-nociceptive synergism of morphine and gabapentin in neuropathic pain induced by chronic constriction injury.
Topics: Amines; Analgesics; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Drug Synergism; Gabapent | 2009 |
Gabapentin-induced delirium and dependence.
Topics: Adult; Amines; Analgesics, Non-Narcotic; Cyclohexanecarboxylic Acids; Delirium; Gabapentin; gamma-Am | 2009 |
Antinociceptive effects of NCX-701 (nitro-paracetamol) in neuropathic rats: enhancement of antinociception by co-administration with gabapentin.
Topics: Acetaminophen; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dos | 2009 |
Abnormal gait, due to inflammation but not nerve injury, reflects enhanced nociception in preclinical pain models.
Topics: Amines; Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Axotomy; Carrageenan; | 2009 |
Neuropathic pain treatment: a further step forward.
Topics: Amines; Analgesics; Antidepressive Agents, Tricyclic; Chronic Disease; Cyclohexanecarboxylic Acids; | 2009 |
Synthesis and in vivo evaluation of bicyclic gababutins.
Topics: Amines; Amino Acids; Animals; Blood-Brain Barrier; Bridged Bicyclo Compounds; CHO Cells; Cricetinae; | 2010 |
Treatments for neuropathic pain differentially affect delayed matching accuracy by macaques: effects of amitriptyline and gabapentin.
Topics: Amines; Amitriptyline; Analgesics; Analgesics, Non-Narcotic; Animals; Cyclohexanecarboxylic Acids; D | 2010 |
Chemical composition and evaluation of the anti-hypernociceptive effect of the essential oil extracted from the leaves of Ugni myricoides on inflammatory and neuropathic models of pain in mice.
Topics: Amines; Analgesics; Animals; Anti-Inflammatory Agents; Behavior, Animal; Bicyclic Monoterpenes; Carr | 2010 |
Reporting of trials of gabapentin.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Neural | 2010 |
A tropomyosine receptor kinase inhibitor blocks spinal neuroplasticity essential for the anti-hypersensitivity effects of gabapentin and clonidine in rats with peripheral nerve injury.
Topics: Acetylcholine; Amines; Analgesics; Animals; Carbazoles; Choline O-Acetyltransferase; Clonidine; Cycl | 2011 |
[Neuropathic pain in children].
Topics: Adolescent; Amines; Amitriptyline; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive A | 2010 |
Intrathecal gabapentin and clonidine synergistically inhibit allodynia in spinal nerve-ligated rats.
Topics: Amines; Animals; Clonidine; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Response Relat | 2010 |
Low dose of donepezil improves gabapentin analgesia in the rat spared nerve injury model of neuropathic pain: single and multiple dosing studies.
Topics: Amines; Analgesics; Animals; Cholinesterase Inhibitors; Cyclohexanecarboxylic Acids; Disease Models, | 2010 |
A novel rat forelimb model of neuropathic pain produced by partial injury of the median and ulnar nerves.
Topics: Amines; Analgesics; Animals; Behavior, Animal; CD11b Antigen; Cold Temperature; Cyclohexanecarboxyli | 2011 |
Molecular basis for the dosing time-dependency of anti-allodynic effects of gabapentin in a mouse model of neuropathic pain.
Topics: Amines; Animals; Calcium Channels; Circadian Rhythm; Cyclohexanecarboxylic Acids; Disease Models, An | 2010 |
Effects of gabapentin on brain hyperactivity related to pain and sleep disturbance under a neuropathic pain-like state using fMRI and brain wave analysis.
Topics: Amines; Analgesics; Animals; Axotomy; Brain; Brain Mapping; Brain Waves; Cyclohexanecarboxylic Acids | 2011 |
Calcium channel alpha-2-delta-1 protein upregulation in dorsal spinal cord mediates spinal cord injury-induced neuropathic pain states.
Topics: Amines; Analgesics; Animals; Calcium Channels; Calcium Channels, L-Type; Cyclohexanecarboxylic Acids | 2011 |
Neuropathic pain during treatment for childhood acute lymphoblastic leukemia.
Topics: Adolescent; Amines; Analgesics; Analgesics, Opioid; Antineoplastic Agents; Child; Child, Preschool; | 2011 |
[Pitfalls in the treatment of neuropathic pain in patients with cancer].
Topics: Aged; Amines; Amitriptyline; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Dr | 2011 |
Possible heart failure associated with pregabalin use: case report.
Topics: Amines; Analgesics; Back Pain; Cyclohexanecarboxylic Acids; Diagnosis, Differential; Edema; Female; | 2011 |
Beneficial response to gabapentin portraying with interval change of brain SPECT imaging in a case with failed back surgery syndrome.
Topics: Adult; Amines; Analgesics; Cerebral Cortex; Cerebrovascular Circulation; Cyclohexanecarboxylic Acids | 2011 |
Urine drug testing of chronic pain patients. IV. prevalence of gabapentin and pregabalin.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Neural | 2011 |
Pulsed radiofrequency modulation for lingual neuralgia.
Topics: Amines; Carbamazepine; Cranial Nerve Diseases; Cyclohexanecarboxylic Acids; Excitatory Amino Acid An | 2012 |
Manual acupuncture inhibits mechanical hypersensitivity induced by spinal nerve ligation in rats.
Topics: Acupuncture Points; Acupuncture Therapy; Amines; Analgesics; Analysis of Variance; Animals; Cyclohex | 2011 |
Pharmacological and behavioral characterization of the saphenous chronic constriction injury model of neuropathic pain in rats.
Topics: Amines; Amitriptyline; Analgesics; Animals; Benzoxazines; Chronic Disease; Constriction; Cyclohexane | 2011 |
Biphasic effects of chronic intrathecal gabapentin administration on the expression of protein kinase C gamma in the spinal cord of neuropathic pain rats.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Dizocilpine Maleate; Gabapentin; gamma-Ami | 2011 |
Pharmacological characterization of lysophosphatidic acid-induced pain with clinically relevant neuropathic pain drugs.
Topics: Amines; Analgesics; Animals; Calcium Channels; Cyclohexanecarboxylic Acids; Disease Models, Animal; | 2012 |
Analgesic effect of gabapentin in a rat model for chronic constrictive injury.
Topics: Amines; Analgesics; Animals; Blotting, Western; Calcium-Calmodulin-Dependent Protein Kinase Type 2; | 2011 |
The combined predictive capacity of rat models of algogen-induced and neuropathic hypersensitivity to clinically used analgesics varies with nociceptive endpoint and consideration of locomotor function.
Topics: Amines; Analgesics; Animals; Capsaicin; Cyclohexanecarboxylic Acids; Disease Models, Animal; Duloxet | 2012 |
The efficacy of morphine, pregabalin, gabapentin, and duloxetine on mechanical allodynia is different from that on neuroma pain in the rat neuropathic pain model.
Topics: Administration, Oral; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Cyclohexanecarb | 2012 |
Spinal mechanism underlying the antiallodynic effect of gabapentin studied in the mouse spinal nerve ligation model.
Topics: Amines; Analgesics; Animals; Calcium Channels; CD11b Antigen; Cyclohexanecarboxylic Acids; Disease M | 2012 |
Pain alleviation and patient-reported health outcomes following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain in routine medical practice.
Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; | 2012 |
Evaluation of aqueous and ethanolic extracts of saffron, Crocus sativus L., and its constituents, safranal and crocin in allodynia and hyperalgesia induced by chronic constriction injury model of neuropathic pain in rats.
Topics: Acetone; Amines; Analgesics; Animals; Behavior, Animal; Carotenoids; Constriction; Crocus; Cyclohexa | 2012 |
Study of emotional and cognitive impairments in mononeuropathic rats: effect of duloxetine and gabapentin.
Topics: Affective Symptoms; Amines; Analgesics; Animals; Antidepressive Agents; Cognition; Cognition Disorde | 2012 |
Neuropathic truncal pain--a case series.
Topics: Abdominal Pain; Adolescent; Adult; Amines; Analgesics; Anesthetics, Local; Antidepressive Agents; Ch | 2012 |
Substance misuse of gabapentin.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Neural | 2012 |
Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin litigation.
Topics: Access to Information; Amines; Analgesics; Antimanic Agents; Authorship; Bipolar Disorder; Clinical | 2012 |
Patterns of nerve injury and neuropathic pain in ischemic neuropathy after ligation-reperfusion of femoral artery in mice.
Topics: Amines; Animals; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Femoral Artery; Gaba | 2012 |
Varicella-zoster virus infection and nummular headache: a possible association with epicranial neuralgia.
Topics: 2-Aminopurine; Amines; Analgesics; Antiviral Agents; Comorbidity; Cyclohexanecarboxylic Acids; Famci | 2012 |
The effect of intrathecal gabapentin on neuropathic pain is independent of the integrity of the dorsolateral funiculus in rats.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Injec | 2012 |
Long-term outcome of Cavalier King Charles spaniel dogs with clinical signs associated with Chiari-like malformation and syringomyelia.
Topics: Amines; Analgesics; Animals; Arnold-Chiari Malformation; Breeding; Carbazoles; Cohort Studies; Cyclo | 2012 |
Optimised protocol design for the screening of analgesic compounds in neuropathic pain.
Topics: Amines; Analgesics; Animals; Cohort Studies; Cyclohexanecarboxylic Acids; Double-Blind Method; Drug | 2012 |
Application of ED-optimality to screening experiments for analgesic compounds in an experimental model of neuropathic pain.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Double-Blind Method; Drug Evaluation, Prec | 2012 |
Antioxidants and gabapentin prevent heat hypersensitivity in a neuropathic pain model.
Topics: Amines; Animals; Antioxidants; Calcium Channels; Catalase; Cyclohexanecarboxylic Acids; Drug Combina | 2013 |
Adverse drug reactions to gabapentin and pregabalin: a review of the French pharmacovigilance database.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohe | 2013 |
Intrathecal gabapentin increases interleukin-10 expression and inhibits pro-inflammatory cytokine in a rat model of neuropathic pain.
Topics: Amines; Analgesics; Animals; Antibodies; Behavior, Animal; Cyclohexanecarboxylic Acids; Cytokines; D | 2013 |
Gabapentin in the treatment of SUNCT syndrome.
Topics: Acetates; Amines; Analgesics; Conjunctiva; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Am | 2002 |
SUNCT responsive to gabapentin.
Topics: Acetates; Adult; Amines; Analgesics; Conjunctiva; Cyclohexanecarboxylic Acids; Female; Gabapentin; g | 2002 |
[Neuropathic pain. Often mishandled for years].
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; | 2002 |
Gabbing about gabapentin.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Approval; Gabapentin; gamma-Ami | 2003 |
[Case report on a patient with SUNCT-syndrome].
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Functional Laterality; Gabapentin | 2003 |
Comment on: Serpell et al., gabapentin in neuropathic pain syndromes: a randomised double-blind, placebo controlled trial (Pain 2002; 99: 557-66).
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; ga | 2003 |
Comparative activity of the anti-convulsants oxcarbazepine, carbamazepine, lamotrigine and gabapentin in a model of neuropathic pain in the rat and guinea-pig.
Topics: Acetates; Amines; Animals; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Gabapentin; | 2003 |
Great auricular neuralgia: a case report.
Topics: Acetates; Aged; Amines; Analgesics; Cervical Vertebrae; Cyclohexanecarboxylic Acids; Gabapentin; gam | 2003 |
[Efficacy and tolerability of gabapentin in the treatment of patients with neuropathic pain. Results of an observational study involving 5620 patients].
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; G | 2003 |
Change in opioid use after the initiation of gabapentin therapy in patients with postherpetic neuralgia.
Topics: Acetates; Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Analgesics, Opioid; Cycloh | 2003 |
Conquering peripheral neuropathic pain.
Topics: Acetates; Amines; Analgesics; Anesthetics, Local; Antidepressive Agents, Tricyclic; Cyclohexanecarbo | 2004 |
Pharmacological characterisation of the rat brachial plexus avulsion model of neuropathic pain.
Topics: Acetates; Amines; Analgesics; Analysis of Variance; Animals; Brachial Plexus; Brachial Plexus Neurop | 2004 |
Treatment of postherpetic neuralgia.
Topics: 2-Aminopurine; Acyclovir; Age Factors; Aged; Amines; Analgesics; Analgesics, Opioid; Antidepressive | 2004 |
Oxcarbazepine (Trileptal) monotherapy dramatically improves quality of life in two patients with postherpetic neuralgia refractory to carbamazepine and gabapentin.
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; | 2004 |
Combination therapy for neuropathic pain--which drugs, which combination, which patients?
Topics: Amines; Analgesia; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Drug Therapy, Combin | 2005 |
Effect of systemic and intrathecal gabapentin on allodynia in a new rat model of postherpetic neuralgia.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Diterpenes; Gabape | 2005 |
Behavioral, pharmacological and molecular characterization of the saphenous nerve partial ligation: a new model of neuropathic pain.
Topics: Amines; Amitriptyline; Analgesics; Animals; Behavior, Animal; Benzoxazines; Blotting, Western; Cyclo | 2005 |
Morphine, gabapentin, or their combination for neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2005 |
Morphine, gabapentin, or their combination for neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Nephropathies; Drug Therapy, Combination; | 2005 |
Gabapentin in dermatology.
Topics: Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Lyme Neuro | 2005 |
Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate.
Topics: Amines; Analgesics; Animals; Aspartic Acid; Chronic Disease; Cyclohexanecarboxylic Acids; Excitatory | 2005 |
Occipital neuralgia secondary to respiratory tract infection.
Topics: Amines; Amitriptyline; Analgesics, Non-Narcotic; Carbamazepine; Cyclohexanecarboxylic Acids; Diagnos | 2005 |
Varicella zoster virus induces neuropathic changes in rat dorsal root ganglia and behavioral reflex sensitisation that is attenuated by gabapentin or sodium channel blocking drugs.
Topics: Amines; Animals; Anticonvulsants; Behavior, Animal; Cyclohexanecarboxylic Acids; Disease Models, Ani | 2005 |
Economic evaluation of oral treatments for neuropathic pain.
Topics: Administration, Oral; Amines; Amitriptyline; Analgesics; Carbamazepine; Cohort Studies; Cost-Benefit | 2006 |
Experience with gabapentin for neuropathic pain in adolescents: report of five cases.
Topics: Adolescent; Amines; Analgesics; Child; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminob | 2006 |
Use of antiepileptics and tricyclic antidepressants in cancer patients with neuropathic pain.
Topics: Aged; Amines; Amitriptyline; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; | 2006 |
Abnormal blink reflex studies in a patient with supraorbital neuralgia.
Topics: Adult; Amines; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Blinking; Cyclohexanecarboxylic | 2006 |
Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Cyclohexanols; Dose-Response Relationship, | 2006 |
Does acute pain associated with herpes zoster respond to treatment with gabapentin?
Topics: Acute Disease; Amines; Analgesics; Cross-Over Studies; Cyclohexanecarboxylic Acids; Double-Blind Met | 2006 |
Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit.
Topics: Amines; Analgesics; Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Calcium Channels; | 2007 |
Cognitive function impairment in patients with neuropathic pain under standard conditions of care.
Topics: Adult; Aged; Amines; Analgesics; Cognition Disorders; Cohort Studies; Cyclohexanecarboxylic Acids; F | 2007 |
[Intensified insulin therapy plus antineuritic medication is more effective than antineuritics alone in painful diabetic neuropathy].
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Amines; Analgesics; Clomipramine; Cyclohexanecarboxylic A | 2006 |
The importance of genetic background on pain behaviours and pharmacological sensitivity in the rat spared serve injury model of peripheral neuropathic pain.
Topics: Amines; Analgesics; Analgesics, Opioid; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal | 2007 |
Antinociceptive efficacy of lacosamide in rat models for tumor- and chemotherapy-induced cancer pain.
Topics: Acetamides; Amines; Analgesics; Animals; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Cyclohex | 2007 |
Pregabalin and duloxetine for the treatment of neuropathic pain disorders.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Duloxetine Hydrochloride; Ga | 2007 |
[Gabapentin mitigates neuropathic pain in cancer patients--a case report].
Topics: Adenocarcinoma; Amines; Analgesics; Bone Neoplasms; Cyclohexanecarboxylic Acids; Gabapentin; gamma-A | 2007 |
Gabapentin for the treatment of neuropathic pain in a pregnant horse.
Topics: Amines; Analgesics; Animals; Colic; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobuty | 2007 |
Gabapentin and sexual dysfunction: report of two cases.
Topics: Adolescent; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric | 2008 |
Hemichorea associated with gabapentin therapy with hypoperfusion in contralateral basal ganglion - a case of a paraplegic patient with neuropathic pain.
Topics: Adult; Amines; Analgesics; Basal Ganglia; Cerebrovascular Circulation; Chorea; Cyclohexanecarboxylic | 2008 |
Patient compliance with neuropathic pain treatment.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Neural | 2008 |
Gabapentin as a novel treatment for postherpetic neuralgia.
Topics: Acetates; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Amin | 1996 |
Psychomotor agitation following gabapentin use in brain injury.
Topics: Acetates; Adult; Akathisia, Drug-Induced; Amines; Analgesics; Brain Injuries; Cyclohexanecarboxylic | 1997 |
[Treatment of neuropathic pain with gabapentin ++].
Topics: Acetates; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamm | 1998 |
The anti-allodynic effects of amitriptyline, gabapentin, and lidocaine in a rat model of neuropathic pain.
Topics: Acetates; Amines; Amitriptyline; Analgesics; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma | 1998 |
Symptomatic treatment of painful neuropathy.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; G | 1998 |
[Use of gabapentin in glossopharyngeal neuralgia].
Topics: Acetates; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobut | 1999 |
Gabapentin for postherpetic neuralgia.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Herp | 1999 |
Neuropathic pain.
Topics: Acetates; Amines; Amitriptyline; Analgesics; Antiviral Agents; Cyclohexanecarboxylic Acids; Drug The | 1999 |
Using gabapentin to treat neuropathic pain.
Topics: Acetates; Adult; Amines; Analgesics; Anticonvulsants; Costs and Cost Analysis; Cyclohexanecarboxylic | 1999 |
Gabapentin-induced anorgasmia.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Huma | 1999 |
Gabapentin vs amitriptyline for the treatment of peripheral neuropathy.
Topics: Acetates; Amines; Amitriptyline; Analgesics, Non-Narcotic; Cyclohexanecarboxylic Acids; Drug Adminis | 2000 |
Herpes zoster.
Topics: Acetates; Acute Disease; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobut | 2000 |
Further evidence for the role of the alpha(2)delta subunit of voltage dependent calcium channels in models of neuropathic pain.
Topics: Acetates; Amines; Analgesics; Animals; Calcium Channels; Cyclohexanecarboxylic Acids; Disease Models | 2000 |
Pharmacological and immunohistochemical characterization of a mouse model of acute herpetic pain.
Topics: Acetates; Amines; Amitriptyline; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; | 2000 |
SUNCT syndrome responsive to gabapentin (Neurontin).
Topics: Acetates; Amines; Analgesics; Conjunctival Diseases; Cyclohexanecarboxylic Acids; Gabapentin; gamma- | 2000 |
[Treatment of chronic and neuropathic pain. Established amitriptyline and the new gabapentin].
Topics: Acetates; Amines; Amitriptyline; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; | 2000 |
The effects of GABA(B) agonists and gabapentin on mechanical hyperalgesia in models of neuropathic and inflammatory pain in the rat.
Topics: Acetates; Amines; Analgesics; Animals; Baclofen; Cyclohexanecarboxylic Acids; Electric Stimulation; | 2001 |
Three-month follow-up of shoulder-hand syndrome induced by phenobarbital and treated with gabapentin.
Topics: Acetaminophen; Acetates; Amines; Analgesics; Anticonvulsants; Arthralgia; Cyclohexanecarboxylic Acid | 2001 |
The putative OP(4) antagonist, [Nphe(1)]nociceptin(1-13)NH(2), prevents the effects of nociceptin in neuropathic rats.
Topics: Acetates; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Res | 2001 |
[Pharmacotherapy for neuropathic pain caused by injury to the afferent nerve fibers].
Topics: Acetates; Amines; Analgesics, Non-Narcotic; Cyclohexanecarboxylic Acids; Drug Approval; Gabapentin; | 2001 |
Gabapentin therapy for genitofemoral and ilioinguinal neuralgia.
Topics: Acetates; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Femoral Neuropathy; Gabapen | 2001 |
Case reports - reversal of sensory deficit associated with pain relief after treatment with gabapentin.
Topics: Acetates; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobuty | 2002 |
Comment on Rice ASC, Maton S, the Postherpetic Neuralgia Study Group (UK), gabapentin in postherpetic neuralgia: a randomized, double blind, placebo-controlled study.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Herp | 2002 |
Comment on Rice ASC, Maton S, the Postherpetic Neuralgia Study Group (UK), gabapentin in postherpetic neuralgia: a randomized, double blind, placebo-controlled study.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Herp | 2002 |
Gabapentin: resistant neuropathic pain and malignancy.
Topics: Acetates; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Resistance; Gabapentin; gamma | 2001 |